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Myelodysplasia (MDS) is characterised by inefficient haematopoiesis with dysplastic 
features of blood and bone marrow, reduction of mature blood cells and continuous 
bone marrow failure (BMF). Acute myeloid leukaemia (AML) is characterised by the 
accumulation of immature myeloid blasts in the bone marrow. MDS and AML are 
mostly sporadic clonal disorders affecting older patients. Familial occurrence of 
MDS/AML is rare, and most of these cases occur in the setting of genetic syndromes.  
However, it has also been reported to be caused by germline heterozygous mutations 
in genes including RUNX1, CEBPA, TERC, TERT, GATA2, SRP72, and ANKRD26.  
 
Our group has collected 115 families that have two or more individuals with BMF with 
at least one of whom has MDS or AML. The aim of this project was to identify disease 
causing gene variants that can lead to familial MDS/AML. Identification of 
predisposing variants to familial MDS/AML is critical for effective management in 
these families. This will also provide new insights into the biology of MDS/AML in 
general.  
 
Herein, we have characterised a subset of families with MDS/AML as well as identified 
candidate disease genes using a range of genetic studies. Specifically, we have: i. 
Identified new genetic variants in some of the known disease genes such as RUNX1 
and GATA2. ii. Our studies have substantiated the discovery of DDX41 as a disease 
gene as we have identified several families harbouring novel heterozygous loss of 
function (LoF) DDX41 variants. iii. Identified germline heterozygous LoF RTEL1 
variants in a subset of families with myelodysplasia and liver disease. This defines a 
new disease group in this field, RTEL1 can now be added to the list of familial 
MDS/AML disease genes. iv. We have identified nine new candidate disease genes 
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which are involved in RNA splicing, transcription factor, DNA modification, cell 
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Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SET domain-containing protein 4 
SF2 Superfamily 2  
SF3B1 splicing factor 3b subunit 1 
SF3B2 splicing factor 3b subunit 2 
SF3B3 splicing factor 3b subunit 3 
SFTPA2 surfactant protein A2  
SFTPC surfactant protein C  
SLX1 SLX1 structure-specific endonuclease subunit  
SLX4 SLX4 structure-specific endonuclease subunit 
SMC1A structural maintenance of chromosomes 1A 
SMC3 structural maintenance of chromosomes 3  
SNPs single nucleotide polymorphisms 
SRP72 signal recognition particle 72 
SRSF2 serine and arginine rich splicing factor 2 
SSC saline-sodium citrate 
ssDNA single-stranded DNA  
STAG1/2 stromal antigen 1/2 
STING stimulator of interferon genes 
T/S telomeric to single-copy gene ratio 
TBE tris-borate-EDTA 
TBK1 TANK binding kinase 1 
TBS-T Tween-20 
TCFs ternary complex factors 
T-circle telomeric-circle 
TE tris-EDTA 
TERC telomerase RNA component 
TERT telomerase reverse transcriptase 
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TET2 tet methylcytosine dioxygenase 2 
THC2 thrombocytopenia 2 
TINF2 TERF1 interacting nuclear factor 2 
TLR Toll-like receptors 
TNRC6C trinucleotide repeat containing 6C 
TP53 tumor protein p53 
TRANK1 tetratricopeptide repeat and ankyrin repeat containing 1 
TRF1 telomere repeat binding factor 1  
TRF2 telomere repeat binding factor 2  
TRIF TIR-domain-adapter-inducing interferon-β 
TRIM21 tripartite motif containing 21 
TSCA Truseq Custom Amplicon 
TTP1 TINF2-interacting protein 2  
TTS upstream of the transcription start site 
U2 snRNP U2 small nuclear ribonucleoproteins complex 
U2AF1 U2 small nuclear RNA auxiliary factor 1 
UBE2T ubiquitin conjugating enzyme E2 T 
UTR untranslated region 
V volt 
V/cm volt/centimetre 
VAF variant allele frequency 
vs versus 
VUS variant of unknown significance  
WAS Wiskott-Aldrich syndrome 
WASp WAS protein 
WES whole exome sequencing 
WHO World Health Organization 
WRAP53 WD repeat containing antisense to TP53 
WT1 Wilms tumor 1 
XL X-linked  
XLN X-linked neutropenia 
XP xeroderma pigmentosum  
XPD Xeroderma pigmentosum group D  
XPF ERCC excision repair 4, endonuclease catalytic subunit 
XRCC2 X-ray repair cross complementing 2 
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-Y loss of Y  
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1.1 General introduction  
 
Myelodysplasia and acute myeloid leukaemia are mostly sporadic haematopoietic 
malignancies typically affecting older patients, though a small subset has been 
associated with germline mutations. Familial cases of myelodysplasia/acute myeloid 
leukaemia are rare, but are extremely relevant for the investigation of the molecular 
pathogenesis of myelodysplasia and acute myeloid leukaemia in general as many 
genes associated with these familial myeloid neoplasms are also recurrently mutated 
in sporadic cases (Liew & Owen, 2011; West et al., 2014). Large-scale sequencing of 
cancer genomes has now been completed for thousands of cancer samples. This 
initial discovery phase has uncovered many novel genes, pathways, and mutational 
processes implicated in cancer development (Vogelstein et al., 2013). Furthermore, it 
has been demonstrated that the mutation/deletion status of a set of genes could be 
used to build a clinically relevant prognostic system as independent variables from 
clinical parameters. Moving forward, studies are warranted to clarify how to integrate 
this increased knowledge of gene mutations in our understanding of leukaemogenesis 
and into clinical practice (Haferlach et al., 2014).  
 
 
1.2 Myelodysplasia syndromes 
 
Myelodysplasia syndromes (MDS) are a heterogeneous group of bone marrow 
disorders derived from clonal haematopoietic stem cells with increased proliferation 
or resistance to apoptosis, leading to an over production of abnormal differentiated 
blood cells. This produces inefficient haematopoiesis with morphological dysplastic 
features of blood and bone marrow, reduction of blood cells with various degrees of 
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cytopenia and continuous bone marrow failure (Figure 1.1) (Tefferi & Vardiman, 
2009). The incidence rate of sporadic myelodysplasia in 2016 was approximately 3 to 
4 cases per 100,000 population per year, with 30 cases per 100,000 population per 
year in patients >70 years old (Cancer Network - www.cancernetwork.com/cancer-




Figure 1.1. Schematic of a normal haematopoietic stem cells differentiation. Driver mutation(s) 





There are many MDS subtypes with varying clinical features and pathogenesis 
depending on which blood cells are affected. Any or all of the blood cells may be 
affected in MDS and its diagnosis depends mainly on the degree of dysplasia and 
blast percentages in peripheral blood and bone marrow. MDS should be classified 
according to the World Health Organization (WHO) criteria, as revised in 2016 (Arber 
et al., 2016). In the revised WHO MDS criteria the terms “refractory anemia” and 
“refractory cytopenia” were replaced by “myelodysplastic syndrome” followed by the 
appropriate modifiers: single vs multilineage dysplasia, ring sideroblasts, excess 
blasts, or the del(5q) cytogenetic abnormality (Table 1.1, adapted from Arber et al., 
2016).   
 
MDS can evolve into a form of leukaemia, usually acute myeloid leukaemia (AML) in 
30% of cases (Mufti et al., 2008). The clinical phenotype of patients with MDS are 
diverse with respect to the number and severity of cytopenias, cellularity and blast 
count in the bone marrow, rate of progression to AML, overall survival and response 
to treatment. MDS is an extremely heterogeneous group of disorders, ranging from 
mild conditions with a near-normal life expectancy to forms approaching AML. Much 
of this phenotypic heterogeneity is likely due to the variety of genetic alterations that 
contribute to disease pathogenesis.   
 
Somatically acquired genetic abnormalities, including karyotypic abnormalities, gene 
alterations and aberrant epigenetic regulation of gene expression lead to the 
development of MDS (Bejar et al., 2011). However, single genetic alterations are 
unlikely to be the sole disease-causing abnormalities in myeloid neoplasms. Instead, 
a combination of two or more of these genetic modifications may be needed in 
cooperation with global changes in epigenetic states and cellular environment (Bejar 
et al., 2011).  
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Furthermore, there is no single factor known to cause these genetic alterations, in 
many cases it is probably due to a combination of different factors such as smoking, 
some anti-cancer treatments, exposure to certain chemicals (such as benzene) and 
exposure to high levels of ionising radiation. 
 
Sporadic MDS, de novo MDS and the closely related secondary AML evolving from 
an antecedent MDS are predominantly sporadic diseases that affect the elderly, with 
a median age of diagnosis over 70 years, and generally carry a poor prognosis 
(Sekeres et al., 2008; Steensma, 2015b; Khwaja et al., 2016). Although, adult patients 
less than 50 years of age are sporadically affected by MDS. In addition, in children, 
refractory cytopenia of childhood and juvenile myelomonocytic leukaemia (JMML) are 
considered distinct entities and are more related to congenital bone marrow failure 
and familial leukaemia syndromes than to adult MDS (Niemeyer & Baumann, 2011). 
Furthermore, Hirsch et al. (2017) found that high-risk MDS (with excess blasts) was 
more common among early onset (range, 20-50 years old) MDS patients (35% 
against 24%, P=0.048) while lower-risk MDS (with single lineage dysplasia, MDS with 
ring sideroblasts with single and multilineage dysplasia and, MDS with multilineage 
dysplasia) predominated in MDS patients over 50 years of age (28% against 41%, 
P=0.042). Additionally, the number of mutations tended to be higher in advanced 
WHO subtypes and high-risk prognostic groups, which is also associated with 
increasing intratumoral subpopulations and worse prognosis (Haferlach et al., 2014).  
 
Congenital disorders such as Down syndrome, Fanconi anaemia (FA), dyskeratosis 
congenita (DC) and Bloom syndrome are also associated with MDS. In these 
syndromes affected individuals usually present with MDS at an earlier age (Germing 
et al., 2008), suggesting a “multiple-hit” mechanism of cancer development with 
genetic and environmental factors. The genetic variations in haematopoietic cells, 
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whether inherited or acquired, can affect apoptosis and cell differentiation which are 
crucial to increase the susceptibility of the affected precursor cell to further DNA 
damage, contributing to an accumulation of secondary genetic alterations that 
conclusively results in the development of definite MDS and AML (Tefferi & Vardiman, 
2009). 
 
Finally, although MDS is classified as cancer by WHO and is treated by oncologists 
in many settings, and MDS shares some biological features with leukaemia or other 
overt neoplasms, there are other features of MDS that are not typical of cancer, such 
as response to immunosuppressive therapy in some cases and stability for more than 
a decade in others (Shlush & Minden, 2015). 
 
 
1.2.1 Patterns of acquired genetic variants in MDS 
 
The spectrum of genetic abnormalities in MDS implicates a wide range of molecular 
mechanisms in the pathogenesis of this disorder, including RNA splicing, transcription 
factors, DNA modification, chromatin regulation, cell signalling and epigenetic 
regulators (Haferlach et al., 2014). RNA splicing is the most commonly mutated 
pathway in MDS and occurs early in disease evolution. These mutations play a major 
role in determining the clinical features of the disease, with differences in 
morphological features seen on bone marrow biopsy as they may influence the 
subsequent genomic evolution of the disease. It happens because the patterns of 
cooperating mutations are very different between the genes with driver mutations 
(Papaemmanuil et al., 2013). Specific alterations present in individual patients with 
MDS may explain much of the heterogeneity in clinical phenotype associated with 
MDS and can predict prognosis and response to therapy (Bejar et al., 2011).  
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Chromosomal abnormalities are present in approximately half of patients with MDS. 
The most common of these are loss of 5q (-5q), loss of 7 or 7q (-7/7q), trisomy 8 (+8), 
loss of 20q (-20q), and loss of Y (-Y) (Haase et al., 2007; Bejar et al., 2011). Del(5q) 
is the only cytogenetic or molecular genetic abnormality that is considered a specific 
MDS subtype by WHO criteria. The presence of +8, -Y, or del(20q) is not considered 
to be MDS-defining in the absence of diagnostic morphologic features of MDS (Arber 
et al., 2016).  
 
Acquired somatic variants have been identified in several genes in MDS (Table 1.2), 
where the genes involved in chromatin regulation (ASXL1 and EZH2), DNA repair and 
transcriptor factor (TP53), transcriptor factor (RUNX1), RNA splicing (SF3B1, SRSF2, 
and U2AF1), and DNA methylation (TET2 and DNMT3A) are the most frequently 
mutated (Arber et al., 2016). However, deleterious variants in most of these genes 
can be found in different myeloid neoplasms and are not specific for MDS (Bejar et 
al., 2011). 
 
The number of somatic variants increases linearly with age and on average, patients 
over 50 years of age have more somatic variants in spliceosomal, epigenetic modifier, 
and RAS gene families. Furthermore, there are age-related differences in molecular 
features among elderly patients with MDS, where somatic variants in the genes 
involved in RNA splicing (SRSF2) and DNA methylation (TET2 and DNMT3A) occur 
with a high frequency. While somatic variants in genes involved in chromatin 
regulation (ASXL1), DNA methylation (TET2), DNA repair and transcriptor factor 
(TP53 and RUNX1) are the most frequently mutated genes in patients with early onset 













































































































































































































































































































































































































































































































































































































































































































































































































































































































It is known that there are haematological neoplasm-associated genetic abnormalities 
in the blood of some healthy people, especially older adults called clonal 
haematopoiesis of indeterminate potential (CHIP) (Biernaux et al., 1995; Steensma 
et al., 2015a). Although, acquired clonal mosaicism predicts an increased risk of 
development of a neoplasm, indicating that such alterations can represent disease-
initiating events in some cases by promoting clonal expansion (Jacobs et al., 2012). 
The most common genes identified with variants in healthy population or in patients 
with non-haematological malignancies in analysis of a large cohort were ASXL1, 
BCORL1, TP53, GNAS, SF3B1, DNMT3A, TET2, JAK2 and PPM1D. In addition, the 
frequency of these variants increased with aging (Xie et al., 2014; Jaiswal et al., 2014; 
Genovese et al., 2014; Kwok et al., 2014).  
 
Further studies are required to determine the best management and monitoring of the 
patients with CHIP, to describe whether they have a higher risk of developing 
malignancies or any other outcome. The specific genetic variants, number of variants, 
and variant allele frequency may also influence the risk of progression and could 





1.3 Acute myeloid leukaemia  
 
Leukaemia is a cancer of the white blood cells, it is classified according to the type of 
white blood cell affected and the speed with which the cancer progresses. AML is one 
type of leukaemia and is an aggressive disorder characterised by a fast clonal 
proliferation of very large numbers of malignant immature myeloid cells in the bone 
marrow (Figure 1.2) (Kupsa et al., 2012). These cells will never mature into proper 
blood cells, fundamental to a healthy immune system, and so patients with AML have 
an increased risk of infection. Normal blood cells are prevented from being made by 
the clustering of cancer cells in the bone marrow. Most of the complications of 
leukaemia are caused by the lack of normal cells in the blood (bone marrow failure), 




Figure 1.2. Schematic of haematopoietic stem cells differentiation. Differences in cell 
morphology and proliferation are shown when the haematopoietic stem cells are mutated 
leading to the development of MDS and AML. 
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AML accounts for less than 1% of all new cancer cases in 2015 in the UK. There were 
approximately 3,100 new cases of AML between 2013 and 2015 in the UK, with 
approximately 8 cases diagnosed every day.  Cancer research UK predicts that 1 in 
200 men and 1 in 255 women will be diagnosed with AML during their lifetime 
(http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/leukaemia-aml). As in MDS, different factors play a role in AML 
development. Cigarette smoke is a minor risk for AML (Bjork et al., 2009) and benzene 
exposure increases the risk of leukaemia (Vlaanderen et al., 2010). Patients who are 
receiving radiotherapy or chemotherapy to treat some other cancers may go on to 
develop AML. When this happens, it is called secondary leukaemia or therapy-related 
leukaemia. The risk of developing AML from other blood disorders is also low 
(Greaves, 1997). 
 
AML is a heterogeneous genetic disorder characterised by the accumulation of 
genetic abnormalities. The critical initiation step towards the disease pathogenesis 
occurs with the generation of chimeric fusion genes from translocation/inversion 
events or with preleukaemic mutation rising in the haematopoietic stem/progenitor cell 
(Hou et al., 2014). These preleukaemic events precede the development of 
leukaemia, which happens when further mutations co-occur later in the progenitor 
cells (Shlush et al., 2014). The presence of mutations that precede development of 
leukaemia likely reflects a cell’s cumulative inability to completely repair the multitude 
of mutations that occur randomly over time (Tomasetti & Vogelstein, 2015). 
 
Studies have shown that translocations/inversions underlie disease pathogenesis in 
approximately 80% of AML in children and 30% in young adults, whereas only a 
minority of AMLs in older adults have balanced rearrangements. Moreover, 
approximately 40% of adult AML with a highly heterogeneous clinical outcome have 
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normal karyotype but might exhibit molecular abnormalities that retain the normal 
characteristics of multipotent differentiation (Grimwade & Mrozek, 2011). Chimeric 
fusion genes are insufficient to induce leukaemic transformation in their own right. 
However, they may provide a competitive advantage, generating populations of cells 
in which secondary mutations may arise and be selected for (Miyamoto et al., 2000). 
  
Leukaemias often comprise heterogeneous mixtures of subclones (Welch et al., 
2012). Studies in large cohorts have shown that the development of AML follows 
specific and ordered evolutionary trajectories (Papaemmamuil et al., 2016) and the 
identification of this stepwise acquisition of mutations during the development of the 
disease is possible with the use of next generation sequencing (NGS) approaches. 
The use of NGS with an extensive sequencing depth have allowed the quantification 
of the differences in the relative proportion of co-occurring mutations within the tumour 
at the time of diagnosis (Mardis et al., 2009).   
 
Variant allele frequency (VAF) is the comparison of the proportion of reads that 
contain the mutant allele to that of wild-type allele reads, with the obtained relative 
proportions able to infer clonal architecture (Figure 1.3). Such analysis has 
demonstrated the emergence of new clones carrying novel mutations at different 
times during the evolution of the leukaemia (Walter et al., 2012) and also those 
mutations that persist after treatment failure, prioritising obvious critical molecular 
drivers of leukaemia development and relapse to target therapy (Ding et al., 2012). 
Mutations with a high VAF are predicted to occur early, whereas mutations present 
only in a minority of cells are likely to be acquired at later stages of leukaemia 
development. High VAF may also be observed as a result of acquired uniparental 
disomy, for example in a proportion of AMLs with associated FLT3-ITD and TET2 




Figure 1.3. Clonal evolution and clonal heterogeneity of AML. Mutation of DNMT3A is the 
earliest event and occurs before the disease development. NPM1c occurs as the disease-
defining mutation in the founding clone, with further acquisition of a FLT3-ITD mutation in a 
clone during leukaemia expansion, which become dominant at diagnosis. Quantification of 
VAF of each mutation, allows the demonstration of the evolution of the disease according to 
the temporal acquisition of mutations (adapted from Grimwade et al., 2016). 
 
 
The outcome of AML patients greatly differs according to their genetic abnormalities 
and the overall survival of AML patients is correlated with the number of driver 
mutations independent of the patient’s age and white cell count. In addition, the 
clinical effect of some driver mutations is modified by the wider genomic context in 
which they occur due to gene-gene interactions, in which the prognostic effect of one 
gene is significantly altered if another gene is co-mutated (Papaemmanuil et al., 
2016). Although, studies in healthy individuals have demonstrated that mutation 
frequency increases as a function of age and clonal expansion in older adults was 
confirmed by the presence of mutations associated with myeloid malignancies, 
increasing the risk of blood cancer development (Genovese et al., 2014; Jaiswal et 
al., 2014; Xie et al., 2014; McKerrell et al., 2015). 
  
Undoubtedly, a more complete genetic characterisation of haematological 
malignancies has great potential to elucidate the molecular basis for the clinical 
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heterogeneity of these disorders and to identify disease subtypes with shared 
outcomes and responses to therapy (Bejar et al., 2011).   
 
 
1.3.1 Patterns of acquired genetic variants in AML 
 
The discovery of somatic chromosomal abnormalities including balanced 
translocations in the leukaemic cells of some patients established that AML is a 
genetic disease (Rowley, 1973; Rowley et al., 1977). This blood disorder is 
characterised by the accumulation of genetic abnormalities such as the formation of 
chimeric fusion genes because of gene translocations and inversions listed in Table 
1.3. These chromosomal rearrangements occur between genes that encode 
haematopoietic transcription factors (RARA, RUNX1, or CEBPA), epigenetic 
regulators (KMT2A, NSD1, KAT3A), and components of the nuclear pore complex 
(NUP98, NUP214) (Grimwade et al., 2016). 
 
The WHO classifications recognised these recurrent chromosomal rearrangements 
as separate entities that are sufficient to diagnose AML without evidence of bone 
marrow blasts percentage ≥20%. In this classification, molecular groups in adult AML 
include t(15;17), t(9;11), t(8;21), inv(16), t(16;16), t(6;9), inv(3), t(3;3), t(1;22), MLLT3-
KMT2A, DEK-NUP214, RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA, as well as 

























































































































































































































































































































































































































































































































































































































































































































































































































































The outcome for AML patients differs considerably according to the cytogenetic 
abnormality and there are variations even in outcomes between patients with the 
same chromosomal abnormality. In addition, genomic heterogeneity in AML is 
associated with complex epigenetic heterogeneity (Li et al., 2016). However, 
approximately half of AML patients have normal karyotype and their outcome is also 
heterogeneous. The advances in technology provided important insights into the 
molecular abnormalities underlying AML with normal cytogenetics and those with 
chromosome losses or gains that were previously poor understood (Grimwade et al., 
2016).  
 
Systematic studies of the genomic landscape of AML have generated an extensive 
catalogue of leukaemia genes. The AML biology consists of many different genetic 
alterations in patients that typically have more than one driver mutation. The disease 
evolves over time, with multiple competing clones coexisting at any time (Walter et 
al., 2012). 
 
The molecular landscape of AML in young adults (<60 years) consists of variants in 
genes involved in signalling pathway (FLT3, RAS, KIT, CBL, NF1, and PTPN11), 
epigenetic modifier genes (DNA methylation: DNMT3A; DNA demethylation: TET2, 
IDH1/2, WT1; chromatin regulation: ASXL1/2, PHF6, BCOR, and EZH2), splicing 
factor genes (SRSF2, SF3B1, U2AF1, and ZRSR2), cohesion complex members 
(RAD21, SMC1A, SMC3, and STAG1/2), transcription factor genes CEBPA and 
RUNX1 and, tumour suppressor NPM1 (Grimwade et al., 2016). The same chromatin 
and splicing factors genes are also frequently mutated in high-risk myeloproliferative 
neoplasms and in MDS (Haferlach et al., 2014; Papaemmanuil et al., 2016). 
 
This elucidation of the molecular landscape of AML has already facilitated the 
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identification and development of novel and targeted therapy agents that includes 
novel epigenetic therapies, anti-apoptotic agents, and selective inhibitors of nuclear 
export and immunotherapies that target a number of specific cellular processes such 
as intracellular signalling, transcriptional control, epigenetic regulation, and mRNA 
splicing (Chen et al., 2013). It has been demonstrated how important it is to target an 
early and/or driver mutation as it will be present within all clones for the eradication of 
disease (Fielding et al., 2014). On the other hand, recent studies have shown that 
minimal residual disease assessment using NGS provides a more powerful predictor 
of disease outcome than mutational profile, defining patients at risk of relapse (Klco 
et al., 2015).  
 
The knowledge of the clonal architecture and the role of clonal haematopoiesis in the 
development and prognosis of blood cancers are essential for the development of 
effective therapies. Furthermore, as the complete prognostic significance of additional 
mutations or combinations of mutations is currently unknown, a key challenge will be 
to determine which are the most informative molecular markers that most reliably track 
leukaemic populations irrespective of the recognised clonal heterogeneity, rather than 
pre-leukemic clones that can persist in patients in long-term remission following 
chemotherapy. As consequence, it is necessary to refine and optimise combinational 
knowledge of mutation complement for prognostication along with demographic 
characteristics and type of AML (de novo, secondary or therapy related). Finally, 
correlation of mutational data with genome-wide scale via epigenetic and proteomic 
analysis data sets may also further refine our understanding of AML biology, improve 




1.4 Familial myelodysplasia and/or acute myeloid leukaemia with germline 
predisposition syndromes 
 
Family history of myelodysplasia and/or acute myeloid leukaemia (MDS/AML) is here 
defined as the presence of two or more relatives with bone marrow failure, where at 
least one of them presents with MDS or AML. Familial occurrence of MDS/AML is 
rare, less than 300 families were reported to have mutations in one of known disease 
causing gene (published mutations is listed in Tables A1.1 – A1.9 in Appendix 1). 
Several of these cases occur in the setting of genetic syndromes associated with 
increased risk of developing MDS or AML, including inherited bone marrow failure 
syndromes, such as Fanconi anaemia, severe congenital neutropenia, Shwachman-
Diamond syndrome and dyskeratosis congenita. However, rare familial cases of 
MDS/AML have been reported outside the context of such syndromes who carry 
germline predisposing mutations (Gao et al., 2014). 
 
Genomic investigation of families with MDS/AML has revealed multiple genes that 
when altered predispose to the disease development. Patients who carry mutation 
within these genes often have other concomitant characteristics, particularly in those 
diagnosed in adulthood. Table 1.4 summarises the known genes predispositions to 
inherited MDS/AML.  
 
WHO classification included familial MDS/AML in the myeloid neoplasms with a 
predisposition germline mutational group, which comprises MDS, 
MDS/myeloproliferative neoplasms (MPN), and AML that occur on the background of 
a predisposing germline mutations with the following classification: (1) myeloid 
neoplasms with germline predisposition without a pre-existing disorder or organ 
dysfunction with mutations in CEPBA, (2) myeloid neoplasms with germline 
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predisposition and pre-existing platelet disorders with mutations in RUNX1, 
ANKRD26 and ETV6, (3) myeloid neoplasms with germline predisposition and other 
organ dysfunction with mutations in GATA2, myeloid neoplasms associated with bone 
marrow failure syndromes, myeloid neoplasms associated with telomere biology 
disorders, myeloid neoplasms associated with Down syndrome and JMML associated 
with neurofibromatosis, Noonan syndrome or Noonan syndrome-like disorders (Arber 
et al., 2016). These patients must have a different management and their families 
should get genetic counselling. 
 
In familial neoplasms, mutations are frequently present in the heterozygous state, 
most commonly resulting in loss of function alleles and subsequent haploinsufficiency, 
although gain-of-function mutations have also been reported in GATA2 (Godley, 
2014). 
 
Table 1.4. Genes frequently mutated in familial MDS/AML 
Predisposition genes to familial MDS/AML  
Transcription factor  
RUNX1 Song et al. (1999) 
CEBPA Smith et al. (2004) 
GATA2 Hahn et al. (2011); Ostergaard et al. (2011) 
ANKRD26 Noris et al. (2013) 
ETV6 Zhang et al. (2015) 
  
Cell signaling   
SRP72 Kirwan et al. (2012) 
  
Telomere maintenance  
TERC Kirwan et al. (2009) 
TERT Kirwan et al. (2009) 
  
RNA splicing  






1.4.1 Familial platelet disorder with propensity to myeloid 
malignancy (FPD/AML) 
 
Familial platelet disorder with propensity to myeloid malignancy is an autosomal 
dominant familial MDS/AML syndrome caused by germline mutations in RUNX1, 
which is located on chromosome 21. Besides reports of missense mutation in the 
DNA biding domain, the majority of mutations in this gene are frameshift, nonsense, 
or deletion that result in premature protein truncation, leading to protein loss-of-
function or confer dominant-negative effects to the remaining RUNX1 allele (Sakurai 
et al., 2014). Often, patients with FPD/AML present with life-long mild to moderate 
thrombocytopenia with platelet defects and it can vary even within affected families 
from individuals with a normal platelet count, to severe thrombocytopenia or to 
childhood MDS/AML at the time of diagnosis (Song et al., 1999). The haematological 
malignancies described in FPD/AML patients include MDS, AML, and T-cell acute 
lymphoblastic leukemia (ALL) with 40% lifetime risk to develop MDS or AML and an 
average age at diagnosis of 33 years (Owen et al., 2008). 
 
 
1.4.2 Thrombocytopenia 2 
 
Thrombocytopenia 2 is an autosomal dominant disorder caused by germline 
mutations in the 5’ untranslated region (5’ UTR) of ANKRD26 on chromosome 10. 
These mutations might enhance ANKRD26 expression and dysregulation of 
apoptosis might be the pathogenetic mechanism. (Pippucci et al., 2011). 5’ UTR has 
been described to be involved in transcription regulation and it is important for the 
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regulation of translation of transcripts by differing mechanisms (Cenik et al., 2011). 
Hence, ANKRD26 has a role in transcriptional and translational regulation. 
 
Thrombocytopenia 2 is characterised by moderate thrombocytopenia with or without 
bleeding propensity, similar to FPD/AML (Pippucci et al., 2011). The prevalence of 
thrombocytopenia 2 is not well described and individuals carrying ANKRD26 




1.4.3  Thrombocytopenia 5 
 
Thrombocytopenia 5 is an inherited autosomal dominant MDS/AML predisposition 
syndrome associated with germline missense mutations in ETV6 on chromosome 12. 
These mutations appear to have a dominant negative function, disrupting the nuclear 
localization of the protein and resulting in reduced expression of platelet-associate 
genes. Individuals with germline mutations in ETV6 present with variable degree of 
thrombocytopenia and mild to moderate bleeding tendencies and they are at 
increased risk for all haematological malignancies, including MDS, AML, chronic 
myelomonocytic leukaemia (CMML), B-lymphoblastic leukaemia, and plasma cell 
myeloma (Zhang et al., 2015). It is noteworthy mentioning that ETV6 and DDX41 were 
discovered as familial MDS/AML causing genes in 2015 by Zhang et al. (2015) and 
Polprasert et al. (2015) respectively during the course of this study. DDX41 will be 





1.4.4 Familial AML with mutated CEBPA 
 
Germline heterozygous mutations with high penetrance in CEBPA are the cause of 
familial AML, an inherited autosomal dominant disorder (Smith et al., 2004; Tawana 
et al., 2015). Patients carrying mutations in this gene located on chromosome 19, 
present long-term survival, with median age of AML onset of 24.5 years. They also 
appear to have a significant risk of late AML recurrence and this typically represent 
independent leukaemic episodes, characterised by a unique molecular profile that is 
distinct from that of the preceding tumour (Tawana et al., 2017). Frameshift mutations 
in CEBPA commonly occur in the N-terminal combined with C-terminal in-frame 
insertions or deletions (disrupting the DNA binding or leucine zipper domains) and, 
they are frequently accompanied by mutations in GATA2 or WT1 in familial AML 
(Fasan et al., 2014). 
 
 
1.4.5 Familial MDS/AML with mutated GATA2 
 
GATA2 deficiency is a clinically heterogeneous predisposition to MDS caused by 
germline mutations on chromosome 3. Patients carrying GATA2 mutations are at 
significantly increased lifetime risk of MDS/AML, with a median age at onset of 29 
years and they can present without any haematopoietic or organ system involvement 
prior to the development of MDS or AML. There are two distinct syndromic 





Emberger syndrome is clinically characterised by primary lymphedema, 
cutaneous/extragenital warts, low CD4/CD8 T-cell ratio, and sensorineural hearing 
loss with a predisposition to MDS/AML. The MonoMac syndrome is characterised by 
pulmonary alveolar proteinosis, monocytes, dendritic cells and B/natural killer cell 
deficiencies, leading to the development of atypical mycobacterial or fungal infections, 
and MDS/AML predisposition. Both phenotypes can overlap, and these syndromes 
are considered to be part of the same autosomal dominant genetic disorder with 




1.4.6 Familial aplastic anaemia/MDS with SRP72 
 
Only two families with autosomal dominant MDS and aplastic anaemia (AA) in 
adulthood have been identified to date as a result of germline mutations in the gene 
SRP72. The reported mutations are one missense and one deletion that caused a 
truncated protein. Little is known regarding the lifetime risk or incidence of this unusual 
condition given the rarity of these germline mutations (Kirwan et al., 2012).  
 
 
1.4.7 Bone marrow failure syndromes 
 
Typically, bone marrow failures are a group of disorders presenting in young age with 
characteristic physical features along with bone marrow failure and a predisposition 
to MDS/AML and other cancers. The majority of individuals with bone marrow failure 
syndromes will have syndromic phenotypic abnormalities such as pancreatic 
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dysfunction or multiple congenital anomalies at presentation. Patients with severe 
congenital neutropenia, Fanconi anaemia, Shwachman-Diamond syndrome and 
dyskeratosis congenita are at significantly increased risk for treatment-induced 
malignancies (Dokal & Vulliamy, 2010; Schulz et al., 2012). 
 
 
1.4.7.1 Fanconi anaemia 
 
Fanconi anaemia (FA) is a rare, autosomal recessive or rarely X-linked genetic 
predisposition to bone marrow failure with congenital limb anomalies including absent 
thumbs and other radial ray defects. FA cells are characterised by increased 
chromosomal fragility and breakage when treated with DNA cross-linking agents. 
Patients with FA present with progressive bone marrow failure with pancytopenia, up 
to 30% of familial MDS/AML incidence and there is an increased risk of solid tumours, 
particularly squamous cell carcinomas of the head and neck. Approximately 40% of 
patients with FA lack physical abnormalities associated with the disease and are also 
less likely to develop early-onset bone marrow failure (Rosenberg et al., 2008). 
Furthermore, apparently healthy relatives of a FA patient should be referred for 
genetic counselling and management of solid tumour risks as FA is caused by biallelic 
mutations in the 21 FA complementation groups, FANCA-FANCW. Mutations in 
FANCA is responsible for 70% of FA cases, followed by FANCC with 14%, while 
mutation in the remaining genes of this group account for up to 3% of the cases. 
However, BRCA1, BRCA2, PALB2 and RAD51C are also part of this group and, when 
mutated these genes are associated with autosomal dominant predispositions to solid 
tumour development, mainly ovarian and breast cancer (Bogliolo & Surrallés, 2015; 




1.4.7.2 Dyskeratosis congenita 
 
Patients with dyskeratosis congenita (DC) are at increased risk for bone marrow 
failure, MDS, or AML, solid tumours, and pulmonary fibrosis. DC is a telomere biology 
disorder characterised by very short telomeres and classically by a diagnostic triad of 
dysplastic nails, lacy reticular skin pigmentation, and oral leukoplakia; the median age 
at onset is 37 years. However, these features are not present in all individuals with 
DC and they may or may not develop over time (Dokal, 2011; Tummala et al., 2015). 
Pathogenic germline mutations can be detected in approximately half of DC cases 
and there are 12 known disease genes: DKC1, TERC, TERT, NOP10, NHP2, ACD, 
TINF2, WRAP53, CTC1, RTEL1, PARN and NAF1 (Walne et al., 2013; Walne et al., 
2016). Additionally, germline mutations in TERT and TERC have also been 
associated with idiopathic AA and idiopathic pulmonary fibrosis (Yamaguchi et al., 
2005). 
 
MDS and AML heterogeneity is not only explained by its morphological diversity, but 
also by the increasing number of molecular pathways and hallmarks that participate 
in disease initiation and evolution. The main biological hallmarks in sporadic MDS and 
AML have been well described and include both genomic and epigenomic alterations 
in transcription factors, epigenetic modulators, miRNA, microenvironment and innate 
immunity (Bejar et al., 2011). The most common mutations in these sporadic diseases 
are in epigenetic modifiers (TET2, IDH1/2, DNMT3A, EZH2 and ASXL1) as well as in 
genes involved in spliceosome machinery (U2AF1, SRSF2 and SF3B1) (Shahrabi et 
al., 2016; Cedena et al., 2017) Furthermore, it is well known that inducing 
differentiation and apoptosis of leukaemic blasts by DNA-hypomethylating agents 
such as azacytidine (AZA) and decitabine (DAC), represent well-tolerated alternative 
treatment approaches to most patients with MDS and AML as they are older and 
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exhibit a poor prognosis (Bohl et al. 2018). Clinical responses to AZA and DAC 
support epigenetic alterations as a fundamental pathophysiology in sporadic MDS 
and subsets of sporadic AML (Fenaux et al., 2009; Traina et al., 2014). These 
hypomethylating agents are nucleoside analogs that integrate into DNA and inhibit 
DNA methyltransferases (Saygin & Carraway, 2017), affecting the proliferation of 
malignant cells. (Moudra et al., 2016). 
 
Although mutations in epigenetic genes were not found to cause familial MDS/AML 
so far, some known familial MDS/AML causing genes such as RUNX1, CEBPA and 
TERT have been involved with epigenetic mechanisms in sporadic forms of MDS and 
AML. Additionally, ANKRD26 mutations might have a role in transcriptional and 
translational regulation as it occurs in its 5’UTR. 
 
RUNX1 mutations were observed to be almost mutually exclusive with recurrent 
genetic abnormalities in sporadic AML, and they frequently co-occurred with 
mutations in epigenetic modifiers (ASXL1, IDH2, KMT2A, EZH2), components of the 
spliceosome complex (SRSF2, SF3B1) and STAG2, PHF6, BCOR (Gaidzik et al., 
2016). RUNX1 is also subject to translocations that promotes fusion proteins with 
aberrant transcriptional activities (Loke et al., 2018). The RUNX1-ETO t(8;21) is 
perhaps the most frequent chromosomal translocation associated with AML. The 
translocation creates a fusion protein that consists of N-terminal portion of RUNX1 on 
chromosome 21 and full-length eight-21 (ETO) on chromosome 8, producing the 
chimeric gene RUNX1-ETO. In addition to blocking differentiation, RUNX1-ETO is 
also shown to induce growth arrest in AML cells and leads to the silencing of myeloid 
maturation genes. RUNX1-ETO recruits histone deacetylases and DNMT1 to RUNX1 
DNA binding sites and acts as a potent negative regulator of transcription of the genes 
normally controlled by RUNX1, such as CEBPA. (Buchi et al., 2014). RUNX1-ETO 
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might suppresses endogenous DNA repair in cells to promote mutagenesis, which 
facilitates acquisition of cooperating secondary events. RUNX1 also induces DNA 
demethylation by recruiting DNA demethylation machinery to its binding sites, which 
likely contributes to hematopoietic development (Suzuki et al., 2017). 
 
It is well known that mutations in CEBPA cause cell differentiation inhibition in AML. 
However, Sinha et al. (2015) found that pathogenic somatic variants in CEBPA, WT1 
and IDH2 were found to be genetic drivers of DNA hypermethylation in sporadic AML 
using an integrative analysis of The Cancer Genome Atlas data (Cancer Genome 
Atlas Research Network, 2013) based on Boolean implications.  
 
Genetic and epigenetic regulations of TERT seem to play important roles in 
pathophysiology and clinical outcome in human cancers. The dysregulation of TERT 
in malignant cells can be explained by alteration of the TERT through mutations, DNA 
methylation, histone methylation, histone acetylation, non-coding RNA, and guanine-
quadruplexes (GQ) structures (Zhao et al., 2016). Normal human somatic cells have 
a non-methylated/hypomethylated CpG island within the TERT promoter region, while 
telomerase-positive cells have at least a partially methylated promoter region. 
Chromatin remodelling changes the state of histones present within the TERT 
promoter by influencing the binding of transcription factors. Non-coding RNAs can 
target epigenetic-modifying enzymes, as well as transcription factors involved in a 
post-transcriptional manner by binding to the 3’UTR of TERT mRNA, or by affecting 
the presence of transcription factors responsible for the transcription or repression of 
TERT (Lewis & Tollefsbol, 2016). 
 
The full epigenetic landscape of the TERT promoter region in sporadic AML is 
characterised by the heterogeneous upstream TERT promoter methylation profile 
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with conservative hypomethylated transcription start sites alleles. This distinct 
epigenetic change of TERT promoter implies alteration of the secondary or tertiary 
structure of the TERT promoter region such as CG structures.  These can modify 
configurational interactions with transcription factors and control TERT expression in 
leukaemia cells. GQ structures within the promoters in cancer related genes, such as 
MYC, KIT, KRAS and TERT, lead to down-regulation of gene expression (Zhao et al., 
2016). 
 
Finally, most of germline heterozygous mutations including missense, frameshift, 
nonsense, or deletion resulting in premature protein truncation, that cause familial 
MDS/AML were found in transcription factors genes (5) as well as in telomere 
maintenance (2), cell signalling (1) and RNA splicing (1) genes. Which is in contrast 
with sporadic form of these diseases where the majority of mutations were found in 
epigenetic modifiers and RNA splicing genes. Despite the progress made in the 
comprehension of these haematological malignancies, more study needs to be 
performed to fully characterise the occurrence of these somatic and germline variation 
in the biological and clinical setting. Furthermore, genes that are known to cause 
familial MDS/AML can be associated with complex phenotypes such as GATA2, 
TERC and TERT, or mainly with familial MDS/AML phenotype such as RUNX1, 
CEBPA, SRP72, ANKRD26, ETV6 and DDX41. 
 
Research on inherited forms of MDS/AML allowed the acknowledgement that these 
diseases are more common than initially realised and can frequently be present in 
adulthood, rather than exclusively in childhood. These disorders are heterogeneous 
regarding their underlying genetic mutations, clinical presentations, and progression 
to MDS/AML. However, as a group, they all share the unique requirement for a high 
index of clinical suspicion to allow appropriate genetic counselling, genetic testing, 
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and mutation-specific clinical management (University of Chicago Hematopoietic 
Malignancies Cancer Risk Team, 2016).  
 
 
1.5 Our cohort of families with familial MDS/AML  
 
Over the last 20 years our group has collected a significant number of families (n=115) 
that have two or more individuals with bone marrow failure (AA, MDS or leukaemia) 
with at least one individual who has MDS or AML. At the beginning of this project in 
2014, 12 MDS/AML families had their predisposing genetic variant to the disease 




Figure 1.4. Genetically characterised MDS/AML families. Affected individuals are coloured as 
follows: red: MDS, black: AML, blue: AA, grey: thrombocytopenia, green: other 





Table 1.5. Characterised MDS/AML families with their respective disease causing variant 
Characterised MDS/AML families 
Family Gene Variant Amino acid change 
1 GATA2 c.310 – 311insCC p.L105Pfs*15 
2 TERT c.1892 G>A p.R631Q 
3 TERC c.212 C>G N/A 
4 TERT c.2354 C>T p.P785L 
5 TERC c.309 G>T N/A 
6 SRP72 c.1064 – 1065del p.T355Kfs*19 
7 SRP72 c.620 G>A p.R207H 
8 GATA2 c.121 C>G p.P41A 
9 TERT c.248 G>C p.R83P 
10 GATA2 c.1187 G>A p.R396E 
11 GATA2 c.1061 C>T p.T354M 
12 RUNX1 c.602 G>A p.A201Q 
N/A: not applicable. 
 
 
During this PhD studies, an additional nine families from our familial MDS/AML cohort 
and further 10 families from our DC and idiopathic BMF registries have been 
characterised using WES and targeting sequencing, respectively. Currently there are 
33 MDS/AML families that remain uncharacterised and had whole exome sequencing 






Figure 1.5. Genetically uncharacterised MDS/AML families with WES undertaken. Affected 
individuals are coloured as follows: red: MDS, black: AML, blue: AA, grey: thrombocytopenia, 




1.6 Aims of the project 
 
The overall aim of this project was to identify and characterise disease causing gene 
variants (functional variants such as missense, nonsense, deletions or insertions) that 
can lead to familial MDS/AML in the uncharacterised familial MDS/AML cases using 
whole exome and target sequencing. This includes diagnosis of uncharacterased 
families and/or identification of candidate genes that could be the genetic cause of 
the disease. This work will provide important information for the management of these 
families. 
 
In addition, investigations of these rare families are likely to provide a rare opportunity 
to understand key pathways underlying the susceptibility and the multistep 
progression to MDS/AML and allow the possibility of novel strategies for the 


























The materials and methods described in this chapter are relevant to the results 
chapters 3 to 6 presented in this thesis. All techniques are presented together here 





2.2.1 Patient samples 
 
All samples were part of our international registry of patients with bone marrow failure 
and related diseases. The samples were obtained with informed consent in 
accordance with the Declaration of Helsinki. These studies have received approval 
from the East London and The City Research Ethics Committee. The DNA for each 






Primers were designed in the A plasmid Editor (ApE) software (Biology Labs) to have 
approximately 50% guanine and cytosine content and a melting temperature of 57-
60°C for standard PCR. Genomic and coding DNA sequences used were obtained 
from NCBI - The National Center for Biotechnology Information database 
(https://www.ncbi.nlm.nih.gov/). All primers were synthesised by Sigma-Aldrich and 
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dissolved in sterile water to a stock concentration of 100µM unless stated otherwise. 
Primer sequences can be found in Appendix 2 (Tables A2.1 – A2.7) .   
 
 
2.2.3 Chemicals and reagents 
 
All chemicals and reagents used were of analytical or molecular biology grade and 








2.3.1 DNA quantification  
 
A spectrophotometric analysis was done in all selected samples using ND-1000 
Nanodrop Spectrophotometer V3.7 (Thermo Scientific, MA, USA) to determine the 
average concentrations of DNA. In this spectrophometer, the sample is exposed to 
ultraviolet light at 260nm, and a photo-detector measures the light that passes through 
the sample. The more light absorbed by the sample, the higher the DNA concentration 
in the sample. Furthermore, the purity of DNA can be calculated by the ratio of the 
absorbance at 260 and 280nm (A260/280) that is ~1.8 for pure DNA. 
 
When it was required to detect and quantify small amounts of double stranded DNA, 
Quant-iT™ PicoGreen® dsDNA Assay Kit (Invitrogen, USA) was used as in this 
method there is no interference from contaminants, such as salts, urea, ethanol, 
chloroform, detergents, proteins, and agarose. In this method, DNA concentration is 
measured using fluorescent dye that binds to double-stranded DNA. The fluorescence 
intensity is related to the amount of DNA in the sample. A standard DNA sample at 
100µg/ml provided by the supplier, was diluted to 1:10 and then serially diluted to give 
standard curve samples of 500, 125, 31.25, 7.812 and 1.953ng/µl. PicoGreen master 
mix consisted of 0.3% PicoGreen dye in tris-EDTA (TE) was added to 100µl of the 
standard curve samples and the DNA samples being measured in wells of a 96-well 
plate. FLUOstar Optima microplate reader (BMG Labtech, Germany) was used to 
determine the fluorescence of the samples. The acquired data was then manipulated 




2.3.2 Polymerase chain reaction – PCR 
 
Polymerase chain reaction (PCR) was performed using DNA Tetrad 2 Peltier Thermal 
Cycler (Biorad, USA) as follows: 30ng genomic DNA was amplified by PCR in a total 
volume of 20µl containing 1x Reaction Buffer IV (200mM Tris-HCl pH 8.4, 500mM 
KCl, Thermo Scientific, USA), 2mM MgCl2, 0.5µM forward and reverse primers, 2.5% 
dimethyl sulfoxide (DMSO), 280mM deoxynucleotide triphosphates (dNTPs) and, 
0.02 units/µl of Taq DNA polymerase (Thermo Scientific) were used. A non-template 
control was included in each instance to exclude the possibility of contamination. The 
cycling parameters were: initialization step of 5 minutes at 95°C, 35 cycles of 
denaturation step of 30 seconds at 95°C, annealing step of 30 seconds at 58°C and 




2.3.3 Agarose gel electrophoresis 
 
PCR products were visualised and separated using an agarose gel electrophoresis. 
This consisted of 1.5% agarose in 100ml 0.5x TBE (tris-borate-EDTA) buffer and 
10mg/ml ethidium bromide. Samples were loaded with a 5x loading buffer (3x TBE, 
30% glycerol, 0.3% bromophenol blue) and electrophoresed at 120V in 0.5x TBE 
buffer for approximately 30 minutes. Gels were visualised by transillumination with 





2.3.4 DNA restriction digestion 
 
Restriction digestion of DNA fragments were performed for rolling circle amplification 
reaction in chapter 5. About 0.5-1µg of genomic DNA was double digested with RsaI 
and HinfI for detecting telomeric-circles (T-circles) in our patient samples. Enzymes 
and their corresponding buffers were purchased from New England Biolabs at a 
concentration of 20,000 units/µl. A stated DNA quantity was digested with 20,000 
units of enzyme in 10x reaction buffer made to 100µl with sterilised water. Reactions 
were incubated at 37°C overnight followed by reaction precipitation. The pellet was 
precipitated by adding 10µl NaAcetate (3M, pH 5.2), 200µl 96% ethanol to the 
reaction, they were incubated 30 minutes at -20°C, spun 15 minutes at max speed, 
the pellet was then washed with 70% ethanol. The pellet was resuspended in 15.5µl 
distilled water after being air dried.  
 
 
2.3.5 Rolling circle amplification reaction 
 
A modified rolling circle amplification (RCA) protocol from Zellinger et al. (2007) was 
used in chapter 5 to detect T-circles in DNA from patient samples. It is a molecular 
technique for in vitro rolling nucleic acid synthesis from small single-stranded DNA 
minicircles using highly processive DNA polymerases. Briefly, DNA was digested by 
a frequently cutting restriction enzyme which digests the genomic DNA, but not 
telomeric sequence. T-circles then served as template for RCA using telomere-
specific primers and phi29 polymerase. This leads to a synthesis of ~ 100kb long 
single stranded telomeric molecules. The extension products were separated from 
DNA by alkaline electrophoresis and detected by Southern hybridisation.  
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The RCA primer annealing was performed in 0.2ml PCR tubes as follows (this mix is 
for two parallel reactions: +/- phi29): 
Template DNA: 15.5µl 
10 µM Thio-(C3TA3)3:  2,5µl 
10 x annealing buffer:  2µl 
10 x annealing buffer:  0.2M Tris.HCl pH 7.5 
  0.2M KCl 
  1mM EDTA 
 
These reactions were mixed well, spun down, and denatured for 5 minutes at 96°C in 
the PCR machine (DNA Tetrad 2 Peltier Thermal Cycler, Biorad, USA). Afterwards 
the tubes were again mixed by flicking and incubate at room temperature for 30-60 
minutes.  
 
Following primer annealing (primer sequences can be found in Table A2.1, Appendix 
2), RCA reaction was carried out by first splitting the 20µl of annealed DNA into 2 
tubes for +/- phi DNA polymerase reactions. A premix without enzyme were made, 
9µl of the premix were added per each 10µl reaction and then either 1µl (10 units) 
phi29 DNA polymerase (Thermo Fisher Scientific) or water were added. The reaction 
tubes were vortexed, spun down and, incubated at 30°C for 16 hours. Following the 
RCA the tubes were heated at 65°C in a PCR machine for 20 minutes to inactivate 
the enzyme. The whole reaction was then loaded in a denaturing gel.  
Premix: 
10x phi29 buffer (provided by supplier): 2µl 
2 mM dNTP mix: 2µl 




2.3.6 Alkaline gel electrophoresis 
 
Alkaline gel electrophoresis was carried out according to Sambrook & Russel (2006) 
in chapter 5 as part of the T-circle assay. A 0.8% agarose gel was made by boiling 
1.2g of agarose in 150ml of distilled water. 750µl of 10M NaOH and 300µl of 0.5M 
EDTA was added to the melted agarose after it was cooled down to 55°C as the NaOH 
makes the agarose gel fragile at high temperatures. The agarose gel was then mixed 
well and poured into an electrophoresis tray for 30 minutes before the run. 6x alkaline 
loading buffer (6x gel loading buffer II from New England BioLabs, NEB) 
supplemented with NaOH and EDTA (100µl 6 x LB II + 3µl 10M NaOH + 1.2µl 0.5M 
EDTA) was mixed into the DNA samples and then they were loaded and ran at < 3.5 
V/cm in 1L of fresh 1x running buffer (50mM NaOH, 1mM EDTA pH 8). The gel was 
ran at 25V (2 V/cm) for 16-18 hours.  
 
 
2.3.7 Southern blotting 
 
Southern blotting was performed in chapter 5 as part of the T-circle assay and it is a 
modified method from Ming et al. (1994). After the alkaline gel electrophoresis, the 
gel was incubated in 0.25M HCl (10.8ml concentrated HCl in 500ml distilled water) for 
10 minutes, then denatured by soaking it in denaturation solution (0.5M NaOH, 1.5M 
NaCl) for 30 minutes and neutralised in neutralisation solution (0.5M Tris.HCl pH 7.5, 
1.5M NaCl) for 30 minutes. A regular Southern blotting of the gel onto neutral nylon 




As seen in Figure 2.1, a sheet of nylon membrane was cut to the size of the gel and 
a plastic tray was half filled with the transfer buffer, 20x SSC (saline-sodium citrate) 
buffer. Then, by using a glass plate placed vertically on top of the tray a platform was 
made and covered with a wick made from three sheets of chromatography 3mm paper 
saturated in transfer buffer. The treated gel was carefully placed on the wick platform 
to avoid air bubble formation between the gel and the wick. The gel was surrounded 
with cling film to prevent the transfer buffer from being absorbed directly into the paper 
towels. Again, carefully placed the nylon membrane on top of the gel, avoiding air 
bubbles. Three sheets of chromatography 3mm paper cut to size and saturated in 
transfer membrane, were placed on top of the membrane, avoiding air bubbles. A 
stack of absorbent towels with about 10cm high were placed on top of the 
chromatography 3mm paper. Finally, a glass plate and a weight were placed on top 
of the paper stack. The transfer was performed overnight, and a mark was made on 
the membrane to allow identification of the tracks with a cut in the right bottom. The 
membrane was rinsed with 2x SSC and nucleic acid was fixed to the membrane by 
baking it at 80°C for 2 hours in the hybridisation oven (Amersham Life Science). The 
blot was then hybridised for identification of T-circle formation. The transfer pyramid 






Figure 2.1. Capillary blotting apparatus. 
 
 
2.3.8 Hybridisation and chemiluminescence detection 
 
Hybridisation of Southern blot membrane was performed using TeloTAGGG 
Telomere Length Assay version 9.0 (Roche), a non-radioactive chemiluminescent 
assay to determine telomere length that uses digoxygenin (DIG) label probes. Briefly, 
the blot was prehybridised with DIG Easy Hyb granules provided by the supplier for 
30-60 minutes at 42°C. The prehybridised solution was totally discarded, and the blot 
was hybridised with telomere probe overnight at 42°C with gentle agitation on 
Hybridiser incubator HB-1D (Techne). The blot was then washed with stringent buffer, 
blocked using a 1x blocking solution provided by the supplier for 30 minutes at 15-
25°C with gentle agitation. The membrane was incubated with Anti-DIG-AP working 
solution for 30 minutes at 15-25°C with gentle agitation and then washed with 1x 
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washing buffer. Then the membrane was incubated with 1x detection buffer for 2-5 
minutes at 15-25°C with gentle agitation. Detection buffer was discarded, and excess 
liquid was removed from the membrane. The wet membrane was immediately placed 
with DNA side facing up, on an opened hybridisation bag and very quickly ~40 drops 
of substrate solution were applied to it. The membrane was immediately and carefully 
covered with the second sheet of the hybridisation bag and it was incubated for 5 
minutes at 15-25°C. After sealing the hybridisation bag’s edges, the membrane was 
exposed to X-ray film for 20 minutes at 15-25°C. 
 
 
2.3.9 Gel extraction and purification 
 
The QIAquick Gel Extraction Kit was used for gel extraction and purification. This kit 
facilitates removal of nucleotides, enzymes, salts, agarose, ethidium bromide, and 
other impurities from DNA samples. Briefly, gel bands were removed under UV 
illumination and dissolved in a 3x volume of Buffer GE (agarose). DNA was 
precipitated with 100% isopropanol, applied to a Qiagen spin column and washed in 
Buffer PE and eluted in sterilised water or TE and stored at 2-8°C. Buffers GE and PE 
were provided by the manufacturer. 
 
 
2.3.10 Sanger sequencing  
 
Sanger sequencing was carried out by Barts and the London Genome Centre in 
Chaterhouse Square, London. It was used to validate results from WES and dHPLC 
results that were of interest. Prior to sequencing, PCR products were cleaned-up by 
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incubating 5µl of them with 2µl ExoSAP (0.5% exonuclease I, 10% Shrimp alkaline 
phosphatase) at 37°C for 15 minutes followed by 15 minutes at 80°C to deactivate 
the enzymes. Exo-SAP uses Exonuclease I to degrade residual single stranded 
primers and any extraneous single stranded DNA produced by the PCR.  Shrimp 
alkaline phosphatase hydrolyses any remaining dNTPs from the PCR mix, which 
could interfere with sequencing.  
 
Sequencing was carried out using a BigDye® Terminator Cycle Sequencing V3.1 kit 
(Invitrogen, USA). This kit utilises chain terminating chemistry. A mix is used which 
has a DNA polymerase, normal dNTPs and fluorescently labelled dideoxynucleotides 
(ddNTPs) which lack a 3’-OH group necessary for a phosphodiester bond to form 
between two nucleotides. As a result, when a ddNTP becomes incorporated into the 
DNA, the strand is terminated and the ddNTP can emit a fluorescent signal allowing 
the sequence of nucleotides to be established. The sequencing reaction consists of 
1µl purified PCR product, 0.5µl Big Dye Terminator mix, 2µl 5x buffer and 0.05µM 
primer made to 10µl with water. This reaction mix has 25 cycles of denaturation at 
96°C for 60 seconds, primer annealing for 15 seconds at 58°C and extension for 1 
minute at 60°C. Following PCR a standard salt-ethanol precipitation is performed by 
incubating the sample with 30µl 100% ethanol and 125mM EDTA on ice for 30 
minutes then spinning at 8°C for 30 minutes at 4000rpm. Samples were dried and 
washed in 70% ethanol before spinning again at 4000rpm for 10 minutes. Samples 
were dried before being resuspended in formamide. They were heated to 95°C for 3 
minutes to denature the DNA and the presence of formamide helps to maintain this 





Occasionally, some PCR products were sent directly to Barts and the London 




2.3.11 Analysis of sequencing traces 
 
Chromas Lite (Technelysium) was used to examine quality and observe variants in 
the sequence traces (Figure 2.2). The sequence from traces were aligned using the 
online Basic Local Alignment Research Tool (BLAST, NCBI) to the human genome 
reference sequence hg19. References sequences are obtained from NCBI database 
(http://www.ncbi.nlm.nih.gov) and stored in the A plasmid Editor (ApE) software 









2.3.12 RNA extraction 
 
RNA was extracted from primary and WI38-VA13 (foetal lung fibroblasts) cells 
(chapter 4). Cells were lysed using 1ml TRIzol Reagent (ThermoFisher Scientific). 
TRIzol™ Reagent is a monophasic solution of phenol, guanidine isothiocyanate, and 
other proprietary components which facilitate the isolation of RNA. After lysis, 0.2ml 
chloroform was added and samples centrifuged at 12,000rpm for 15m minutes at 4°C. 
This separates RNA into an upper aqueous layer, distinct from the red lower organic 
layer containing proteins and DNA. The clear aqueous phase was transferred to a 
fresh tube and 0.5ml 100% isopropanol and the RNA was precipitated, incubating at 
room temperature for 10 minutes then spinning at 4°C for 10 minutes to pellet the 
RNA. The pellet was washed in 75% ethanol to remove contaminants and air dried 
before resuspending in water. RNA was stored at 20°C. 
 
 
2.3.13 Reverse Transcriptase PCR 
 
cDNA was synthesised using reverse transcriptase PCR, where random hexamers 
and Superscript III reverse transcriptase (Invitrogen) were used according to the 
manufacturer's protocol. Briefly, up to 5µl RNA was incubated with 50ng of random 
hexamers (Invitrogen), 1µl 10mM dNTPs and sterile water to 10µl at 65°C for 5 
minutes then on ice for 1 minute to denature the RNA. The cDNA was then 
synthesised using a mix of 10x RT buffer, 25mM MgCl2, 0.1M dithiothreitol (DTT), 40 
units/µl RNaseOUT and 200 units/µl SuperScript III Reverse Transcriptase enzyme 
(Invitrogen). Samples were incubated as follows: 10 minutes at 25°C, 50 minutes at 
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50°C, 5 minutes at 85°C before chilling on ice. The cDNA was treated with RNase H 
(Invitrogen) for 20 minutes at 37°C to remove RNA and stored at -20°C. 
 
 
2.3.14 Monochrome multiplex quantitative PCR 
 
In chapters 4 and 5, patient’s telomere length was relatively compared to standard 
DNA in peripheral blood cells using DNA Monochrome multiplex quantitative PCR 
(MMqPCR) described by Cawthon (2009). This method compares the ratio of a 
telomeric PCR product (T) to a single-copy gene (S, T/S ratio). Genomic DNA 
samples were diluted to 50ng/µl in TE and allowed to equilibrate overnight. Samples 
were then diluted to 2ng/µl in distilled water. The reference DNA used for the standard 
curve was diluted to 15ng/µl and then serially diluted to 5.00, 1.67, 0.56 and 1.85ng/µl 
samples for a five-point standard curve. For each sample the final input of genomic 
DNA was 10ng and for the standard curve this was 75, 25, 8.33, 2.78 and 0.925ng. 
10µl of master mix was added to the DNA, this mix consisted of Roche SYBR Green 
Master I reaction mix (Roche Applied Science), telomeric primers at 30µlM each and 
S primers at 6nM each. Therefore, in the same reaction, telomeric primers amplified 
a 79bp telomeric amplicon and S primers amplified a single copy gene amplicon 
(human beta-globin, see Table A2.2, Appendix 2). The cycling parameters were: 
stage 1 consists of an initialization step of 15 minutes at 95°C, in stage 2, two cycles 
of denaturation step of 15 minutes at 94°C, annealing step of 15 minutes at 49°C and 
in stage 3, 40 cycles of denaturation step of 15 minutes at 94°C, annealing step of 15 
minutes at 62°C and an extension step of 15 minutes at 74°C with fluorescent signal 
acquisition for conventional qPCR. These are followed by two steps: an incubation at 
84°C for 15s and an incubation at 88°C for 15s with a second fluorescent signal 
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acquisition. The acquired data was then manipulated in Microsoft Excel to obtain the 
patient’s telomere length. 
 
 
2.3.15 Denaturing high-performance liquid chromatography 
 
Denaturing high-performance liquid chromatography (dHPLC) was used to scan 
variants in known disease causing genes and candidate genes in chapters 3 and 6. 
DNA fragments generated by standard PCRs (primer sequences can be seen in 
Tables A2.3 – A2.6, Appendix 2) were partially denatured at an ideal temperature in 
the range of 50–70°C, mixed pair wise, and scanned for variants by denaturing high-
performance liquid chromatography on a Transgenomic Wave DNA fragment analysis 
system (Glasgow, UK). Any fragments showing abnormal elution patterns were re-
amplified and the variant confirmed by forward and reverse Sanger sequencing.  
 
This technique employs the DNASep® cartridge that contains polymeric sorbent with 
alkylated nonporous polystyrene-divinylbenzene (PS-DVB) copolymer microspheres 
for high performance nucleic acid separations. Homoduplexes and heteroduplexes 
are formed from two amplified DNA fragments with different nucleotide sequences 
after denaturing and gradual annealing processes. More than one peak are present 
on the chromatogram because heteroduplexes and homoduplexes have different 
retention times due to less helical fraction in heteroduplexes (Figure 2.3) (Oefner 
& Huber, 2002).  
 
dHPLC method is capable of analysing accurately nucleic acid in a high resolution 
and is sufficiently sensitive for the reliable detection of nearly 100% of DNA sequence 




Figure 2.3. Denaturing high pressure liquid chromatography. This method can reveal single 
nucleotide variation through comparison of two DNA fragments by denaturing and reannealing 
the samples, then detecting the resulting duplex products. A. Reannealing of two identical 
DNA fragments forming a homoduplex chromatography elution pattern shown by the blue 
arrow. B. Reannealing of two different DNA fragments forming a heteroduplex chromatography 









2.3.16 Whole exome sequencing  
 
Whole exome sequencing (WES) was undertaken on a total of 42 uncharacterised 
families with familial MDS/AML to identify disease causing genes during the course 
of this project. Of these, 8 families were processed by myself using Nextera Rapid 
Capture Exome and Expanded Exome Enrichment kit to prepare the libraries and the 
remaining samples were done by Dr Amanda Walne (Centre for Genomics and Child 
Health, Blizard Institute). WES was undertaken on multiple unrelated individuals from 
these families and when available, distantly affected individuals of the same family 
were also sequenced. Once a variant in a candidate gene of interest was found, 
dHPLC was used to screen additional families from our cohort for that specific gene. 
Abnormal patterns of elution were validated through Sanger sequencing.  
 
 
2.3.17 Nextera library preparation (enrichment of exonic fragments)      
 
A library of DNA was built and amplified (library enrichment), using the Nextera rapid 
capture enrichment kit (Illumina, UK). DNA was fragmented and adapter sequences 
(specific oligonucleotides) were added onto the ends of those fragments. Once 
constructed, these libraries were clonally amplified in preparation for sequencing 
(Metzker, 2010; Grada & Weinbrecht, 2013). 
 
The Nextera library preparation kit uses modified transposons for cleaving and adding 
adapter sequences onto DNA template to generate indexed sequencing libraries that 
can be carried through enrichment for targeted sequencing applications (Figures 2.4 




Figure 2.4. Sample preparation. P5 and P7: adaptors for cluster generation generated for 
sequencing; Index 1 and Index 2: adaptors for identification of the DNA library after 
sequencing. Schematic illustration of the steps of sample preparation for whole exome 




The success of Nextera enrichment depends on using an accurately quantified 
amount of input DNA, adding too much of material can lead to undertagmentation and 
likewise adding to little can lead to overtagmentation. To achieve consistent DNA 
quantification is important to avoid UV absorbance methods. It is recommended that 
the Nextera library prep to have an optimal size range within 200bp to 1kb. Larger 
fragments cluster inefficiently in the flow cell leading to lower than expected output. In 
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addition to excess DNA input, enzymatic inhibitors such as EDTA, detergents, 
proteins and phenol can also lead to undertagmentation. When little DNA input is 
added to the prep reaction, an overtagmentation can occur and it means that the DNA 
fragment is over cleaved. The clean up step is designed to remove fragments smaller 
than 200bp, so shorter DNA fragment will be removed resulting in lower unknown 




2.3.18 Tagmentation of genomic DNA and first PCR amplification 
 
50ng of genomic DNA with a concentration of 5ng/µl was tagged and fragmented by 
Nextera transposome. The Nextera transposome simultaneously fragmented the 
genomic DNA and added adapter sequences to the ends allowing amplification by 
PCR. Following clean up, the purified tagmented DNA was amplified by a short PCR 
program of 10 cycles (Figure 2.4). The cycling program was as follows: 72°C for 3 
minutes, 98°C for 30s, 10 cycles of denaturation step of 10s at 98°C, annealing step 
of 30s at 60°C and an extension step of 30s at 72°C, a final elongation of 5 minute at 
72°C and finally, held at 10°C.  
 
Indexes needed for sequencing (indexes 1 and 2) as well as common adaptors 
required for cluster generation (P5 and P7) were added during the tagmented DNA 





2.3.19 First hybridisation and first capture 
 
After the PCR clean-up, the DNA library was denatured, and the first hybridisation 
was performed (Figure 2.5 and 2.6). In this process the denatured DNA library was 
mixed with capture probes to targeted regions of interest. Following the binding of the 
probes to their specific region (Figure 2.6), streptavidin beads captured the probes 
hybridised to the targeted regions of interest (Figure 2.7). Two heated washes 
removed non-specific binding from the beads. The enriched library was then eluted 
from the beads (Figure2.8) and prepared for a second round of hybridisation, then 




Figure 2.5. Denaturation of double-stranded DNA library. Adaptors and indexes not shown, 
see Figure 2.4. Schematic illustration of the steps of sample preparation for whole exome 







Figure 2.6. Hybridisation of biotinylated probes to targeted regions. Schematic illustration of 
the steps of sample preparation for whole exome sequencing using Illumina Nextera Rapid 




Figure 2.7. Enrichment using streptavidin beads. Schematic illustration of the steps of sample 
preparation for whole exome sequencing using Illumina Nextera Rapid capture Exome Kit 






Figure 2.8. Elution of the enriched library from beads. Schematic illustration of the steps of 
sample preparation for whole exome sequencing using Illumina Nextera Rapid capture Exome 
Kit (adapted from http://www.gtbiotech.com.tw). 
 
 
2.3.20 Targeted resequencing – design of probes 
 
The targeted resequencing in chapters 4 and 5 was performed using the Illumina 
Truseq Custom Amplicon (TSCA) kit by Birmingham Women's NHS Foundation Trust 
in Birmingham, UK. TSCA permits to focus on genomic regions of interest through 
sequencing of customised amplicons. The Illumina Design Studio software 
(https://designstudio.illumina.com) was used to design the TSCA oligonucleotide 
probes. When the coordinates of the genomic region of interest is logged in this 
software, it is divided into ~250bp target regions and the probe design is automatically 
performed by using an algorithm that considers a range of factors, including GC 
content, specificity, probe interaction, and coverage. Probes are given estimated 
success scores and it can be filtered with user-defined tags, and then added to, or 
removed from, the design to improve coverage (the gene panel can be seen in Table  
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A3.1, Appendix 3). 
 
 
2.3.21 Targeted resequencing library preparation 
 
Libraries containing the target regions were prepared for sequencing for each DNA 
sample and subjected to a clean-up and normalisation process following the protocol 
of the Illumina TSCA kit. The first step for library prep hybridisation of the costumed 
probes was to add 150ng of genomic DNA input per sample, 5µl of the customised 
probes and a hybridisation buffer provided by the manufacturer. These samples were 
incubated at 95°C for 1 minute, cooled slowly for 80 minutes to 40°C to denature 
double stranded DNA and allow the binding of the probes to their specific DNA 
fragment (Figure 2.9). The second step is the extension/ligation, in which a DNA 
polymerase adds bases from probe 1 and then extends all the way down the 
downstream probe. A ligase comes in and finishes the job by ligating the extended 
piece to the downstream probe. This fills the gap between the two probes, 
synthesising a strand complementary to the genomic DNA. Samples were incubated 
for 45 minutes at 37°C with an extension ligation mix provided by the manufacturer 
for this extension/ligation to happen. The amplicons are ready after the ligase fills the 
gap. 
 
The last step is PCR, when the indexes and the oligonucleotides complementary to 
the flow cell are added and finally the whole fragment is amplified. The probes have 
complementary sequences to the genomic DNA allowing them to bind either side of 











A PCR reaction is carried out after the samples are denatured using 50mM NaOH, 
this reaction amplifies the single stranded products using primers complementary to 
the probes. Six base pair index sequence is used to tag the amplicons of an individual 
and it is incorporated into the primers which also contain a sequence complementary 
to an oligonucleotide on the flow cell for sequencing. This is similar to the adapters 
P5 and P7 seen in Figures 2.4 and 2.9, used in the preparation of samples for exome 
sequencing, as described in section 2.3.18. Extension/ligation product, PCR master 
mix, primers and TruSeq DNA polymerase provided with the Illumina kit were used 
for the PCR reaction. This PCR amplification was carried out under the following 
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conditions: initialization step of 3 minutes at 95°C, 23 cycles of denaturation step of 
30 seconds at 95°C, annealing step of 30 seconds at 66°C and an extension step of 
60 seconds at 72°C and finally, a final elongation of 5 minutes at 72°C.  
 
Magnetic AMPure beads were used to enrich the amplicon library. They bind to DNA 
fragments of a preferred size (≥200bp), this is based on the ratio of DNA to beads 
(1:1). Samples were cleaned up from small unbound fragments of DNA by placing 
them on a magnetic stand. The amplicon library was removed from the beads with an 
elution buffer provided by the manufacturer. Each library has to have an equal quantity 
of DNA to ensure a good quality of the sequencing, for that libraries for each individual 
were normalised using a magnetic library beads provided by the manufacturer as they 
bind to a specific number of DNA. The beads were mixed and added to each DNA 
library and incubated for 30 minutes on a microplate shaker at 1800rpm. During this 
process the beads bound to DNA leaving excess in solution. Samples were placed 
on a magnetic stand and the excess DNA washed away. The library bound to the 
beads was removed using 0.1N NaOH freshly made. This solution denatures the DNA 
resulting in single stranded libraries which were mixed with a storage buffer provided 
by Illumina.  
 
The libraries for each individual were pooled into a single tube. The amplicons of each 
individual are distinguishable when pooled by the indices that were added to each 
amplicon in the PCR amplification step. The pooled library was denatured by 
incubating at 96°C for 2 minutes to break any bonds within and between fragments, 
removing hairpin structures to ensure the DNA remained single stranded and 
linearized. It was then immediately placed in an ice-water bath for 5 minutes. The 




2.3.22 Sequencing of exome library 
 
Nextera Rapid Capture Kit was used for the preparation of exome libraries that were 
sequenced on the NextSeq 550 System at University College London while TSCA 
library was sequenced by Birmingham Women's NHS Foundation Trust in 
Birmingham, UK. 
 
Sequencing occurs on a flow cell which is a glass slide with lanes and clustering is 
the first step in which each fragment is isothermally amplified. Each lane has a 
channel coated with a lawn, composed of two types of oligos (shown as P5 and P7 in 
Figures 2.4 and 2.9). These are complementary to the adapters ligated to the ends of 
each DNA fragment during sample preparation (Figure 2.10). Single stranded DNA 
fragment can therefore hybridise to one of the oligos when the prepared samples are 
added to the flow cell. A complementary strand is synthesised by a polymerase 
enzyme and then the double stranded fragment is denatured, and the original 






Figure 2.10. Schematic illustration of the cell flow and DNA fragment prepared for sequencing. 
Adapters such as indices and regions complementary to the cell flow oligos were added to the 




The strands are clonally amplified through bridge amplification. In this process the 
strand folds over and the adapter region hybridises to the second type of oligo on the 
flow cell. This forms a single stranded bridge as polymerases generate the 
compliment strand. This is denatured to give two single stranded fragments which can 
form separate bridges and undergo bridge amplification for millions of time, resulting 
in clonal amplification of all the fragments (Figure 2.11). The clusters were sequenced 
using sequencing-by-synthesis, a method based on reversible dye-terminators that 





Figure 2.11. Schematic illustration of bridge amplification and generation of clonal clusters of 




2.3.23 Variant calling 
 
The raw data generated from NGS is processed to remove adapter sequences and 
low-quality reads and then it is aligned to a reference sequence or assembled de novo 
(Pop & Salzberg, 2008) as described below.   
 
Variant calling of exome data was performed by our collaborator Dr Vincent Plagnol 
(Genetics Institute, University College London). WES reads were de-multiplexed and 
Novoalign version 2.08.03 (Novocraft Technologies) was used to align the raw fastq 




Figure 2.12. Schematic illustration of data analysis. Sequences of pooled sample libraries are 
separated by the unique indices introduced in the sample preparation. Reads for each sample 
are locally clustered and forward and reverse reads are paired creating contiguous sequences. 
These contiguous sequences are aligned to the reference genome for variant identification. 




After binary alignment map (BAM) files were generated, duplicate reads were 
removed using Picard tools MarkDuplicates. Each sample had a genomic variant call 
format (gVCF) file containing the variant calling that was performed using the 
haplotype caller module of Genome Analysis Toolkit (GATK- 
https://www.broadinstitute.org/gatk, version 3.1-1). The individual patient gVCF files, 
in combination with UCL-exomes consortium that covers 2,500 clinical exomes, were 
combined into merged VCF files for each chromosome containing on average 100 
samples each. The final variant calling was performed using the GATK Genotype 
GVCFs module jointly for all samples (cases and controls). Variants quality scores 
were then re-calibrated according to GATK best practices separately for indels and 
single nucleotide polymorphisms (SNPs). Resulting variants were annotated using 
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ANNOVAR based on Ensembl data. Candidate variants were filtered based on 
function (non-synonymous, presumed loss-of-function or splicing) and minor allele 
frequency of < 0.5% in our internal control group, as well as the National Heart, Lung, 
and Blood Institute (NHLBI - https://www.nhlbi.nih.gov/) exome sequencing dataset. 
Splice variants were flagged within 5bp of the exon-intron junction. All relevant 
variants identified were validated by Sanger sequencing on a 3130xl Genetic Analyzer 
with a BigDye Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems) (Tummala 
et al., 2015). 
 
 
2.3.24 Mammalian cell culture 
 
Primary and WI38-VA13 cell lines have been used in to make cDNA in chapters 4 and 
5. These lines are adherent and were cultured in Dulbecco’s Modified Eagle Medium, 
high glucose ClutaMAX (DMEM, ThermoFisher Scientific) which was supplemented 
with penicillin (100units/ml) streptomycin (100ug/ml) and 10% foetal calf serum (Life 
Technologies). Cells were cultured in humidified conditions at 37°C with 5% CO2. 
Cells were passaged 1 in 10 when they reached 90% confluence by removing growth 
media, washing in 1x phosphate buffered saline (PBS) and applying 0.25% Trypsin-
EDTA for ~3 minutes. This allows cells to detach from the flask. DMEM was added to 
neutralise the reaction and the cells were pelleted, washed in PBS and seeded as 





2.3.25 Polyacrylamide gel electrophoresis and Western blotting 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blotting were used to visualise specific proteins from lysates in chapter 5. 
Lysates were denatured in a sample loading buffer (2% SDS, 5% DTT, 0.002% 
bromophenol blue, 10% glycerol and 62.5mM Tris-HCl, pH 6.8) at 90°C for 5 minutes 
and loaded onto a 4-12% bis-tris polyacrylamide gradient gel (Invitrogen) alongside a 
10-250kDa protein size marker (Kaleidoscope Pre-stained Protein Standard, BioRad). 
Samples were run at 150V for ~90 minutes in Invitrogen NuPAGE MES SDS Running 
buffer (50mM MES - 2-ethanesulfonic acid, 50mM Tris base, 0.1% SDS, 1mM EDTA, 
pH 7.3) to separate proteins by size. Western blotting was performed using a 
WesternBreeze Chemiluminescent Kit (Invitrogen). Proteins were electrophoretically 
transferred onto a polyvinylidene difluoride (PVDF) membrane which was blocked for 
30 minutes in 10% bovine serum albumin (BSA) – based in tris-buffered saline 
supplemented with Tween-20 (TBS-T). The membrane was washed thoroughly 
before incubating with a primary antibody (against the protein of interest) in 3% BSA 
in TBS-T overnight at 4°C with gentle shaking. The primary antibody was removed, 
the membrane was washed in 1x PBS and the protein visualised using a secondary 
antibody (which targets the primary) conjugated to alkaline phosphatase. The 
chemiluminescent agent CDP-Star was applied which is dephosphorylated by alkaline 
phosphatase at the site of the protein on the membrane. This forms a metastable 
intermediate molecule that emits light as it decomposes. This is detected using X-ray 





2.3.26 In silico analyses  
 
Throughout chapters 3 to 5, in silico analyses were performed to investigate genetic 
variants and predict their biological impact. Eight databases were searched for 
specific information including: National Centre for Biotechnology Information - NCBI 
(https://www.ncbi.nlm.nih.gov/) and Ensembl (https://www.ensembl.org/) where the 
reference coding DNA and genomic DNA sequences were obtained from; Genome 
Bioinformatics Site (https://genome.ucsc.edu/) from University of California Santa 
Cruz (UCSC) was used to view DNA sequence and exon locations; The Exome 
Aggregation Consortium - ExAC (http://exac.broadinstitute.org/) was consulted to 
verify the minor allele frequency of relevant variants; Polyphen-2 (Adzhubei et al., 
2013; http://genetics.bwh.harvard.edu) and MutationTaster2 (Schwarz et al., 2014; 
http://www.mutationtaster.org/) web-based softwares were used to evaluate the 
pathogenicity of a variant; ClustalW2 Multiple Sequence Alignment program 
(https://www.ebi.ac.uk/Tools/msa/clustalw2/) was used to investigate the 
conservation of amino acid residues and finally, UniProt (http://www.uniprot.org/) was 














Variants identified in known disease genes 









Whole exome sequencing is a diagnostic approach for the identification of molecular 
defects in patients with suspected inherited disorders and a powerful resource for 
scientific discoveries. In this chapter we describe the families with MDS/AML from our 
cohort that were characterised during the course of these studies with variants in the 
known disease genes associated with familial MDS/AML and related disorders, 
including Shwachman-Diamond syndrome, Fanconi anaemia and Wiskott-Aldrich 
syndrome. However, many families in our cohort remain uncharacterised. This 
highlights the marked genetic heterogeneity of familial MDS/AML and suggests that 
further unknown genes are involved in the development of MDS/AML. Future studies 
will be necessary to determine the full spectrum of this genetic heterogeneity, reveal 
new insights to the biology of these diseases and help guide clinical management.    
 
 
3.1.1 Genetically uncharacterised familial MDS/AML patients 
 
At the beginning of these studies in 2014, seven genes (RUNX1, CEBPA, TERC, 
TERT, GATA2, SRP72 and ANKRD26) had been identified as predisposing to familial 
MDS/AML. Two other genes (DDX41 and ETV6) also associated with this disease 
were identified in 2015. Since 2014, nine MDS/AML families were genetically 
characterised using WES in this study. Of these, seven will be discussed in this 






Rare germline variants likely to be damaging were identified in the known familial 
MDS/AML causing genes RUNX1, TERT, and GATA2 and also in genes known to 
cause blood related disorders including FANCA, SBDS, and WAS, in a total of seven 
families with MDS/AML (Figure 3.1). Segregation analysis were performed when DNA 




Figure 3.1. Seven characterised families with MDS/AML from our cohort. The altered disease 
causing gene is indicated below each family. Affected individuals are coloured as following 




3.2.1 Variants identified in previously known familial MDS/AML 
causing genes 
 
3.2.1.1 Variants identified in RUNX1  
 
The core binding factor (CBF) is a transcriptional regulator complex composed of α 
and β subunits. Runt related transcription factor 1 (RUNX1), runt related transcription 
factor 2 (RUNX2) and runt related transcription factor 3 (RUNX3) code for the α 
subunits while CBFβ codes for the β subunits. The α subunits bind directly to the DNA 
in the regulatory regions of their targets and the β subunits stabilize the RUNX-DNA 
complex by interacting with the α subunits (Huang et al., 2001). Germline 
heterozygous variants, including nonsense, missense, deletion, frameshift throughout 
the gene and gene deletion or duplication in RUNX1 cause familial platelet disorder 
with propensity to myeloid malignancies (MDS, AML and T-cell ALL). The proposed 
mechanisms that underlie progression to leukaemia in RUNX1 are haploinsufficiency 
for tumour suppression, dominant-negative effects on normal RUNX1 function, 
acquisition of de novo variant in the wild type allele, and acquisition of cooperating 
variants (Jongmans et al., 2010). This disorder is an autosomal dominant syndrome 
characterised by thrombocytopenia and platelet abnormalities that typically can 
develop into AML (FPD/AML) (Owen et al., 2008). In addition, it is also known that 
chromosomal translocations and somatic variants in RUNX1 have been associated 
with several types of sporadic leukaemia and MDS. RUNX1 protein (Figure 3.2A) is a 
transcription factor that regulates enhancers and promoters of many haematopoietic 
genes and it is involved in the development of normal haematopoiesis (Hamadou et 




Here we describe a germline deletion of 162kb in RUNX1 in the index case (II:3, 
Figure 3.2B) of family FML053 and his brothers (II:1 and II:5, Figure 3.2B). The index 
case (II:3, Figure 3.2B) presented with T-cell ALL when he was 10 years old and died 
at age 22 a year after the progression of the disease into AML at age 21 years. All 
siblings had altered platelet aggregation. His elder brother (II:1, Figure 3.2B) had AML 
at age 10 years and his youngest brother (II:5, Figure 3.2B) had mild 
thrombocytopenia. Comparative genomic hybridization-array (CGH-array) analysis 
performed by another group from Hospital das Clínicas da Faculdade de Medicina de 
São Paulo (Brazil) where these samples came from, revealed the deletion in RUNX1, 
chromosome 21q22.12 in Human Genome Issue hg18 (chr21:35,197,917-
35,360,669del). This deletion of 162,752bp of chromosome 21 (NCBI36/hg18) 
affected exons 1 and 2 of RUNX1, outside the cluster region of the Runt Homology 
domain and the transactivation domain (see in Appendix 4, Figure A4.1) and the 
region of 1,097,908bp just before RUNX1. This region included NR_073512 (RUNX1 
processed transcript that do not contain an open reading frame – Ensemble - 
https://www.ensembl.org) and the SET domain-containing protein 4 (SETD4) located 
in the Down syndrome critical region (Jiang et al., 2015). SETD4 encodes a histone 
lysine methyltransferase which is involved in breast carcinogenesis.  SETD4 
knockdown in breast cancer cell lines significantly suppressed their proliferation and 
delayed the G1/S cell cycle transition without affecting apoptosis (Faria et al., 2013). 
To determine the breakpoint location of this deletion in RUNX1, several combinations 
of forward and reverse primers located on either side of the deletion were made with 





Figure 3.2. Characterisation of the RUNX1 germline variant in family FML053. A. Schematic 
of RUNX1 protein (XP_011528068.1). B. Affected individuals are coloured as following black: 
AML and grey: thrombocytopenia. The arrow highlights the index case. The heterozygous 




Of additional interest, a frameshift deletion of 21bp in the domain region of RUNX1 
(c.233-254del) was identified in the index case (II:1, Figure 3.3A) of family FML007 





Figure 3.3. Example of a somatic RUNX1 variant in exon 3. A. Family FML007 with acquired 
RUNX1 deletion. Affected individuals are coloured as following black: AML, blue: AA and grey: 
thrombocytopenia. The black arrow highlights index case. The heterozygous genotyping is 
denoted as (+/-). B. Sanger sequence chromatogram, red arrow shows the variant in RUNX1. 







This variant is likely to cause loss of function, however it was found in 20% of the cells 
according to the peak of the traces from Sanger sequencing compared to the wild 
type sequence (Figure 3.3B). This observation raises the question as to whether this 
is a germline variant, since a germline variant would be expected to account for ~50% 
of the signal. Sanger sequencing done in DNA from fibroblasts confirmed that the 
variant c.233-254del is acquired and it is notable that acquired variants in RUNX1 are 
found in up to 32% of de novo cases with AML (Liew & Owen, 2011). This finding 
highlights the importance of identifying whether a variant is germline or somatic in the 
first instance. It also shows further studies are needed to characterise this family. 
 
 
3.2.2 Variants identified in genes associated with complex 
phenotypes 
 
3.2.2.1 Variants identified in GATA2 
 
GATA family consists of six zinc-finger transcription factor proteins that play essential 
roles in regulating transcription of genes involved in the development of many cell 
types, including haematopoietic, cardiac, and endodermal lineages. GATA1 (GATA 
binding protein 1), GATA2 (GATA binding protein 2) and GATA3 (GATA binding 
protein 3) are essential for normal haematopoiesis, and alterations in these genes 
lead to a variety of blood disorders. Germline variants in GATA1 cause sex-linked 
recessive forms of inherited thrombocytopenia and dyserythropoietic anaemia 
(Crispino & Weiss, 2014) and acquired variants in this gene are associated with 
transient abnormal myelopoiesis and AML associated with Down syndrome 
(Wechsler et al., 2002). Germline variants in GATA2 are responsible for GATA2 
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deficiency syndrome, while acquired variants are associated with sporadic forms of 
MDS and AML (Shiba et al., 2014; Collin et al., 2015). GATA2 expression is essential 
for maintenance of haematopoietic stem cells as it activates GATA1, which drives the 
differentiation of these stem cells into erythroid/megakaryocytic lineage (Grass et al., 
2003). Germline variants in GATA3 are responsible for the syndrome of 
hypoparathyroidism, deafness, and renal anomalities (Van Esch et al., 2000) and 
somatic variants are seen in breast cancer and ALL (Perez-Andreu et al., 2013; Ping 
et al., 2016). GATA4, GATA5 and GATA6 are involved in heart formation, and 
germline variants are associated with congenital heart disease (Peterkin et al., 2005). 
 
GATA2 deficiency syndrome is an autosomal dominant bone marrow failure disorder 
with systemic features caused by germline heterozygous variants in the gene GATA2 
causing a reduction of its expression consistent with this disorder being associated 
with haploinsufficiency of GATA2 (Collin et al., 2015). This disorder presents variable 
clinical manifestations, including many other predisposing syndromes to MDS/AML 
such as familial MDS/AML, Emberger syndrome, MonoMAC syndrome, and a range 
of bone marrow failures (Hahn et al., 2011; Hsu et al., 2011; Ostergaard et al., 2011; 
Dickinson et al., 2011). Emberger syndrome as described previously, is characterised 
by primary lymphedema in the lower extremities and genitals, MDS with predisposition 
to develop into AML, cutaneous warts, and sensorineural deafness. Emberger 
syndrome can be inherited in an autosomal dominant manner with incomplete 
penetrance and it can also occur sporadically (Ostergaard et al., 2011). The 
MonoMAC syndrome is characterised by severe monocytopenia and severe 
infections with nontuberculous Mycobacteria, typically M. avium complex (MAC) and 
may present with natural killer cell and B-cell lymphocytopenia, fungal infections, 
pulmonary alveolar proteinosis, and severely decreases dendritic cells, and 
predisposition to MDS/AML or chronic myelomonocytic leukaemia (Vinh et al., 2010).  
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GATA2 variants are typically loss of function with no genotype-phenotype correlations 
(Hyde & Liu, 2011). Several families with GATA2 variants with highly penetrant 
autosomal dominant inheritance have been described with no distinguishing 
phenotypic abnormalities other than early-onset familial MDS/AML (Hahn et al., 
2011). An acquired variant in ASXL1 frequently occur and monosomy 7 is the most 
commonly associated cytogenetic finding although trisomy 8 and trisomy 21 also may 
emerge (Spinner et al., 2014). Furthermore, the prognosis after the development of 
MDS/AML is usually poor (Churpek et al., 2015). 
 
We have identified two loss of function variants in GATA2 in two families from our 
cohort. In family FML026 (Figure 3.4), a stop gain variant in GATA2 (c.1084 C>T; p. 
R362*) was identified in the index case (II:1, Figure 3.4A) who developed MDS at 36 
years of age. She had congenital deafness, trisomy 8, had meningitis at age of 10 
years, vulval cancer and fever with no apparent infection. Her brother (II:2, Figure 
3.4A) had MDS and died following matched unrelated donor for monosomy 7. This 
novel nonsense variant is located in the highly conserved zinc finger 2 DNA binding 
domain (Figure 3.4 B and C) and causes truncation of the protein. As GATA2 plays 
an essential role in regulating transcription of genes involved in the development and 
proliferation of haematopoietic and endocrine cell lineages (Gao et al., 2014), it is 





Figure 3.4. Characterisation of GATA2 variant in exon 6. A. Family FML026 with GATA2 
variant. Affected individuals are coloured in red indicating MDS. The black arrow highlights 
index case. The heterozygous genotyping is denoted as (+/-). B. Sanger sequence 
chromatogram, red arrow shows the variant in GATA2. C. Schematic showing the position of 
the variant in GATA2 protein (NP_116027.2). 
 
 
The second GATA2 variant (c.630_643del, p.K212Tfs*65) was identified in family 
FML052 (Figure 3.5). The proband (II:3, Figure 3.5A) had MDS with lymphedema at 
age 16 years, however there was no family history. This GATA2 14bp deletion (Figure 
3.5B and C) is likely to be de novo (spontaneously arising variants that can be passed 
to the next generation) and a pathogenic variant as the protein would possibly lose its 
function. GATA2 deficiency syndrome often explains sporadic cases of bone marrow 
failure, in the absence of a family history, arising from de novo germline GATA2 




Figure 3.5. Characterisation of GATA2 variant in exon 4. A. Family FML052 with GATA2 
variant. Affected individuals are coloured in red indicating MDS. The arrow highlights the index 
case. The genotyping is denoted as follows: wild-type (+/+) or heterozygous (+/-). B. Sanger 
sequence chromatogram, red arrow shows the variant in GATA2. C. Schematic showing the 




3.2.2.2 Variant identified in TERT  
 
Telomerase reverse transcriptase (TERT) gene is located on chromosome 5 and 
encode a protein of 1,132 amino acids, which is the catalytic subunit of telomerase. 
Telomerase is a ribonucleoprotein complex that consists of the protein TERT and its 
integral RNA subunit telomerase RNA component (TERC). It maintains the telomeres, 
which are essential structural elements that seal and protect the ends of 
chromosomes from recombination and end-to-end fusion. In normal somatic cells, 
telomeres gradually shorten after successive cell division, resulting in senescence 
(Gomez et al., 2012). Regulation of TERT impacts on telomerase activity and it is 
considered to have a critical role in tumour formation (Mosrati et al., 2015). Impaired 
telomerase activity and extremely short telomeres induce chromosomal instability, 
causing bone marrow failure, fibrosis of the lungs and liver, and tumour formation 
(Calado et al., 2012). 
 
High TERT expression is observed in about 90% of cancer cells that typically have 
high telomerase activity, protecting them from proliferation arrest, senescence and 
apoptosis (Hanahan & Weinberg, 2011). The dysregulation of TERT expression in 
these cells is a result from alteration of the TERT structure by variants, epigenetic 
modifications or aberrant chromatin environments (Zhao et al., 2016) and these are 
associated with melanoma, gliomas and haematological malignancies. Two somatic 
variants (228C>T and 250C>T) in the promoter region of TERT were reported at 
positions -124 and -146 base pairs upstream of the TERT translation start site in 
melanomas (Horn et al., 2013; Huang et al., 2013). Each variant independently 
generates a novel E-twenty-six (ETS) transcription factor biding site (GGA/T) and has 
been shown to increase the transcriptional activity of the TERT promoter (Killela et 
al., 2013). TERT promoter variants occur frequently in several tumours, including 
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gliomas, liposarcomas, urothelial carcinomas and hepatocellular carcinomas (Huang 
et al., 2015). Haematological malignancies are not reported to carry these variants in 
TERT promoter regions but display enhanced telomerase activity and shortened 
telomeres (Mosrati et al., 2016). However, abnormal hypermethylation of CpG islands 
in a variety of gene promoters is the hallmark epigenetic changes in both AML and 
MDS (Cancer Genome Atlas Research Network, 2013). Zhao et al. (2016) analysed 
the methylation status of the TERT promoter region and identified a distinct epigenetic 
landscape of the TERT promoter region in patients with AML and MDS/AML. In their 
studies, haematopoietic cell lines presented with a highly methylated upstream region 
and a hypomethylated region around the transcription start site. Furthermore, CpG 
methylation rates were much higher in the cell lines than their corresponding primary 
leukaemic cells. Primary cells and their cell lines displayed a trend of increasing 
methylation intensity toward the 5’ end while the regions around the transcription start 
site remained unmethylated in primary cell populations and relatively hypomethylated 
in the cell lines. These results demonstrated that methylation profiling of leukaemia 
cell lines does not represent the methylation pattern observed in the original primary 
leukaemic cells. This finding can be explained by the evolution of specific TERT 
promoter methylation patterns in regions occurring in cancer cell lines during the 
process of transformation from the original primary leukaemic cell (Smiraglia et al., 
2001; Ahmed et al., 2013; Varley et al., 2013). 
 
Germline variants in TERT can lead to familial MDS/AML and to telomere biology 
disorders including DC, HH (West et al., 2014). Telomere biology disorders are 
associated with abnormal telomere maintenance and predisposition to MDS/AML and 
patients may present initially with bone marrow failure, MDS, or pulmonary fibrosis, 
without demonstrating mucocutaneous features of DC (Yamaguchi et al., 2003). 
These disorders are caused by a number of genes in three inheritance patterns. 
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Autosomal recessive DC and HH may be caused by variants in NOP1, TERT, NPH2, 
WRAP53, CTC1, RTEL1 and PARN (Dokal, 2011; Keller et al., 2012; Walne et al., 
2013b; Tummala et al., 2015). X-linked recessive DC is associated with variants in 
DKC1 (Heiss et al., 1998). Autosomal dominant DC results from variants in TERT, 
TERC, TINF2, and RTEL1 (Ballew et al., 2013; Savage et al., 2008; Vulliamy et al., 
2001). Heterozygous variants in TERT and TERC may result in familial MDS/AML 
predisposition syndromes (Kirwan et al., 2009). In familial MDS/AML, variants in 
TERT have an autosomal dominant form of inheritance with variable clinical 
manifestations and age at onset, incomplete penetrance and anticipation, in which 
progressively shorter telomeres passed down through generations (Vulliamy et al., 
2004; Armanios, 2009).    
 
The proband (III:5, Figure 3.6A) of family FML058 is a 40-year-old male with MDS 






Figure 3.6. Characterisation of TERT variant in exon 2. A. Family FML058 with TERT variant. 
Affected individuals are coloured as following red: MDS, black: AML and grey: 
thrombocytopenia. The arrow highlights index case. The heterozygous genotyping is denoted 
as (+/-). B. Sanger sequence chromatogram, red arrow shows the variant in TERT. C. 






His mother (II:10, Figure 3.6A) died aged 60 years of MDS and had pulmonary 
infections and liver cirrhosis. Two of his uncles died of MDS with infections, one (II:9, 
Figure 3.6A) at 65 years old; and another (II:13, Figure 3.6A) at 56 years old with an 
addition of diabetes, arthritis and heart disease. His uncle aged 51 years (II:14, Figure 
3.6A) had thrombocytopenia evolving to MDS with lung infections and his cousin (III:1, 
Figure 3.6A) died of AML. Deletion of a single nucleotide (c.1445delA, p.H482Pfs*27) 
resulting in a frameshift and truncation of the protein (Figure 3.6B and C) was 
identified in TERT in individuals II:7, II:12, II:14, II:15, III:6 and III:8 seen in Figure 
3.6A through direct sequencing. Interestingly, this TERT variant has an incomplete 
penetrance as there are four asymptomatic carriers (II:7, II:12, II:15, III:8, Figure 3.6A) 
in this family and striking incidence of MDS occurring with pulmonary symptoms, and 
late onset of disease.  
 
 
3.2.2.3 TERT promoter region and ANKRD26 5’UTR screening 
in our cohort of patients by dHPLC 
 
As described above, two highly recurrent somatic variants in TERT promoter region 
were found in melanoma, bladder and hepatocellular cancer cells: C>T at -124bp 
(described as 228C>T) and C>T at -146bp (described as 250C>T), these positions 
are according to Human Genome Issue hg19 (Figure 3.7). In addition, Horn et al. 
(2013) identified one germline variant in a family with melanoma (T>G at -57, shown 
in light blue in Figure 3.7B) and two tandem variants (CC>TT, shown in pink in Figure 
3.7B) occurred at -124/-125bp and at -138/-139bp that also creates binding motifs for 






Figure 3.7. TERT core promoter. A. Mutations 228C>T and 250C>T created Ets/TCF binding 
motifs in melanoma (adapted from Horn et al., 2013). B. TERT promoter region sequence 
showing the TERT coding sequence; the primer position used in this study to cover the full 
length of TERT promoter region; the novel variant and SNPs found in this study; the highly 
recurrent somatic and germline variants identified in melanoma by Horn et al., 2013. 
 
 
Since germline TERT variants can be found in both sporadic AML (Calado et al., 
2009) and familial MDS/AML (Kirwan et al., 2009), we investigated whether TERT 
promoter variants also occur in MDS/AML families as it had not been described to 
date. We screened 52 patients from our cohort of familial MDS/AML, 26 constitutional 
MDS/AML (individuals presenting MDS/AML alongside with one or more somatic 
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abnormalities), 12 familial MDS with other type of cancer beyond leukaemia and 10 
idiopathic cases for variants in the TERT full core promoter (489bp from -424 to +65) 




Figure 3.8. BAM file of TERT promoter region. The horizontal red arrow shows that TERT 
promoter region is not fully covered by WES. 
 
 
The SNP rs35226131 (G>A at position -269) was found in four patients and in three 
of them another SNP rs2853669 (T>C at position -245) was also present (Figure 3.9). 
In addition, one of these patients have a novel variant G>A at -215bp upstream of the 
transcription start site (TTS) (Figure 3.9B and C). Overall, this novel variant identified 
in TERT promoter is likely to be of unknown significance as there is no sufficient 
evidence for pathogenicity. However, considering that there are available samples 
from the patient harbouring this novel variant, a Luciferase assay could be performed 
in cell lines established from a patient cell and in the controls. The promoter activity 
of the constructs containing this novel variant at -215bp of the TERT promoter could 
be compared to the wild type.  
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Figure 3.9. Denaturing high performance liquid chromatography (dHPLC) TERT promoter 
results. A and B. Abnormal dHPLC elution patterns in patient samples 2-5 shown by the blue 
arrows. The abnormal dHPLC elution patterns correspond to SNPs identified in patients 2-5 
as indicated by ‘rs’ numbers and an additional novel variant shown in red was identified in 
patient 5. The respective Sanger sequencing chromatograms are shown in C. 
 
 
Furthermore, the same group of patients described above was screened for the 5’ 
untranslated region (UTR) of ankyrin repeat domain 26 gene (ANKRD26) by dHPLC 
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as this region is also not covered by WES (Figure 3.10). ANKRD26 encodes a protein 
containing N-terminal ankyrin repeats which function in protein-protein interactions 
and, variants in ANKRD26 5’UTR were identified in families with an autosomal 








Bluteau et al. (2014) demonstrated that THC2 is caused by the impaired binding of 
RUNX1 and Fli-1 proto-oncogene, ETS transcription factor (FLI1) to the altered 
ANKRD26 which results in the ANKRD26 down regulation by these same 
transcription factors and a subsequent ANKRD26 overexpression in megakaryocytes. 
Patients with variants in ANKRD26 are more predisposed to myeloid malignancies, in 
particular AML and the thrombocytopenia in these patients is characterised by normal 
platelet size, moderate thrombocytopenia, and absent or mild bleeding tendency 
(Noris et al., 2013; Marconi et al., 2017). Through dHPLC screening, few SNPs (c.1-
59G>A rs3737056, c.1-140C>G rs41299222 and c.1-229A>C rs7897698) were 




Figure 3.11. Denaturing high performance liquid chromatography (dHPLC) ANKRD26 5’UTR 
results. A. Abnormal dHPLC elution patterns of SNPs identified in patients 2-4, shown in blue 




3.2.3 Variants identified in genes associated with inherited 
syndromes with predisposition to MDS/AML 
 
3.2.3.1 Shwachman-Diamond syndrome 
 
Ribosomes are essential machines that read genetic code in the cells, translating 
them into proteins. The ribosomal large 60S and small 40S subunits are pre-
assembled in the nucleus and then exported to the cytoplasm to be matured. Genetic 
variants that occur in genes involved in the ribosome biogenesis cause disorders 
called ribosomopathies such as Diamond–Blackfan anemia, DC, Shwachman–
Diamond syndrome, del(5q) myelodysplastic syndrome, Treacher Collins syndrome, 
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Cartilage–hair hypoplasia, North American Indian childhood cirrhosis and isolated 
congenital asplenia (Warren, 2017). 
 
Shwachman-Diamond syndrome (SDS) is an autosomal recessive disorder caused 
by biallelic variants in SBDS and is associated with bone marrow failure and 
predisposition to MDS/AML. It is characterised by multiple developmental anomalies 
including skeletal abnormalities, cognitive impairment, exocrine pancreatic and poor 
growth (Myers et al., 2014). SBDS is a cofactor for elongation factor-like GTPase 1 
(EFL1) to disassociate the eukaryotic initiation factor 6 (eIF6) from the late subunit 
joining the 60S ribosomal subunit in the cytoplasmic maturation (Finch et al., 2011; 
Weis et al., 2015). Recently, biallelic variants in DnaJ heat shock protein family 
(Hsp40) member C21 (DNAJC21) were described by our group (Tummala et al., 
2016) and another (Dhanraj et al., 2017) causing SDS like disease. DNAJC21 plays 
a role in cytoplasmic maturation of the 60S ribosomal subunit (Myers et al., 2014). 
However, whilst no homozygotes for a loss of function variant have been reported in 
SBDS, suggesting that these alterations are embryonic lethal, two cases carrying 
homozygous nonsense variants were reported in DNAJC21 (Shammas et al., 2005; 
Tummala et al., 2016). 
 
Boocock et al. (2003) found that more than 90% of patients with SDS carry recurrent 
biallelic variants in SBDS including one of three common pathogenic SBDS variants: 
183_184TA>CT, 258+2T>C, or the combination of 183_184TA>CT and 258+2T>C. 
The variant 258+2T>C disrupts the donor splice site of intron 2, while 183_184TA>CT, 
introduces an in-frame stop codon (K62X). In our cohort, recurrent biallelic variants in 
SBDS (c.184A>T, p.K62*, rs120074160 and c.258+2T>C, rs113993993) were found 
in the family FML041 (Figure 3.12). This was possible through data analyses from 
whole exome sequencing performed in all our familial MDS/AML patients that had 
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good quality of DNA sample. The index case (II:2) and her twin (II:1, Figure 3.12A) 
did not fulfil the classical clinical criteria of SDS at the time of diagnosis. It is well 
known that inherited bone marrow failure syndromes are heterogeneous disorders 
with overlapping features and predisposition to MDS or AML. Patients with SDS often 
present with a combination of exocrine pancreatic insufficiency with malabsorption 
and neutropenia in infancy with propensity to develop bone marrow failure 
malignancies (Lindsley et al., 2017). In addition, they may have low birth weight, short 
stature, metaphyseal dysostosis, neurocognitive deficits, immunodeficiency among 
other less common findings (Myers et al., 2014).    
 
The index case (II:2, Figure 3.12A) of family FML041 was a 23 years old woman; she 
and her twin (II:1, Figure 3.12A) had longstanding history of MDS since 6 months of 
age. Both twins had an extensive past medical history including in the index case (II:2, 
Figure 3.12A) a cleft of her soft palate at birth, speech delay in childhood, hearing 
loss, a history of congenital hip dislocation, mild short stature, dysmorphic features 
with round face, small nose, pinched alae nasi, long smooth filtrum, rounded ears and 
mild joint hyperextensibility. Her twin sister (II:1, Figure 3.12A) was also noted to have 
recurrent chest infections and asthma. II:1 (Figure 3.12A) died following the 
transformation of MDS to AML. The index case (II:2, Figure 3.12A) died a year later 
with refractory AML post allograft. Whole exome sequencing data revealed biallelic 
variants (c.184A>T, p.K62* rs120074160 and c.258+2T>C, rs113993993) in exon 2 
of SBDS are likely to be the disease causing in this family (Figure 3.12B and C). These 
compound heterozygous germline variants are frequently seen in patients with SDS, 






Figure 3.12. Characterisation of SBDS variants in exon 2. A. Family FML041 with SBDS 
variants. Affected individuals are coloured as following red: MDS and black: AML. The arrow 
highlights index case. The compound heterozygous state is denoted as (-/-). B. Sanger 
sequence chromatogram showing the variant in SBDS. C. Schematic showing the position of 
the variant by the red arrow in SBDS protein (NP_057122.2). 
 
 
3.2.3.2 Fanconi anaemia 
 
Fanconi anaemia (FA) is associated with congenital abnormalities in multiple organs, 
haematological manifestations at a young age such as bone marrow failure, MDS, 
and AML (Alter et al., 2010). FA is characterised by increased chromosomal breakage 
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upon exposure to DNA crosslinking agents, diepoxybutane (DEB), or mytomycin C. It 
is a rare recessive DNA repair deficiency resulting from biallelic damaging variants in 
one of at least 20 genes (FANCA, FANCC, FANCD1/BRCA2, FANCD2, FANCE, 
FANCF, FANCG, FANCI, FANCJ/BRIP1, FANCL, FANCM, FANCN/PALB2, FANCO, 
FANCP, FANCQ/ERCC4/XPF, FANCS/BRCA1, FANCT/UBE2T, FANCU/XRCC2, 
FANCV/MAD2L2/REV7 and FANCW/RFWD3). Damaging variants in the X-linked 
gene FANCB and heterozygous damaging variants in FANCR/RAD51 can also cause 
FA (Auerbach, 2009). These genes are involved in repairing DNA crosslinks 
associated with the FA/BRCA pathway. Complete molecular diagnosis of the disease 
causing gene and specific pathogenic variants are required for confirmation of FA and 
efficient clinical management (Flynn et al., 2014). This is due to the fact that different 
FA complementation groups demonstrate variable outcome. While variants in FANCA 
lead to a mild disease and later onset of bone marrow failure, variants in FANCG 
usually result in severe haematological malignancies (Faivre et al., 2000). 
 
Biallelic variants in Fanconi anaemia complementation group A (FANCA) (Figure 
3.13A) are responsible for the development of the disease in most cases of FA. Large 
and small deletions, small insertions, and single nucleotide variation are the type of 
disease causing variants found in FANCA (Kimble et al., 2017). We have identified 
biallelic variants in one family of our cohort of familial MDS/AML.  
 
The proband (III:2, Figure 3.13B) of family FML004 was a female with mild short 
stature associated with non-severe AA at the age of 38 years. She developed AA after 
receiving treatment for her tongue and throat cancer. Her mother (I:1, Figure 3.13B) 
had short stature and her brother (III:1, Figure 3.13B) died at age of 19 years with 
AML. Her maternal aunt had stomach cancer in her forties and a further maternal 




Figure 3.13. Characterisation of FANCA variants in exons 27 and 36. A. Schematic of FANCA 
protein (NP_000126.2). B. Family FML004 with FANCA variants. Affected individuals are 
coloured as following blue: AA and black: AML. The arrow highlights index case. The 
compound heterozygous state is denoted as (-/-). C. Sanger sequence chromatogram, red 
arrows show variants in FANCA. 
 
 
Two other maternal aunts have died of breast cancer in their fifties and further aunt 
had two thumbs. Her maternal grandmother had throat cancer and stomach problems 
and died in her sixties. The index case had some chromosome instability. This result 
was not within the normal range but neither was a diagnostic of FA. However, very 
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rare biallelic variants (c.2505-1G>T and c.3626+5G>C) likely to be pathogenic were 
identified in FANCA by exome sequence performed in the index case and validated 
by Sanger sequencing (Figure 3.13C). Hence, despite II:1 not presenting with typical 
congenital abnormalities nor radial-ray, which are features frequently seen in FA, our 
results support the diagnosis of FA for this patient.   
 
 
3.2.4 Variants identified in genes associated with other inherited 
syndromes  
 
3.2.4.1 Wiskott-Aldrich syndrome  
 
Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive disease characterised 
by thrombocytopenia, bloody diarrhoea, immunodeficiency, recurrent infections, 
inflammatory symptoms, and eczema. It was described in 1937 and 1954 by Dr. Alfred 
Wiskott and Dr. Robert Aldrich respectively. The presentation of WAS is very 
heterogeneous ranging from mild to severe, in which severe conditions such as the 
development of autoimmunity and lymphoproliferative disorders and lymphoid 
malignancies may occur. The presentation of these disorder typically occurs in early 
life while the diagnosis may sometimes be in adulthood due to its heterogeneity (Ochs 
et al., 2009; Worth & Thrasher, 2015). Damaging variants in WAS gene are 
associated with the development of WAS. These variants are typically missense, 
splice site, nonsense, insertions and deletions are distributed along WAS (Shcherbina 
et al., 2003; Jin et al., 2004). Furthermore, the WAS related disorder X-linked 
neutropenia (XLN) is a very rare type of severe congenital neutropenia and MDS with 
recurrent infections that develop in an early infancy with a diverse presentation from 
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that of WAS. Only four WAS missense variants have been reported to cause XLN to 
date, including p.L270P, p.S272P, p.I276S, and p.I290T (Devriendt et al., 2001; 
Ancliff et al., 2006; Beel et al., 2009; Kobayashi et al., 2017). WAS is located on the 
X chromosome and encodes the WAS protein (WASp) which is member of a family 
of actin nucleation-promoting factors that translate surface signals into actin 
polymerization through the actin-related protein, Arp2/3 complex. It is important in 
actin polymerization, cytoskeletal remodelling and it is only expressed in 
haematopoietic cells (Thrasher & Burns, 2010). As WASp regulates the actin 
cytoskeleton processes including immune synapse formation, cell signalling, 
migration and cytokine release in most haematopoietic lineages, it participates in 
innate and adaptive immunity and is consequently important for normal function of 
immunological processes (Baptista et al., 2016).  
 
Family FML032 (Figure 3.14A) from our cohort was found to have a single nucleotide 
deletion (c.1336delA, p.K446Rfs*24) causing premature stop codon in the WASp 
(Figure 3.15B and C). The index case (II:2, Figure 3.14A) was a three months old boy 
who presented with thrombocytopenia on day 1 and progressed to MDS. His six year 
old brother (II:1, Figure 3.14A) developed thrombocytopenia and splenomegaly at 
nine weeks of age and progressed to MDS. The WAS variant p.K446Rfs*24 was 







Figure 3.14. Characterisation of WAS variant in exon 10. A. Family FML032 with WAS variant. 
Affected individuals are coloured in red indicating MDS. The arrow highlights index case. The 
hemizygous genotype is denoted as (-). B. Sanger sequence chromatogram, red arrow shows 








The recognition of familial MDS/AML is essential for effective clinical management of 
patients with an inherited susceptibility and their families. Besides documentation of 
a complete family history, germline genetic testing is also important to help to clarify 
whether a patient may have inherited predisposition to MDS or AML. Germline genetic 
testing is becoming more common to aid this recognition. Such officially recognised 
tests exist for FPD/AML caused by variants in RUNX1; familial AML with variants in 
CEBPA; familial MDS/AML with variants in GATA2; and for inherited bone marrow 
failure syndromes including DC and FA (Nickels et al., 2013). It is important to note 
that the segregation of the germline variant with the disease within the family is crucial 
to assign its pathogenicity. Certain features of the history or laboratory values may 
increase the likelihood of a particular syndrome over others in individual cases.  
 
Here, we characterised seven families part of our familial MDS/AML cohort. Family 
FML053 had a large deletion in RUNX1, carriers exhibited heterogeneity in their 
degree of platelet dysfunction (individual II:5 is thrombocytopenic with no myeloid 
malignancy detected to date) and multiple individuals have developed T-cell ALL and 
acute myeloid leukaemia. Anticipation is a strong characteristic of FPD/AML and a 
close clinical follow up for members of the followed generations in the family is critical 
Disease anticipation leads to occurrence of MDS and AML in younger individuals in 
subsequent generations (Jongmans et al., 2010; Nickels et al., 2013; Sood et al., 
2017). Furthermore, we also identified an example of a deletion of 21bp in RUNX1 in 
FML007 that is actually acquired and, therefore it is not likely to be the disease 
causing variant in this family. This highlights that interpretation of genetic testing in 
blood can be confounding by the presence of somatic variants found in known disease 
causing genes. Despite the recommendation of use of a non-blood tissue to validate 
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a germline variant, we do not have it available in all our families. However, segregation 
analysis within the family can be useful in distinguishing inherited from somatic 
variants.  
 
We have not found CEBPA, SRP72, TERC nor ANKRD26 variants in our 
uncharacterised familial MDS/AML cohort in these studies. However, GATA2 variants 
were found in two families and they are possibly the underlying cause of the disease 
in these families. The proband of family FML026 harbours a nonsense variant with 
variable penetrance as the father did not present with the disease and she is also 
reported to have trisomy 8. Interesting GATA2 variants are usually highly penetrant 
with variable cytogenetic abnormalities, including monosomy 7, trisomy 8 and trisomy 
21 (Hahn et al., 2011).  The proband of the second family FML052 was diagnosed 
with Emberger syndrome and harbours a frameshift deletion of 14bp in GATA2. This 
is likely to be a de novo event as her parents and her brother do not carry this variant 
and it was found in about 50% of the cells according to the peak of the traces from 
Sanger sequencing compared to the wild type sequence.  
 
The large family FML058 with familial MDS/AML was characterised by a deletion of 
one nucleotide in TERT, which caused frameshift and truncation of the protein. 
Affected members in this family presented MDS/AML along with lung infections and 
liver cirrhosis common features seen in patients carrying variants in TERT (Dokal, 
2011).  
 
Patients with rare inherited bone marrow failure syndromes including FA, DC, 
Diamond Blackfan anaemia and SDS can be diagnosed during evaluation of 
haematological manifestations such as MDS or AML as a result of specific clinical 
phenotypes, screening tests or genomic studies (West & Churpek, 2017). This group 
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of disorders may present overlapping features and increased rates of malignancies. 
Despite the common features, these syndromes are very diverse in their 
manifestations and complications (Dietz et al., 2017). Here, we described families 
from our cohort of familial MDS/AML diagnosed with Fanconi anaemia and SDS as 
their initial presentation was atypical. 
 
Our case of FA in family FML004 shows the importance of a molecular diagnosis to 
elucidate a complicated case. The diagnosis of FA of the proband of FML004 was not 
confirmed until the identification of biallelic variants in FANCA. Taking into account 
that she did not present with classical FA clinical features such as abnormal skin 
pigmentation, radial ray defects, and organ and skeletal abnormalities and exhibited 
intermediate chromosome breakage instability for a classical diagnosis of FA. This 
marked heterogeneity means diagnosis of FA is not always straightforward and it is 
important to consider this diagnosis in young patients presenting with cancers (Fargo 
et al., 2014). 
 
Family FML041 was found to have recurrent biallelic variants in SBDS, however the 
proband of this family had not been diagnosed with SDS prior to these findings. 
Regardless of her and her twin sister’s longstanding MDS along with many other 
congenital anomalies, she did not present with the classical exocrine pancreatic 
insufficiency compatible with a diagnosis of SDS. Again, it was through genetic 
studies that a diagnosis of SDS was made.  
 
Family FML032 is another interesting case as both young brothers in this family were 
found to carry a frameshift variant in WAS. Although both boys presented with 
thrombocytopenia at an early age they both progressed to MDS. However, neither of 
them presented with immunodeficiency, eczema nor repeated respiratory infections 
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that are typically seen in WAS. This family highlights that early presentation of 
thrombocytopenia with evolution into MDS, can also arise from variants in WAS in the 
absence of typical WAS features. 
 
Finally, the incorporation of next-generation sequencing as a standard practice into 
clinic may change the clinician’s diagnostic approach. As a consequence, it is 
important to consider that diagnosis of an underlying germline variant raises the issue 
of using an allogeneic stem-cell transplant (STC) for consolidation therapy, since 
transplant is the only way to eradicate the bone marrow of the underlying predisposing 
allele. Furthermore, in order to get appropriate counselling and treatment, any new 
outcome that occurs after a STC in patients with inherited bone marrow failure 
disorders, needs to be distinguished from an event derived from STC or clinical 














Germline heterozygous DDX41 variants in a 








Considering that germline heterozygous mutations have been identified in DEAD-box 
helicase 41 gene (DDX41) in patients with familial MDS/AML in 2015 by Polprasert et 
al., we have decided to investigate variants in this gene in our cohort using a 
combination of whole exome and targeted sequencing.  
 
Subsequently, heterozygous germline loss of function (LoF) variants in the gene 
DDX41 (canonical transcript, NM_016222.3, NP_057306.2, 622 amino acids) that 
segregate with disease in four families with MDS/AML were identified and are 
described in this chapter.  
 
 
4.1.1 Familial myelodysplasia and acute myeloid leukaemia with 
germline predisposing variants in DDX41  
 
Recently, alterations in DDX41 were identified to cause familial MDS/AML. Although, 
the age of onset and potential function of DDX41 differ this gene from the previous 
familial MDS/AML predisposing genes (Polprasert et al., 2015).      
 
The median age of MDS or AML onset in carriers of germline DDX41 variants is 62 
years, which is similar to the diagnosis age of sporadic MDS and AML. While the other 
predisposition syndromes occur in an earlier age of onset (Tawana & Fitzgibbon, 
2016). Another different aspect is that most of the carriers of variants in DDX41 have 
normal blood counts up until the development of MDS or AML, unlike other 
predisposing genes such as GATA2 and RUNX1 that are often characterised by 
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extended pre-leukemic cytopenic phases (Lewinsohn et al., 2016). These features 
make it harder to diagnose familial MDS/AML in patients carrying germline DDX41 
variants.  
 
Finally, DDX41 has been implicated by functional studies to be involved in innate 
immune response, mRNA splicing, ribosome biogenesis and post-transcriptional 
regulation of protein translation in cell growth (Cheah et al., 2017). Despite all these 
function implications, the role of DDX41 in leukemogenesis is yet to be established 
(Li et al., 2016). 
 
 
4.1.2 DDX41 – DEAD-box helicase 41 structure and function 
 
RNA and DNA helicases are considered to be enzymes that catalyse the separation 
of double-stranded nucleic acids in an energy-dependent manner. They utilise the 
energy derived from a nucleoside triphosphate (NTP) hydrolysis to dissociate 
duplexes or displace bound proteins (Linder & Jankowsky, 2011). However, not all 
helicases have purely a double-stranded unwinding activity and they might be 
involved in various functions (Cordin et al., 2006). 
 
DExD/H box family of RNA helicases are part of the large SF2 helicase superfamily. 
There are 59 highly conserved DExD/H helicases in eukaryotes (Zhang et al., 2011b) 
which play important roles in RNA metabolism, including ribosome biogenesis, RNA 
processing and folding, ribonucleoprotein modelling, RNA nuclear export, in the 
regulation of RNA translation and transcription, and in nonsense-mediated RNA 
decay. DExD/H box RNA helicases can have different functions in these processes 
such as RNA chaperones, ATP-dependent RNA helicases and unwindases, as 
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RNPases by mediating RNA-protein association and dissociation (Pyle, 2008) or as 
co-activators and co-repressors of transcription (Wortham et al., 2009). In addition, 
several DExD/H box family members are involved in viral replication. They are 
captured and regulated by viral proteins (Schröder, 2010), and are involved in viral 
RNA maturation (Yount et al., 2008). They can also mediate antiviral host defence 
activating the host innate immune response (Rehwinkel & Sousa, 2010).  
 
Within the DExD/H box family, RNA helicases share at least eight conserved motifs 
(I, Ia, Ib, II, and III in the N terminal domain and motifs IV, V, and VI in the C terminal 
domain) contained within two RecA-like domains joined by a short flexible link (Cordin 
et al., 2006; Jiang et al., 2017; Omura et al., 2016). These proteins are further 
distinguished based on variations within their amino acid sequence of the conserved 
helicase motif II (DEAD, DEAH, DExH and DExD helicases). Both RecA-like domains 
contribute to ATP hydrolysis and to the binding site for RNA substrates, facilitating the 
helicase activity of these proteins such as RNA unwinding or protein displacement. In 
addition, most DExD/H box contain variable N- and C- terminal regions that confer 
functional specificity to individual helicases (Fuller-Pace et al., 2006).    
 
DEAD box RNA helicases are the largest family from DExD/H box family, comprising 
more than 500 proteins (Silverman et al., 2003) and are characterised by the 
conserved motif II, Asp-Glu-Ala-Asp (DEAD). The motif DEAD provides the RNA 
helicase function to this protein family by the activities of ATPase and RNA unwinding 
(Jankowsky, 2011). Furthermore, members of this family are linked to human disease, 





DEAD-box helicase 41 (DDX41) contains a disordered N-terminal (amino acids 1-
152) which are responsible for its nuclear localisation, a DEAD domain that consists 
of motifs Q, I (Walker A, P-loop), II (Walker B, dead-BOX), Ia, GG, Ib and III and a 
helicase domain which consists of motifs IV, V and VI (Schmid & Linder, 1992; 
Caruthers et al., 2000; Cordin et al., 2006). Motifs Q, I and II are involved in nucleotide 
biding; motifs Ia, Ib, IV and V are involved in RNA binding and motifs III and VI are 




Figure 4.1. Schematic of DDX41 protein. 
 
 
DDX41 has been shown to participate in the anti-viral innate immunity by functioning 
as a sensor for cytoplasmic viral DNA in mouse myeloid dendritic cells (Zhang et al., 
2011b) and also as a germline-encoded pattern recognition receptor when interacting 
with the bacterial second messengers cyclic di-GMP (c-di-GMP) and cyclic di-AMP 
(c-di-AMP), which results in the induction of genes involved in the innate immune 
response in mouse and human cells (Parvatiyar et al., 2012). In addition, Polprasert 
et al. (2015) suggested that DDX41 acts as tumour suppressor and demonstrated that 
alterations in this gene have an impact on mRNA splicing of important downstream 
genes in leukaemic cells. Furthermore, DDX41 has been implicated in ribosome 
biogenesis in studies with CD34+ from cord blood cells and leukaemia cell lines 
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(Kadono et al., 2016) and in post-transcriptional regulation of protein translation in 
studies using colon carcinoma cells (Peters et al., 2017). 
 
 
4.1.3 The role of DExD/H box helicases and DDX41 in the innate 
immunity response 
 
The recognition of pathogenic DNA from viruses, bacteria, fungi and parasites in the 
host organism is important to the initiation of innate immune response, which will help 
the host against the infection of pathogen (Bonjardim et al., 2009).  
 
Innate immune response is a conserved, nonspecific first defence of the organism. It 
includes various defence strategies such as physical barriers (for instance, skin), 
chemicals in the blood, and immune system cells. In innate cells such as 
macrophages, innate immunity response is based on the recognition of pathogen-
associated molecular patterns (PAMPs) through a set of pattern recognition receptors 
(PRRs) that stimulate downstream signalling cascades leading to production of pro-
inflammatory cytokines and type I interferons (IFN-α and IFN-β), which are cytokines 
with potent anti-viral activity (Takeuchi & Akira 2010).  
 
The induction of IFN are mediated by activation of the transcription factors interferon 
regulatory factor 3 (IRF3), interferon regulatory factor 7 (IRF7) or nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB), and by signalling pathways 
downstream of anti-viral PRRs select kinases that phosphorylate and activate IRF3/7 
(Sato et al., 2000).   
Viral PAMPs are mainly genomic RNA, DNA and replication intermediates (Saito & 
Gale, 2007). The main groups of PRRs sensing PAMPs are endosomal Toll-like 
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receptors (TLR), the RIG-like helicases (RLHs) which are part of DExD/H-box family, 
and cytoplasmic DNA receptors (Thompson et al., 2011). Most PRRs utilises the 
kinases TANK binding kinase 1 (TBK1) and inhibitor of κB kinase ε (IKKε) for 
phosphorylation of IRF3/7 while their upstream signalling is quite diverse. In the 
upstream signalling, TLR depends on the adaptor molecule TIR-domain-adapter-
inducing interferon-β (TRIF) (Yamamoto et al., 2002) or on the TIR-domain-adaptor 
molecule myeloid differentiation primary response gene 88 (MyD88) (Kawai et al., 
2004), the RLHs utilise a CARD-domain containing mitochondrial adaptor called 
MAVS (also called IPS-1, Cardif or VISA) (Seth et al., 2005), and most cytosol DNA 
or RNA receptors depend on stimulator of interferon genes (STING), an endoplasmic 
reticulum-resident adaptor molecule (Ishikawa & Barber, 2008).   
 
Several cytoplasmic DNA or RNA receptors have been identified, including RNA 
polymerase III, cyclic-GMP-AMP synthetase (cGAS), DNA-dependent activator of 
IFN-regulatory factors (DAI), gamma-inducible protein 16 (IFI16) and DDX41. Some 
of these intracellular sensors signal via the adaptor STING (Chiu et al., 2009; Sun et 
al., 2013; Takaoka et al., 2007; Unterholzner et al., 2010). 
 
Hence, DExD/H-box helicases are known to contribute to anti-viral immunity, either 
by acting as sensors for viral nucleic acids or by facilitating downstream signalling 
events. The RLH family has the ability to sense double strand RNA (dsRNA) in the 
cytosol and is constituted by DExD/H-box helicase 58 (DDX58, also known as RIG-
I), interferon induced with helicase C domain 1 (IFIH1, also known as MDA5), and 
DExH-box helicase 58 (DHX58, also known as LGP2) (Schmidt et al., 2012). The 
RLHs recognise their specific RNA ligands through their C-terminal regulatory domain 




Other DEAD box helicases participate in the innate immune response, such as DEAD-
box helicase 3 (DDX3) which acts as a sensor for viral RNA in conjunction with RIG-
I and MDA5 (Oshiumi et al. 2010).  Additionally, DDX3 might function downstream of 
TBK1 and IKKε either as a signalling adaptor and/or transcriptional regulator (Soto-
Rifo et al., 2012). DExH-box helicase 9 (DHX9) has been identified as a sensor for 
dsRNA in myeloid cells (Zhang et al., 2011c), and DHX9 and DEAH-box helicase 36 
(DHX36) as sensors for CpG oligonucleotides in plasmacytoid dendritic cells (Kim et 
al., 2010). CpG oligonucleotides are known to induce INF-α and pro-inflammatory 
cytokine production (Krug et al., 2001). In myeloid cells, DEAD-box helicase 1 (DDX1) 
senses dsRNA and then triggers signalling via DExD-box helicase 21 (DDX21) and 
DDX36 that interact with the downstream protein TRIF to trigger type I interferon 
responses (Zhang et al., 2011a). DExD/H-box helicase 60 (DDX60) is proved to act 
in conjunction with RIG-I or MDA5 to mediate responses to viral dsRNA (Miyashita et 
al., 2011).   
 
Furthermore, certain bacterial species can release cyclic diguanosine 
monophosphate (c-di-GMP) or cyclic diadenosine monophosphate (c-di-AMP), which 
are secondary messengers that regulate the bacteria metabolism, motility and 
virulence and can also modulate the innate immune response in mammalians cell by 
acting as PAMPs. c-di-GMP and c-di-AMP can be detected by PRRs and activate the 
IFN response, however the cytoplasmic RIG-1 (DDX58) nor the Toll-like receptor 
family of PRRs are involved in the detection of cyclic dinucleotides (Hengge, 2009; 
McWhirter et al., 2009). STING and DDX41 were identified as an innate sensor of 
cyclic dinucleotides in the cytosol (Burdette et al., 2011; Lee et al., 2015).  
 
Parvatiyar et al. (2012) showed that DDX41 specifically and directly interacts with c-
di-GMP via its DEAD domain motif II and motif I, after being phosphorylated by 
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Bruton’s tyrosine kinase (BTK) followed by induction of type I interferon in mice and 
human cells. Lee et al. (2015) using mice and human cells, demonstrated that BTK 
kinase phosphorylates Tyr414 of DDX41, which is the same site that recognises DNA 
and bind to STING (Figure 4.2).  
 
DDX41 was also identified as an intracellular DNA sensor in myeloid dendritic cells 
that depends on STING to sense pathogenic DNA (Zhang et al., 2011b). Herein, 
DDX41 functions through the STING-TBK1-IRF3 pathway, where STING functions as 
a key scaffolding and adaptor protein to facilitate the signal transduction initiated from 
upstream cytosolic dsDNA receptors to downstream effectors TBK1, NF-κB and IRF3, 
leading to the expression of type I interferon (Liu & Wang, 2016) (Figure 4.2).    
 
Uncontrolled sensing of DNA or RNA and excessive production of type I interferon 
could induce autoimmune diseases, so DDX41 must be degraded or inactivated after 
immune response. Zhang et al. (2013) demonstrated that DDX41 in mice is degraded 
by the E3 ligase tripartite motif containing 21 (TRIM21), using Lys9 and Lys115 of 
DDX41 as the ubiquination sites (Figure 4.2).  
 
Interestingly, Lewinsohn et al. (2016) and Kadono et al. (2016) observed that DDX41 
full length protein 70kDa localises in the nucleus, contradicting the DDX41 function 
as a cytosolic DNA sensor. However, both groups described a short DDX41 isoform 
of 52kDa translated from the second methionine identified in both nucleus and 
cytoplasm in human cells. Although several studies showed that DDX41 is important 
for innate immunity, the exact mechanism of how it functions is still unknown (Jiang 




Figure 4.2. DDX41 as an intracellular DNA sensor through the STING-TBK1-IRF3 pathway. 
Adapted from Lee et al. (2015) and Jiang et al. (2017). 
 
 
Finally, in addition to its involvement in viral recognition and anti-viral immunity, DEAD 
box RNA helicases are also recruited by viruses to facilitate their replication. Some 
viruses do not encode their own RNA helicases and many cellular helicases have 
been identified as essential host factors for RNA unwinding in viral replication. The 
human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are some examples 
(Lorgeoux et al., 2012). DDX1, DDX3 and DEAD-box helicase 5 (DDX5) are required 
for HCV replication (Owsianka & Patel, 1999; Goh et al., 2004; Tingting et al., 2006) 
and DDX1, DHX9, DDX5, DEAD-box helicase 17 (DDX17) and DDX21 have also 
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been reported to be important for the HIV-1 replication (Fang et al., 2004; Naji et al., 
2012). DHX9 is also required for the replication of the foot-and-mouth-disease virus 
(Lawrence et al., 2009) and the influenza virus (Lin et al., 2012).   
 
 
4.1.4 Association of DDX41 variants with myeloid neoplasms and 
defects in mRNA splicing 
 
Besides its roles in innate immunity response, DDX41 is one of the most frequently 
mutated familial MDS/AML predisposition gene, with acquired and inherited variants 
identified (Brown et al., 2017). DDX41 variants profile can be seen in Figure 4.3. In 
addition to poor survival, normal karyotype, long latency and advanced stage at 
diagnosis, familial DDX41 MDS/AML syndrome is also characterised by hypocellular 
bone marrow, erythroid dysplasia and high risk of MDS and AML (Lewinsohn et al., 
2016). Furthermore, DDX41 is located on chromosome 5 and is deleted in 
approximately 26% of MDS with del(5q) resulting in haploinsufficient expression 
(Polprasert et al., 2015). 
 
Polprasert et al. (2015) identified germline and somatic DDX41 variants in several 
MDS/AML cases and showed that half of the cases with germline variants also 
harboured an additional somatic DDX41 variant in the remaining wild-type allele. The 
somatic DDX41 R525H was the most frequent acquired variant and it is located in the 
conserved motif VI at the C-terminal helicase domain where adenosine triphosphate 
(ATP) hydrolyses occurs, causing a lower ATPase activity in the altered helicase 
(Kadono et al., 2016) (Figure 4.3 and Table 4.1). Biallelic variants were also found 
with AML progression in MDS/AML with CEBPA or RUNX1 variants (Pabst et al., 
2008; Preudhomme et al., 2009).  
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In addition, Lewinsohn et al. (2016) identified five DDX41 variants including missense 
and splicing variants predicted to result in truncated proteins in ten families with 
MDS/AML (Figure 4.3 and Table 4.1). They identified the recurrent germline 
D140Gfs*2 variant along with the germline M1I variant, seen subsequently by us and 
others (Cardoso et al., 2016; DiNardo et al., 2016; Berger et al., 2017). 
 
Further DDX41 variants were reported by Li et al. (2016), they have identified one 
family with MDS/AML harbouring two consecutive rare heterozygous germline 
variants (p.L237F and p.P238T) segregating with the disease (Figure 4.3 and Table 
4.1). Herein, the disease had a long latency period consistent with previous studies. 
These variants are located in the DEAD-box domain, affecting a conserved motif that 
includes the ATP binding site and they are both seen in ExAC database with allele 







Figure 4.3. Schematic of DDX41 protein with the type of DDX41 variants identified to date. 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The late onset of familial MDS/AML characteristic of DDX41 variants make it harder 
to obtain an accurate diagnosis for this group of patients and misguided selection for 
an allogenic stem cell transplantation might take place. This is the case reported by 
Berger et al. (2017), where the proband of 58 years presenting AML had a blood stem 
cell transplantation from his healthy brother of 62 years at the time, followed by the 
proband achieving full recovered blood cells count. However, the proband had a 
relapse into MDS four years later to discover that the MDS clone emerged from the 
donor cells. Meanwhile, another brother carrying the recurrent DDX41 p.R525H 
variant was diagnosed with AML at the age of 68 years. The recurrent DDX41 
p.Met1Ile variant was identified in all three brothers.  
 
Polprasert et al. (2015) have demonstrated the tumour suppressor role of DDX41 from 
their DDX41 knockdown experiments in K562 (an immortalised human myelogenous 
leukemia cell line derived from a chronic myelogenous leukemia patient) and CD34+ 
cells results, which displayed an increase of cell growth compared to control. Further 
experiments in HEK293 (human embryonic kidney cells 293) cells using mass 
spectrometry identified spliceosomal proteins to associate and interact with DDX41 
and this was then confirmed by western blotting of endogenous DDX41 protein from 
primary and K562 cells.   
 
In addition, data from the mass spectrometry experiment mentioned above showed 
that the R525H variant reduced the DDX41 interaction with splicing factor 3b subunit 
1 (SF3B1) and pre-mRNA processing factor 8 (PRPF8), crucial components in 
spliceosomes. SF3B1 together with SF3B2 and SF3B3 forms the U2 small nuclear 
ribonucleoproteins complex (U2 snRNP) and somatic genetic alterations in SF3B1 
gene has been linked to MDS and chronic lymphocytic leukaemia patients by 
induction of aberrant transcription, altered pre-mRNA recognition and alternative 
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splicing (Cazzola et al., 2013; Jenkins & Kielkopf, 2017). While somatic genetic 
alteration in PRPF8 has been associated with MDS and AML, where decrease of 
PRPF8 expression is associated with increased exon skipping, probably as a result 
of splicing proofreading defect. PRPF8 is a scaffold protein component of both U2- 
and U12-dependent spliceosomes and is required for the assembly of the U4/U6-U5 
tri-snRNP complex (Kurtovic-Kozaric et al., 2015).   
 
Moreover, Polprasert et al. (2015) performed deep whole RNA sequencing in three 
cases that had deletion (5q-), one case with mutant (p.R525H), and one case that 
showed low expression of DDX41, and 11 wild-type cases. This demonstrated that 
defects in RNA splicing were associated with the altered DDX41 that resulted in 
aberrant exon skipping of 61 genes and exon retention in 95 genes. Zinc finger MYM-
type containing 2 (ZMYM2) was one of the top ten genes that had the most 
differentially misspliced exons. ZMYM2 encodes a zinc finger protein member of a 
family of myeloproliferative and mental retardation (MYM) domain involved in a 
histone deacetylase complex (Gocke & Yu, 2008). The difference of skipping ratio in 
ZMYM2 exon 3 was 13% between mutant and wild-type. The enhanced skipping of 
this exon, was recapitulated by DDX41 knockdown in K562 and CD34+ cells. In 
contrast, overexpression of wild-type DDX41 in U937 cells (monocytes isolated from 
the histiocytic lymphoma of a male patient) led to decreased exon skipping of ZMYM2 
in comparison to mock transduction. In addition to the changes in spliced isoform 
ratios, ZMYM2 mRNA was expressed at significantly lower levels in the cells with low 
DDX41 expression. Low ZMYM2 mRNA levels were associated with down-
modulation of structural maintenance of chromosomes 3 (SMC3), RAD21 cohesin 
complex component (RAD21), and RUNX1, which were also significantly under-




Overexpression as well as variants or deletions of other members of DExD/H-box 
RNA helicase family have been described in several other cancers as well as in 
myeloid neoplasms, where they can act both as tumour suppressors and oncogenes 
(Fuller-Pace, 2013).   
 
Finally, DDX41 and other members of the DEAD/H-box family gene variants are 
identified functionally relevant as a novel family of variants with implications for 
prognosis and treatment of myeloid malignancies, which may lead to approaches of 
therapeutic schedule (Antony-Debré & Steidl, 2015). Nonetheless, the role of DDX41 
in haematopoiesis and leukemogenesis is not yet clear and further studies are 
required to better explain its function and molecular pathway (Jiang et al., 2017). 
 
 
4.1.5 The role of DDX41 in ribosome biogenesis and in post-
transcriptional regulation of protein translation in cell growth  
 
In addition to mRNA splicing deficiency due to defective DDX41 demonstrated by 
Polprasert et al. (2015), Kadono et al. (2016) reported three patients harbouring the 
somatic DDX41 R525H variant that commonly exhibited sporadic AML with bone 
marrow cytopenias and low blast counts as also seen in Lewinsohn et al. (2016). They 
suggested that the cell growth arrest seen in cells harbouring this somatic variant in 
their experiments is due to impaired pre-ribosome RNA (rRNA) processing by the loss 
of ATPase activity of the protein, suggesting that DDX41 plays a role in ribosome 




To investigate the molecular functions of DDX41 in hematopoietic cells, Kadono et al. 
(2016) firstly observed that ectopically expressed DDX41 in murine fibroblasts and in 
THP- leukaemia cell line (human monocytic cell line derived from an acute monocytic 
leukaemia patient) was mostly nuclear regardless of the p.R525H presence. Then, 
they demonstrated that this acquired variant inhibits haematopoietic cell cycle growth 
in mutant cord blood-derived human CD34+ cells compared to the wild-type cells 
control. Subsequently, data from a gene set enrichment analysis in the cultured 
mutant and wild-type cord blood-derived human CD34+ cells, suggested that a certain 
ribosomopathy may occur in the cells expressing DDX41 pR525H as there was a 
suppression of mRNA encoding ribosomal proteins. They have also demonstrated 
that the altered DDX41 presented a lower ATPase activity by an ATPase assay.  
   
In humans, the processing of pre-rRNA occurs mainly in the nucleolus, where 
approximately 4,500 putative nucleoclar proteins and small nucleolar RNAs are 
thought to participate in this process (Ahmad et al., 2009). Kadono et al. (2016) 
proposed that the haematopoietic cell growth deficiency in patients with DDX41 
R525H variant is caused by the inhibition of E2F transcription factor 1 (E2F) activity, 
which is caused by an activation of retinoblastoma tumour suppressor (RB). The RB-
E2F pathway regulates the cell cycle progression and cell death and consists of 
inhibitors and activators of cyclin-dependent kinases, the RB, and the E2F-family of 
transcription factors. According to Kadono et al. (2016), the somatic DDX41 R525H 
variant negatively affects rRNA synthesis, which consecutively releases ribosomal 
proteins. Released ribosomal proteins eventually bind to MDM2 proto-oncogene 
(MDM2) and RB pathway is consecutively activated, resulting in cell growth arrest.  
 
On the other hand, data from Peters et al. (2017) studies in HCT116 colon carcinoma 
cells, supports an oncogene role for DDX41. They identified DDX41 as a negative 
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regulator of cyclin-dependent kinase inhibitor 1A (CDKN1A) or p21 protein translation 
via association with the 3’UTR of its mRNA in the presence of p53 independently of 
stress, however this mechanism is not associated with the transcriptional activity of 
p53. p21 functions as tumour suppressor in several cancer cell lines, including 
HCT116.  
 
p21 is the most studied cyclin-dependent kinase protein inhibitor. It tightly controls 
cyclin-dependent kinase proteins, which are serine/threonine kinases that regulates 
cell cycle. p21 regulates cell growth and apoptosis in the presence of the tumour 
suppressor protein p53 in response to a variety of stress stimuli. p21 also functions 
both as tumour suppressor and as oncogene important in stress pathways. Although 
nuclear p21 functions predominantly as a tumour suppressor by negatively regulating 
DNA replication and cell proliferation, cytoplasmatic p21 acts in an oncogenic manner 
by facilitating cell proliferation, inhibiting apoptosis, and regulating migration 
(Malumbres & Barbacid, 2009).  
 
Interestingly, Peter et al. (2017) also found that DDX41 requires its helicase activity 
to regulate p21 expression at the translational level by generating a DDX41 missense 
variant (G521S) in the motif VI (which is essential for ATP hydrolysis and, thus, 
helicase activity of DEAD-box proteins) and comparing luciferase activities in 
response to either the mutant or the wild-type DDX41 protein in HCT116 cells.  
 
Finally, other DEAD box proteins such as DDX3 and DDX5 have also been 
demonstrated to control expression of p21. They transcriptionally up-regulate p21 
indirectly in a p53-dependent manner (Wu et al., 2011; Nicol et al., 2013). 
Furthermore, as observed in DDX41 and p21, DDX3, DDX5 and DDX17 have been 
described functioning as both tumour suppressor and as oncogene under different 
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intracellular conditions, depending on the cancer type, treatment modalities, and 
several co-factors (Chao et al., 2006; Yang et al., 2007; Botlagunta et al., 2008; 
Germann et al., 2012). Nonetheless, further investigation is required to clarify how 
defected DDX41 in the cells could result into the development of haematological 







We have undertaken a combination of whole exome and targeted sequencing to 
characterise 55 families from our independent cohorts (DC, idiopathic BMF and 
familial MDS/AML registries). The targeted sequencing employed a newly designed 
familial MDS/AML gene panel which included the nine genes, where germline 
heterozygous variants have been identified in association with development of familial 
MDS/AML to date. These are RUNX1, CEBPA, TERC, TERT, GATA2, SRP72, 
ANKRD26, ETV6, and DDX41. This analysis has enabled us to identify four families 
harbouring heterozygous germline DDX41 variants (Figure 4.4A-D); three families 
have novel frameshift variants (c.155dupA, c.1586_1587delCA and c.719delTinsCG) 
and the fourth family has a recurrent missense variant in the initiation codon (c.3G>A, 
rs141601766) described previously by Polprasert et al. (2015) and Lewinsohn et al. 
(2015). Collectively these four families comprise seven cases of MDS and two cases 
of AML (age range, 40 to 70 years). These patients did not have any extra-



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.1 DDX41 germline variants identified in our cohort  
 
In Family 1 (Figure 4.4A), a novel heterozygous germline variant c.155dupA 
(p.Arg53Alafs*16 showed in Figure 4.4E) in DDX41 was identified in the 49 year-old 
female index case (III:1, Figure 4.4A) diagnosed with MDS, refractory anaemia with 
excess blasts (RAEB). Sanger sequencing revealed that her maternal aunt and uncle 
who both developed RAEB also harbour this frameshift variant (individuals II:3 and 
II:2, Figure 4.4A respectively). There are two asymptomatic carriers (individuals II:1 
and II:4, Figure 4.4A), supporting previous observations that haploinsufficiency for 
DDX41 shows variable penetrance (Lewinsohn et al., 2015). Further family history 
included her father who died of chronic myeloid leukaemia (CML), unlikely to be 
related to the DDX41 variant. 
 
In Family 2 (Figure 4.4B), the index case is a 60 year-old male (II:1, Figure 4.4B) with 
AML harbouring a novel heterozygous frameshift variant c.719delTinsCG 
(p.Ile240Thrfs*108), predicted to cause truncation of the protein and consequent loss 
of function. His mother died of AML (I:1, Figure 4.4B). Segregation analysis was not 
possible as there were no family samples available, however the variant allele 
frequency in the index case is 0.494 indicating heterozygosity. This variant is located 
in the DEAD box domain of DDX41, in a highly conserved motif that includes the ATP 






Figure 4.4. Familial MDS/AML caused by LoF DDX41 variants. A-D. Families with MDS/AML 
with variants in DDX41, their age at diagnosis and their respective Sanger sequencing traces. 
Affected individuals are coloured as follows: red, MDS; yellow, CML; black, AML; and green, 
other non-haematological cancer. E. Schematic of DDX41 protein showing the heterozygous 
variants identified in this study. CML, chronic myeloid leukaemia. 
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The 58 year-old female index case in Family 3 (II:2, Figure 4.4C) with MDS, has a 
novel frameshift deletion variant c.1586-1587delCA (p.Thr529Argfs*12) in the 
helicase domain of DDX41 (Figure 4.4E), which is again predicted to cause truncation 
of the protein. Her brother had tongue cancer (II:4, Figure 4.4C), her mother had MDS 
(I:1, Figure 4.4C) and her father had stomach cancer (I:2, Figure 4.4C). In the absence 
of samples of the index case’s parents, Sanger sequencing was undertaken on 
samples from her siblings and children. The siblings (II:3 and II:4, Figure 4.4C) of the 
index case do not harbour the variant c.1586-1587delCA, whilst her daughter (III:2, 
Figure 4.4C) is an asymptomatic carrier. This suggests that the index case and her 
mother (both with MDS) have disease associated with the DDX41 variant, while the 
non-haematological cancers seen in her brother (II:4, Figure 4.4C) and father (I:2, 
Figure 4.4C) are unrelated to DDX41.  
 
The index case of Family 4 (Figure 4.4D) is a 41-year-old female (II:1, Figure 4.4D) 
diagnosed with MDS/RAEB. Her father (I:2, Figure 4.4D) was also diagnosed with 
MDS at age 64 years. The heterozygous missense variant c.3G>A (p.Met1Ile – 
rs141601766, showed in Figure 4.4E) in DDX41 which segregated with disease in 
these two individuals has been reported in ExAC database in 6/117,464 alleles 
(http://exac.broadinstitute.org/, accessed 15th March 2016). Interestingly, both cases 
with the c.3G>A variant also carried a linked 5’UTR variant (c.-44G>A showed in 
Figure 4.4D) previously observed by Lewinsohn et al. (2015). They also demonstrated 
that HEK293 cells ectopically expressing the Met1Ile mutant protein used an 
alternative translation initiation site yielding a smaller cytoplasmatic DDX41 protein 
when compared to the nuclear full-length of 70kDa. Their experiments suggest that 




4.2.2 Telomere length analysis in patients harbouring DDX41 
variants 
 
Kirwan et al. (2009) demonstrated that TERC/TERT familial MDS/AML patients have 
a significant shorter telomere compared to controls. To investigate whether DDX41 
familial MDS/AML families present with short telomeres, we measured the telomere 
length by monochrome multiplex quantitative PCR method (Cawthon, 2009) in the 
DDX41 MDS/AML patients which we had available sample. We found a slightly 
shorter telomere length in these patients compared to controls (p<0.05, Figure 4.5). 






















C o n tro ls
M D S /A M L  p a tie n ts  w ith
D D X 4 1 v a ria n ts
 
Figure 4.5. Telomere lengths are slightly shorter in affected individuals (p<0.05). Telomere 
lengths were measured by MMqPCR using matched age control. 
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4.3 Discussion  
  
Here, we reported four new MDS/AML families harbouring LoF variants likely to be 
disease causing in DDX41 gene with probands presenting slightly short telomeres 
when compared to controls. Further functional studies would be necessary to confirm 
pathogenicity of the variants in these families. Three families presented novel 
frameshift variant causing premature stop in the protein and one is a recurrent variant 
missense in the start transcription codon. Most of the variants found in DDX41 to date 
are heterozygous LoF that cause truncated protein, suggesting that DDX41 familial 
MDS/AML is caused by haploinsufficiency. Additionally, the frequent occurrence of 
asymptomatic carriers demonstrates the variable penetrance of DDX41 variants as 
well as its association with the long latency period of this disease. Indeed, DDX41 has 
only recently been associated with the development of familial MDS/AML and the 
identification of more families with germline DDX41 variants is important to further 
clarify the prevalence and penetrance of these variants, as well as the prognosis of 
individuals that develop the disease (Li et al., 2016).                           
 
The recurrence of the Met1Ile variant in the ExAC database poses an interesting 
question as to the causative role of DDX41 variants in MDS/AML. Excluding any non-
canonical and dubious calls in this database, LoF variants (including Met1Ile) are seen 
to occur at a cumulative frequency of 1 in 1,189 people (46 LoF variants in an average 
of 109,354 alleles). This is in stark contrast to the few LoF variants reported in RUNX1 
(7), CEPBA (0), GATA2 (0) and ETV6 (4). We also note that in a screen of 1,045 
patients with MDS and secondary AML, 16 patients (1 in 65) had germline LoF 
variants in DDX41 (Polprasert et al., 2015). These data indicate that rather than 
establishing a causal Mendelian link between germline LoF DDX41 variants and 
MDS/AML, it is better to think of them as genetic risk factors. Comparing the frequency 
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of LoF DDX41 variants seen in MDS and secondary AML with the frequency seen in 
ExAC database we obtain an odds ratio of 8.05 (p = 5.65x10-5, Fisher’s Exact Test). 
Allowing for a 1/100 probability of getting the disease, this would translate to a relative 
risk of 7.51. It is inevitable therefore, that MDS/AML driven by DDX41 LoF variants 
will sometimes appear as familial. 
 
Patients described in this study presented median age at diagnosis of 58 years 
corroborating with the observation that DDX41 families with MDS/AML develop the 
disease at an age characteristic of de novo disease and this late presentation makes 
it difficult to distinguish hereditary factors from aging and cumulative environmental 
exposures (Sekeres, 2010). The late onset of MDS/AML cases suggests that germline 
variants in DDX41 alone does not cause MDS/AML. This is supported by the 
incidence of several other somatic variants in genes known to cause sporadic 
hematologic malignancies and familial MDS/AML such as TP53, RUNX1, LUC7L2, 
DNMT3A and ASXL1 alongside to the predisposition for somatic DDX41 variants in 
patients carrying germline DDX41 variants seen in Polprasert et al. (2015) and Berger 
et al. (2017). Polymorphisms in GATA2, TERT, ANKRD26, ASXL1 and DNMT3A were 
also found in our patients carrying DDX41 germline variants. In addition, population-
based studies have revealed that clonal haematopoiesis might occur during aging, 
whereby TET2, DNMT3A, TP53 and ASXL1 are the most altered genes (Jaiswal et 
al., 2014).  
 
Works on DDX41 function have so far implied the involvement of this RNA helicase 
in different pathways such as immune response, mRNA splicing, ribosome biogenesis 
and regulation of protein translation. Intriguingly, none of the reported DDX41 
MDS/AML families presented impaired immune system. As consequence, DDX41 
involvement in immune response is yet to be linked to a disease phenotype.   
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Despite of the genetic underlying cause of familial MDS/AML in patients with germline 
variants in DDX41, its precise mechanism is far to be elucidated. Polprasert et al. 
(2015) using different assays in myeloid and primary cells, demonstrated a tumour 
suppressor role for DDX41 along with the findings that DDX41 interacts with several 
spliceosome proteins and that the somatic DDX41 variant p.R525H altered the native 
DDX41 interactome especially for major components in U2 and U5 spliceosomes. 
Furthermore, they demonstrated that DDX41 defects impaired mRNA splicing of 
several genes in patient-derived cells. Additionally, while investigating the cause of 
sporadic AML in three patients harbouring the somatic DDX41 p.R525H variant, 
Kadono et al. (2016) demonstrated as expected that this somatic variant is 
responsible for the loss of ATP hydrolysis of DDX41 as well as for the cell growth 
arrest in mutated CD34+ cells from cord blood. This cell cycle inhibition was caused 
by a disruption of pre-rRNA synthesis. It is not yet clear how this disruption occurs, 
although their data from a gene set enrichment analysis from mutated CD34+ and 
patient-derived cells showed that the cell cycle was inhibited by the suppression of 
E2F activity through the RB-E2F pathway. They concluded that this event coupled 
with age-dependent epigenetic alterations or additional somatic variants might 
collaborate with the somatic DDX41 p.R525H to cause AML in the analysed patients.  
 
Conversely, Peters et al. (2017) identified DDX41 as negative regulator of p21 mRNA 
translation p53-dependent and independently of stress suggesting an oncogene role 
for DDX41 as p21 functions in several cancer cell lines in an antiapoptotic manner. 
This result is consistent with data from a genome-scale RNA-mediated interference 
screen in HeLa cells (human epithelial cells) demonstrating reduced cell numbers 
following knockdown of DDX41 (Kittler et al., 2007). Although being contradictory to 
Polprasert et al. (2015) results, other DExD/H-box RNA helicases were described as 
oncogene or tumour suppressor depending on the cancer type, treatments modalities, 
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and several co-factors. Comparatively, DDX5 transcriptionally up-regulates p21 
indirectly in a p53-dependent manner (Bates et al., 2005; Chao et al., 2006) exhibiting 
tumour suppressor activity (Nicol et al., 2013) whilst demonstrating oncogenic 
functions when up-regulating pro-proliferative genes such as cyclin D1 (CCND1) and 
MYC proto-oncogene, bHLH transcription factor (MYC), as well as genes required for 
DNA replication (Yang et al., 2007). Interestingly, Polprasert et al. (2015) identified 
variants in other members of the DExD/H-box RNA helicase family in about 4% of 
patients in their cohort, while we have identified rare variants in these genes in 18% 
of ours suggesting that RNA helicase variants represent an entire new family of 
variants in myeloid neoplasms.   
 
Furthermore, Peters et al. (2017) demonstrated that DDX41 requires its helicase 
activity to regulate p21 expression at the translation level. Thus, the somatic p.R525H 
variant is possibly hypomorphic as it severely affects the helicase activity of DDX41 
based on its location. Therefore, this somatic variant probably disrupts most of the 
putative DDX41 functions described to date.   
    
In summary, we reported on novel germline heterozygous LoF DDX41 variants 
exhibiting variable penetrance in families with MDS/AML and tendency to short 
telomeres. Our analysis suggests that rather than establishing a causal Mendelian 
link between DDX41 germline LoF variants and MDS/AML it is appropriate to consider 
these as genetic risk factors. Furthermore, additional studies are required in order to 






















Due to the fact that there is a considerable clinical heterogeneity and overlapping 
features seen in patients with dyskeratosis congenita and Hoyeraal Hreidarsson 
syndrome and that these are bone marrow failure disorders that can develop into 
myelodysplasia and/or acute myeloid leukaemia, we analysed our cohort of patients 
with dyskeratosis congenita, Hoyeraal Hreidarsson, aplastic anaemia, 
myelodysplasia and/or acute myeloid leukaemia families in search of disease causing 
variants in genes in patients with these phenotypes.  
 
As a result, in this chapter we associate heterozygous loss of function variants in the 
telomere maintenance gene regulator of telomere elongation helicase 1 (RTEL1), with 
liver disease and myelodysplasia, for the first time. Previously germline biallelic 
variants in RTEL1 have been shown to cause dyskeratosis congenita and Hoyeraal 
Hreidarsson syndrome and germline heterozygous variants in this gene are known to 
cause pulmonary fibrosis (which is present in approximately 20% of dyskeratosis 
congenita patients). This study therefore extends the range of phenotypes associated 
with germline RTEL1 variants by adding myelodysplasia and liver disease to the 
clinical spectrum of patients. 
 
 
5.1.1 RTEL1 protein structure and function  
 
RTEL1 is an iron-sulphur (FeS) ATP-dependent DNA helicase with 1,243 amino 
acids, classified as a RAD3-related helicase, which belongs to the DEAH subfamily 
of the Superfamily 2 (SF2) helicases. The Rad3-related DNA helicase is located in 
165 
 
the N-terminal side of the protein and consists of four domains: two Rec-A-like motor 
domains; helicase domain (HD1 and HD2); a Fe-4S cluster; and an ARCH domain 
(Figure 5.1). RTEL1 is part of a subclass of FeS cluster-containing DNA helicases 
known as XPD family, which includes the proteins Xeroderma pigmentosum group D 
(XPD), DEAD/H-box helicase 11 (DDX11) and Fanconi anemia group J protein 




Figure 5.1. Schematic of RTEL1 protein. Putative functions of RAD3, Hamonin-N-like 
(HN_RTEL1) and PIP domains are shown (NP_116575; ENST00000508582). 
 
 
The XPD family of helicases are characterised by a FeS cluster composed of four 
conserved cysteine residues attached to iron ions. Studies in XPD protein revealed 
that its helicase activity is lost when the FeS domain is removed and that this domain 
recognises single-stranded DNA (ssDNA) and double-stranded DNA (dsDNA) (Pugh 
et al., 2008). Therefore, it is likely that the other FeS cluster containing helicases, 
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including RTEL1 also recognise ssDNA and dsDNA based on the sequence similarity 
of the helicase core domain (Uringa et al., 2011).  
 
In addition to its helicase motifs and FeS domain, RTEL1 has a conserved eight amino 
acid PIP box (Warbrick, 1998) (Figure 5.1). PIP box is a proliferating cell nuclear 
antigen interacting protein (PCNA) interaction motif and PCNA is a highly conserved 
eukaryotic protein that functions in DNA replication and acts as a cofactor for DNA 
polymerases.  
 
Variants in XPD, FANCJ and DDX11 cause the genetic disorders xeroderma 
pigmentosum (XP) (Andressoo et al., 2005), Fanconi anaemia (Bridge et al., 2005) 
and Warsaw breakage syndrome (van der Lelij et al., 2010), respectively. 
Furthermore, variants in RTEL1 cause dyskeratosis congenita (Walne et al., 2013a), 
Hoyeraal Hreidarsson syndrome (Ballew et al., 2013; Deng et al., 2013; Le Guen et 
al., 2013), familial pulmonary fibrosis (Kannengiesser et al., 2015; Cogan et al., 2015) 
and myelodysplasia and liver disease (Cardoso et al., 2017; work presented in this 
chapter).  
 
RTEL1 is essential in maintaining genome stability by disassembling DNA secondary 
structures formed during DNA repair, DNA recombination, and DNA replication and it 
is also essential in telomere maintenance (Barber et al., 2008; Vannier et al., 2014).  
RTEL1 interrupts D-loop formation in homologous recombination upon DNA double-
strand breaks (DSBs) formation (Barber et al., 2008; Uringa et al., 2011; Vannier et 
al., 2012) and it is also crucial for the disruption of G-rich DNA secondary structures 
and T-loops during DNA replication, thereby protecting telomere length (Ding et al., 




5.1.2 RTEL1 in homologous recombination 
 
The stability of the genome is critically dependent on the coordinate action of DNA 
repair pathways during cell cycle (Chapman et al., 2012). Homologous recombination 
(HR) is an essential conserved process for dividing cells. In mitosis, HR is required 
not only for the accurate repair of DNA DSBs but also for the restart of stalled 
replication forks. In meiosis, HR is crucial for DSB repair and limitation of excessive 
crossing over, which is required for accurate chromosome segregation at the first 
meiotic division (Youds et al., 2010).  
 
In HR, the sister chromatid or the homologous chromosome is used as a template for 
repair through synthesis-dependent strand annealing pathway (SDSA). This involves 
temporary engagement of a homologous DNA duplex that serves as an information 
donor by acting as a template for DNA synthesis at the repair site (Pâques & Haber, 
1999).  
 
Studies have shown that in HR DNA repair, a DSB is rearranged to produce 3’ single-
stranded DNA tails that are bound by the DNA strand exchange protein RAD51 to 
form a nucleoprotein filament (Sung et al., 2003). These filaments are the catalyst for 
strand invasion into homologous duplex DNA, resulting in the formation of a 






Figure 5.2. RTEL1 role in homologous recombination. A. Homologous recombination 
pathways of double-strand break repair. B. Model for RTEL1 promoting synthesis-dependent 
strand annealing producing a non-crossover repair product. Adapted from Villeneuve (2008) 
and Uringa et al. (2010). 
 
 
The invading 3’ end forms a D-loop and provides a primer for DNA synthesis, which 
can be resolved either through displacement of the invading strand from the D-loop 
and annealing to the other DSB end (synthesis-dependent strand annealing), 
resulting in a non-crossover repair product, or by the capture of the other resected 
end by the altered strand of the D-loop to form a double Holliday junction (dHJ). HR 
can be completed by endonucleolytic cleavage of the two HJs, which may result in a 
crossover repair product (Barber et al., 2008). 
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Therefore, HR repairs DSBs through either a crossover or a non-crossover event 
(Bishop et al., 2004). Meiotic DSBs are not randomly distributed along chromosomes 
but tend to occur in specific regions (Handel & Schimenti, 2010). This ensures that 
each pair of homologs gets at least one obligate crossover, however how specific 
DSBs are selected to become crossover is unknown. A mechanism called crossover 
interference regulates the distribution of crossovers along the chromosome in such 
way that crossovers tend to occur further apart from each other than expected by 
chance. Furthermore, crossover homeostasis occurs when the number of meiotic 
DBSs is reduced, the number of crossover is maintained at the expense of non-
crossover (Martini et al., 2006). 
 
Barber et al. (2008) demonstrated that RTEL1 actively reverts HR at an early stage 
after strand invasion by D-loop dissociation activity in the presence of calcium, 
promoting a non-crossover repair product (Figure 5.2) and inhibiting the formation of 
D-loops in vitro. Biochemical studies done by the same group revealed that human 
RTEL1 disrupts D-loops in HR in both mitotic repair and regulating meiotic 
recombination. Subsequent studies demonstrated that RTEL1 controls excessive 
crossover products in meiosis and thus impacts on the outcome of the HR reaction 
(Sung & Klein, 2006; Youds et al., 2010). 
 
Inappropriate HR can give rise to genome instability and cancer as a result of 
erroneous chromosomal rearrangements and the persistence of intermediate 
recombination structures such as D-loops that cannot be resolved. Hence, HR must 
be tightly regulated and temporally coordinated with cell-cycle progression and 
replication (Barber et al., 2008). HR is also important for the formation of T-loop 
structure at telomeres, which protects the chromosome end from degradation and 
inappropriate repair (Vannier et al., 2014). 
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Although, Barber et al. (2008) were the first to demonstrate that RTEL1 is a conserved 
anti-recombinase protein, RTEL1 was originally identified through genomic mapping 
of loci that control telomere length in mice (Zhu, et al., 1998). Then the role of RTEL1 
in telomere homeostasis was proposed by Ding et al. (2004) when Rtel1 knockout in 
mice was found to be embryonic lethal and inefficient removal of DNA secondary 
structures at telomeres could be the reason. This was based on the fact that RTEL1 
is most related to human FANCJ and C. elegans DOG-1, which unwind DNA 
secondary structures.   
 
 
5.1.3 RTEL1 in telomere maintenance  
 
Telomeres are DNA-nucleoprotein complexes that maintain genomic stability by 
protecting the ends of eukaryotic chromosomes (Uringa et al., 2011). In most 
eukaryotic species, telomeric DNA consists of short G-rich repeat sequences 
synthesized by telomerase (Greider & Blackburn, 1985; Singer & Gottschiling, 1994). 
Telomeric DNA in vertebrates consists of a double-strand region composed of 
TTAGGG repeats associated to proteins, forming the sheltering complex (de Lange, 
2005) (Figure 5.3).   
 
An important function of telomeres is to distinguish normal chromosome ends from 
DSBs, which avoid chromosome end-to-end fusions and inappropriate recombination 
events (de Lange, 2009). Most proteins that are specific for telomere maintenance 
(such as telomerase and RTEL1) are recruited to telomeres via the shelterin complex 




Figure 5.3. Schematic of the human telomere structure and the shelterin complex. Adapted 
from Titia de Lange (2004). 
 
 
The shelterin complex includes telomere-specific binding proteins such as telomere 
repeat binding factor 1 (TRF1), telomere repeat binding factor 2 (TRF2), repressor 
activator protein 1 (Rap1), TINF2-interacting protein 2 (TTP1), protection of telomeres 
1 (POT1) and ACD, shelterin complex subunit and telomerase recruitment factor 
(ACD) that function to regulate telomerase and protect the telomeres (de Lange, 2005; 
Bauman & Cech, 2001). In the absence of such proteins, DNA repair-specific proteins 
are recruited to chromosome ends to avoid chromosome fusions (Mieczkowski et al., 
2003), chromosome end reallocation (Hackett & Greider, 2003) or other forms of 
potentially lethal DNA damage (Takai et al., 2003; Zhu et al., 2003). 
 
Telomeric DNA shortens in each round of DNA replication because of incomplete 
replication of lagging strand DNA (Lansdorp, 2005) and it could also be lost by C 
strand degradation (Makarov et al., 1997), oxidative stress (von Zglinicki, 2002), and 
possibly other mechanisms. Telomere length is maintained by telomerase, a reverse 
transcriptase that utilizes an associated RNA component (TERC) as a template to 
add de novo telomeric sequences to the 3’ end of the G-rich strand of the telomere 
(Greider & Blackburn, 1985; Shippen-Lentz & Blackburn, 1990), or by an alternative 
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telomere length (ALT) maintenance mechanism that utilises HR in some cancer cells. 
Cells with short telomeres that lack telomerase activity typically lose the ability to 
proliferate after a variable number of cell divisions (Blackburn, 2001). It is known that 
a minimum number of telomere repeats is required at each chromosome end for 
proper telomere function and to distinguish telomeres from DSBs. Excessive telomere 
shortening accelerates aging, but telomere elongation may facilitate cancer (Deng et 
al., 2013). 
 
The telomere consists of a 3’ single-strand G-rich overhang that invades into duplex 
telomeric TTAGGG repeats to form a T-loop structure (Griffith et al., 1999; Doksani et 
al., 2013). The T-loop structure requires both HR and shelterin complex for its 
assembly as they catalyse the invasion of the single-stranded telomere end into the 
subtelomeric region, displacing the identical sequence strand of the duplex telomeric 
DNA generating a D-loop at the base of the T-loop (Figure 5.4) (de Lange, 2004; 
Verdun & Karlseder, 2006 and Amiard et al., 2007). The D-loop is also an intermediate 
in the DNA repair pathway via homologous recombination as described previously. 
 
HR has been shown to cause deletion of the protective T-loop to permit telomere 
replication (Wang et al., 2004). RTEL1 unwinds the T-loop structure by disrupting D-
loop to allow telomerase access to complete chromosome end replication during cell 
cycle. Failing to open the T-loop for replication and/or transcription may lead to large 




Figure 5.4. T-loop structure. T-loop protects the telomere from being identified as a DSB and 
it is formed by the telomere end that folds back onto itself. D-loop is created when the 3’ 
overhang invades the double-stranded telomere. Black spiral indicates RTEL1. Adapted from 
Uringa et al. (2010). 
 
 
In the absence of RTEL1, the T-loops are inappropriately resolved by SLX4 nuclease 
complex, resulting in loss of the telomere as a circle (T-circle) (Figure 5.5). SLX4 
nuclease complex consists of SLX4 structure-specific endonuclease subunit (SLX4) 
and its associated nucleases MUS81 structure-specific endonuclease subunit 
(MUS81), ERCC excision repair 1, endonuclease non-catalytic subunit (ERCC1), and 
SLX1 structure-specific endonuclease subunit (SLX1). Studies have shown that the 
SLX4 nuclease complex is a Holliday junction-resolving enzyme that colocalises and 
interacts with the shelterin components TRF2 and Rap1 at telomeres (Muñoz et al., 
2009; Svendsen et al., 2009; Svendsen & Harper, 2010; Wilson et al., 2013).  It is 
possible that SLX4 nuclease complex is located at the telomeres to resolve persistent 
HR intermediates that may arise infrequently in normal cells. In contrast, SLX4 activity 
to resolve T-loops in RTEL1 deficient cells can also lead to telomere damages 





Figure 5.5. Schematic model of the role of RTEL1 in T-circle formation. Adapted from Vannier 
et al. (2012). 
 
 
Vannier et al. (2012) observed that inactivation of RTEL1 in vertebrate cells resulted 
in a rapid accumulation of T-circles and changes in telomere length and telomere loss. 
Furthermore, RTEL1 is required to prevent 3’ single strand telomere end from 
invading the telomeres of other chromosomes. This might prevent telomere 
175 
 
recombination events, chromosome entanglements and subsequent breakage when 
attached chromosomes attempt to segregate during mitosis (Uringa et al., 2011).   
 
Mammalian telomeres are difficult regions to replicate and resemble fragile sites, 
which are hot spots for deletions and other chromosome rearrangements and are 
associated with an increased frequency of HR (Miller et al., 2006). Sfeir et al. (2009) 
showed that TRF1 recruits RTEL1 and Bloom syndrome RecQ like helicase (BLM) to 
prevent telomere fragility by resolving telomeric G-quadruplex structures (Figure 5.6). 
Although, Vannier et al. (2012) established that RTEL1 and BLM act in different 
pathways to facilitate telomeric DNA replication. 
 
In addition to the T-loop configuration, the guanine (G)-rich nature of the telomere 
poses a challenge for telomere maintenance by causing telomere fragility. In vitro, 
single-stranded G-rich telomeric sequences are capable of forming stable secondary 
structures called G-quadruplex (G4-DNA) DNA that prevent DNA replication (Vannier 
et al., 2012). In vivo, G4-DNA might form at telomeres during lagging strand 
replication, repair and transcription of G-rich telomeric DNA (Ding et al., 2004). 
Vannier et al. (2013) found that RTEL1 is able to unwind telomeric G4-DNA structures 
in vitro, suggesting that it also plays a role in suppressing telomere fragility. Thus, 
RTEL1 performs two functions essential for telomere integrity: it facilitates T-loop 
disassembly and telomeric G4-DNA unwinding.  
 
Additionally, RTEL1 is essential to facilitate DNA replication as described previously. 
The presence of RTEL1 within the replication foci is dependent on a PIP box 
interaction with PCNA, which is a processitivity factor for DNA polymerase and an 
integral component of the replisome during S-phase. Telomeric G4-DNA unwinding 
activity of RTEL1 is dependent on the replisome association between RTEL1 and 
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PCNA. Moreover, the RTEL1-PCNA interaction is also necessary to prevent 




Figure 5.6. Schematic model of the role of RTEL1 in suppressing G4-DNA structure. Adapted 




5.1.4 RTEL1 in human diseases 
 
5.1.4.1 RTEL1 germline biallelic variants leading to 
dyskeratosis congenita and Hoyeraal-Hreidarsson 
syndrome 
 
Germline biallelic variants in RTEL1 are associated with dyskeratosis congenita (DC) 
and its severe clinical variant Hoyeraal Hreidarsson syndrome (HH), which are caused 
by telomere dysfunction (Walne et al., 2013a; Deng et al., 2013; Jullien et al., 2016).  
 
DC is also known as Zinsser-Engman-Cole syndrome and it is a rare inherited multi-
system bone marrow failure syndrome which is characterised by the presentation of 
abnormal skin pigmentation, nail dystrophy, oral leukoplakia and a variety of other 
abnormalities including bone marrow failure, pulmonary, gastrointestinal, endocrine, 
skeletal, urological, immunological and neurological abnormalities (Walne et al., 
2013a; Walne et al., 2016). Its clinical features can manifest at variable ages, even 
within the same family (Alter et al., 2012).  
 
Usually ectodermal dystrophy is the first abnormality to appear in DC patients followed 
by over 50% of patients developing haematopoietic disorders (Walne & Dokal, 2008). 
A number of DC cases have been described where the patient has presented with 
anaemia or other related bone marrow failure disease, pulmonary fibrosis and/or liver 
disease with high risk of cancer development (Alter et al., 2009). Some studies have 
shown that pancytopenia associated with DC develops more as a result of an intrinsic 
defect in the haematopoietic stem cells rather than as a result of a defective 
haematopoietic microenvironment (Marsh et al., 1992). 
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Furthermore, Fanconi anaemia (FA) and DC are related disorders and clinical 
features overlap between them such as pancytopenia and bone marrow hypoplasia 
as well as a range of minor abnormalities in addition to mental retardation and 
generalised growth impairment (Dokal & Vulliamy, 2008). However, there are also 
clear differences between these two diseases, the main distinguishing feature is the 
difference in chromosomal breakage in culture when peripheral blood lymphocytes 
are stressed with clastogenic agents such as diepoxybutane, with breaks commonly 
appearing in FA. Whereas, in the majority of cases, chromosome breakage analysis 
of DC is reported as normal (Dokal, 2006). The chromosomal instability seen in DC 
patient cells usually tends to be chromosomal rearrangements such as end-to-end 
fusions instead of chromosomal breakage seen in FA patients. 
 
HH is a rare and severe multi-system disorder which is characterised by early onset 
of bone marrow failure, intrauterine growth retardation, developmental delay, 
microcephaly, cerebellar hypoplasia and immunodeficiency (Vulliamy et al., 2006). 
There is a high frequency of mortality from cancer and pulmonary fibrosis in patients 
with DC and HH (Tummala et al., 2015), however bone marrow failure is the major 
cause of death in this group of patients. 
 
DC and HH are clinically and genetically heterogeneous diseases with defective 
telomere maintenance being their principal pathology and they are associated with 
short telomeres (Dokal, 2011). Approximately two thirds of patients have germline 
variants in genes encoding components of telomerase (TERT, TERC, DKC1, NOP10, 
NHP2) (Jullien et al., 2016; Deng et al., 2013; Ballew et al., 2013; Tummala et al., 
2015; Walne et al., 2013b), or other factors related to telomere maintenance (TINF2, 
WRAP53, CTC1, RTEL1, PARN, and ACD) (Walne et al., 2013a; Tummala et al., 
2015 and Cogan et al., 2015). Rare damaging variants in these genes segregate with 
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disease in autosomal dominant (AD), autosomal recessive (AR) or X-linked (XL) 
recessive patterns of inheritance. The molecular basis of the various DC and HH 
pathologies is therefore thought to be an accelerated telomere shortening and a 
consequent impairment of cell proliferation (Pereboeva et al., 2013). Vulliamy et al. 
(2004) observed disease anticipation associated with progressive telomere 
shortening in the development of AD form of DC in families harbouring variants in 
TERC, which implies that the disease become more severe in successive generations 
and the telomere lengths were significantly shorter in the affected children compared 
to their affected parents. Genetic anticipation has been reported also in TERT and 
TINF2 pedigrees by Armanios et al. (2005) and Savage & Bertuch (2010). In addition, 
haploinsufficiency is the mechanism that leads to the AD-DC phenotype in most cases 
(Armanios et al., 2005).  
 
Walne et al. (2013a) and Deng et al. (2013), demonstrated that defective human 
RTEL1 has a damaging effect on telomere maintenance, suggesting that incorrect 
resolution of T-loops is a mechanism for telomere shortening in humans. 
 
Overall, about 30% of DC and HH cases remain genetically uncharacterised 
highlighting the need to search for new disease causing genes (Tummala et al., 2015). 
 
 
5.1.4.2 RTEL1 germline heterozygous variants leading to 
pulmonary fibrosis 
 
Up to 20% of cases of idiopathic interstitial pneumonia (IIP) occur in two or more 
members of the same family, comprising the syndrome of familial interstitial 
pneumonia (FIP). The most common and severe form of interstitial pneumonia is 
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pulmonary fibrosis; which is a progressive scarring of the alveolar interstitium, often 
leading to hypoxemic respiratory insufficiency. It is characterised by an accumulation 
of extracellular matrix and fibroblasts in the distal lung (Kannengiesser et al., 2015). 
Approximately one in five cases of pulmonary fibrosis run in families (King et al., 
2011).  
 
Familial and sporadic pulmonary fibrosis diseases are clinically and histologically 
indistinguishable, but familial pulmonary fibrosis tends to present at an earlier age and 
might differ slightly in radiological pattern (Spagnolo et al., 2014).  The age of disease 
onset is between 50 to 70 years and it can be associated with environmental 
exposures, such inhalation of fibrogenic dusts or aerosolised organic antigens; drug 
toxicity; systemic diseases such as connective tissue diseases; by genetic variation; 
or occur isolated, sporadic disease without extra-pulmonary involvement (as seen in 
IIP) (Steele, et al., 2005).  
 
Rare heterozygous variants causing FIP were identified in genes involved in 
pulmonary surfactant metabolism such as surfactant protein A2 (SFTPA2), surfactant 
protein C (SFTPC) and ATP-binding cassette subfamily A, member 3 (ABCA3) (Wang 
et al., 2009; Thomas et al., 2002; Nathan et al., 2012), and in genes related to 
telomere biology such as TERT, TERC, dyskerin (DKC1), TINF2, PARN poly(A)-
specific ribonuclease (PARN), RTEL1 and nuclear assembly factor 1 
ribonucleoprotein (NAF1) (Armanios et al., 2007; Tsakiri, et al., 2007; Kropski et al., 
2014; Fukuhara et al., 2013; Stuart et al., 2015; Cogan et al., 2015; Stanley et al., 
2016). These variants are reported to segregate with an autosomal dominant pattern 
of inheritance and are associated with short telomeres and variable penetrance. Short 
telomeres are commonly identified in blood cells in patients with sporadic and FIP 
also in the absence of known variants in telomere-related genes. 
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Interestingly, variants in TERT, TERC, DKC1, TINF2, PARN, and RTEL1 were 
primarily described being responsible for DC and HH and pulmonary disease is found 
in 20% of DC patients with variants in these genes. However, the mechanism by which 
telomerase dysfunction and short telomeres lead to lung fibrosis is unknown. It is 
possible that telomerase pathway variants lead to premature senescence of 
progenitor cells of the distal lung, resulting in a proliferative defect and failure of repair 
mechanisms following injury to the alveolar epithelium. Further studies are necessary 
to clarify the mechanistic role of RTEL1 and the other genes involved in telomere 








By undertaking whole exome and targeted sequencing in 429 patients with diverse 
bone marrow failure phenotypes (DC, HH, AA and MDS/AML) we have identified 35 
patients with 27 RTEL1 variants (canonical transcript, NM_032957.4, NP_116575.3, 
1,243 amino acids). These are detailed in Table 5.1. Based on the minor allele 
frequency (MAF) in the population reported on ExAC database, the type of variant 
(missense, nonsense and indels), the telomere length, the Combined Annotation 
Depletion (CADD) score (Kircher et al., 2014), and their segregation as well as 
information found in the literature, we classified these variants into four different 
groups: (1) biallelic variants, (2) heterozygous loss of function (LoF) variants, (3) 
heterozygous missense variants of unknown significance and (4) heterozygous 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2.1 RTEL1 germline variants identified in our cohort  
 
5.2.1.1 Patients with biallelic RTEL1 variants  
 
Four homozygous and one compound heterozygous (Table 5.1 and 5.2) were 
identified in five patients from unrelated families (Families 1 to 5), two of whom 
presented with AA, two with DC and one with HH. The six variants identified fall in the 




Figure 5.7. RTEL1 variants. Biallelic variants are shown in blue, and heterozygous LoF 
variants are shown in red. Conserved protein domains (NP_116575.3) include the P-loop 
NTPase (yellow); the Rad3 domain (green) that includes the DEAD2 domain (red) and the 
Helicase C-terminal domain (purple); Harmonin N-like domain (blue); PIP-box – the 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The proband of Family 1 (II:2, Figure 5.8) was a 36 year old female presenting with 
AA and short stature who had the homozygous missense variant, c.2942 G>A, 
p.R981Q. This RTEL1 variant is seen in the ExAC database in a heterozygous state 
with a frequency of 1 in 119,934. Hence, the homozygous occurrence of c.2942 G>A, 
p.R981Q is predicted to be extremely rare and in the context of very short telomeres 
and a high CADD score (Table 5.1), we believe this variant is likely to be disease 
causing in this patient.  
 
In Family 2, the female proband (III:3, Figure 5.8) had AA and short telomeres (Table 
5.1 and 5.2). She had a bone marrow transplant at age 12 years from her HLA-
matched brother, but developed significant complications following post-transplant. 
This included bone marrow failure and pulmonary fibrosis and she died aged 16 years. 
Her donor (brother) went on to develop AA which was responsive to therapy with 
danazol (III:4, Figure 5.8). The proband’s maternal grandmother died of pulmonary 
fibrosis aged 70 years (I:1, Figure 5.8). Both siblings, offspring of a consanguineous 
marriage, were homozygous for the missense variant c.3286 G>T, p.G1096W, seen 
in ExAC in a heterozygous state with the frequency of 1 in 118,164. We believe this 
variant is pathogenic in this case. The proband’s asymptomatic parents in their forties 
were heterozygous for this variant (II:1 and 2, Figure 5.8). 
 
The proband of Family 3, was a 14-year-old male (II:2, Figure 5.8) from a 
consanguineous marriage with features of DC as well as very short telomeres (Table 
5.1 and 5.2). He was homozygous for the novel missense RTEL1 variant c.2300 G>A, 
p.R767Q, which we believe to be disease causing. His asymptomatic parents (I:1 and 
2, Figure 5.8) and one of his asymptomatic younger brothers (II:6, Figure 5.7) were 




Figure 5.8. Families with biallelic RTEL1 variants and sequencing traces of index cases. 
Families 1, 2, 3 and 5 are homozygous; Family 4 is compound heterozygous. The genotyping 
is denoted as follows: wild-type (+/+), heterozygous (+/-) or biallelic (-/-). The age at study is 
given in years. Affected individuals are coloured in black. NA: not available. 
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The proband of Family 4 (II:2, Figure 5.8) was a 15-year-old female with DC with short 
telomeres (Table 5.1 and 5.2). She was found to harbour a compound heterozygous 
variant, a novel in-frame deletion c. 2785_2787delCAG, p.Q929del and a recurrent 
nonsense variant c.2992 C>T, p.R998* (MAF: 2 in 119,914 in ExAC).  
 
The proband (II:4, Figure 5.8) in Family 5 was diagnosed with HH when she was 2 
years old. She came from a family with history of multiple consanguineous marriages 
through generations. She had intrauterine growth restriction, bone marrow failure, low 
B cell numbers, developmental delay, cerebellar hypoplasia. She also had ataxia and 
feeding and swallowing difficulties. She was found to be homozygous for a novel 
missense variant, c.1716 C>G, p.I572M. However, it is very unlikely this variant is 
causing the severe phenotype observed, as her asymptomatic mother (I:1, Figure 5.8) 




5.2.1.2 Patients with heterozygous loss of function RTEL1 
variants  
 
Three LoF RTEL1 variants (Table 5.1 and 5.3) were found in patients from four 
unrelated families (Families 6-9, Figure 5.9), one of whom presented with DC and the 
others with MDS and/or liver disease. Liver disease and myelodysplasia/BMF were 
the common clinical feature in families 6, 8 and 9 (Figure 5.9). The clinical features of 
the four families with LoF variants in RTEL1 are summarised in Table 5.3. The three 
LoF variants are seen to cluster at the C terminal end of the harmonin domain of 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The proband of Family 6 (II:2, Figure 5.9) was diagnosed with DC at age 77 years. 
He progressively developed pulmonary fibrosis, liver disease and bone marrow failure 
(pancytopenia) with some dysplasia. He died shortly after diagnosis with multi-system 
complications. He harboured the heterozygous nonsense RTEL1 variant c.3028 C>T, 
p.R1010* (MAF: 10 in 119,716 in ExAC), reported previously in patients by Ballew et 
al (2013) and as a compound heterozygote by Moriya et al (2016). He had three 
daughters and one son (age 54, 52, 49 and 47 years, respectively), and all but one of 
his daughters (III:4, Figure 5.9) harboured this variant. Among his three children 
harbouring this nonsense variant, one of his daughters had features of liver disease 
(III:3, Figure 5.9), the other daughter and son were asymptomatic (III:2 and 5, Figure 
5.9). The variant was also identified in two of his asymptomatic granddaughters (IV:3 
and 6, Figure 5.9).     
 
The proband in Family 7 (II:1, Figure 5.9) was a 45 years old female with MDS, nail 
dystrophy and short telomeres (Table 5.1 and 5.3). She carried the same 
heterozygous nonsense variant c.3028 C>T, p.R1010* as seen in Family 6.  
 
In Family 8 (II:1, Figure 5.9), the proband was a 55-year-old male with MDS and liver 
disease, which progressed to cirrhosis and required liver transplantation. He was 
heterozygous for the nonsense variant c.2992C>T, p.R998* (MAF: 2 in 119,914 in 
ExAC) which has been reported as a compound heterozygote causing DC and HH 
(Walne et al., 2013a; Deng et al., 2013 and Ballew et al., 2013) and as a heterozygote 
causing familial interstitial pneumonia (Cogan et al., 2015). His brother (II:2, Figure 
5.9) aged 47 years harboured the same nonsense variant and also had MDS and liver 





Figure 5.9. Families with heterozygous LoF RTEL1 variants and sequencing traces of index 
cases. The genotyping is denoted as follows: wild-type (+/+) and heterozygous (+/-). The age 
at study is given in years. Affected individuals are coloured in black. NA: not available. 
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The proband of Family 9 (III:2, Figure 5.9) was diagnosed with MDS. He had liver 
disease, interstitial lung disease, abnormal skin pigmentation and severe 
osteoporosis. He died aged 54 years from multi-system complications. He harboured 
a novel 16bp deletion that caused a frameshift and a premature stop codon 
(c.3012_3028del, p.E1005Kfs*80). His parents were asymptomatic but his maternal 
grandmother (I:1, Figure 5.9) died aged 46 years with liver and lung disease. His 32-
year-old daughter (IV:1, Figure 5.9) was an asymptomatic carrier of the same variant.  
 
 
5.2.1.3 Families with heterozygous variants of unknown 
significance and heterozygous likely benign variants  
 
A variant might be of unknown significance (VUS) when there is no validated 
association of this variant to a disease risk. In this study, we have identified 12 
unrelated patients harbouring heterozygous missense variants of unknown 
significance (Table 5.1 and 5.4), as these variants are missense that are either not 
seen in the ExAC population or are present at an allele frequency of less than 1 in 
10,000. This makes it difficult to assign a clear status to these and hence we have 
categorised them as VUS. We notice that there is lower average CADD score for 
these VUS (average 15.43, range 0.001 – 33), compared to those that we believe to 
be disease causing (average 30.13, range 12.9 – 37, Table 5.1). 
 
Additionally, 14 unrelated patients were identified with nine heterozygous missense 
variants that we believe to be likely benign (Table 5.1 and 5.4) due to their occurrence 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.2.2 Short telomeres and T-circles in distinguishing the pathogenic 
status of RTEL1 variants 
 
We have measured telomere lengths by MMqPCR (Cawthon, 2009) in peripheral 
blood DNA acquired from all patients bar one, which had poor DNA quality (Table 5.1, 




Figure 5.10. Age adjusted telomere length of RTEL1 patients. Age adjusted telomere length 
values (delta-tel) were measured by subtracting the observed T/S ratio from the expected T/S 
ratio, using the equation derived from the line of best fit through the plot of T/S ratios from 
healthy control samples against age. Patients with TERC variants are included as a group with 
known short telomeres. Centiles were calculated from the control delta-tel values as follows: 
99th centile = 0.95, 90th centile = 0.42, 50th centile = 0.06, 10th centile = -0.34, 1st centile = 
-0.54. The different genotypes are represented as follows, TERC: circles (n=44); RTEL1 
variants: biallelic: squares (n=5); loss of function (LoF): triangles (n=6); variants of unknown 





In agreement with previous studies reporting the impact of RTEL1 variants on 
telomere length, we observed that patients with biallelic variants and those with 
heterozygous loss of function variants had significantly shorter telomeres than 
controls as determined by the age-adjusted T/S ratio (p = 0.0005 and p = 0.003 
respectively, 1 way ANOVA with Dunn’s multiple comparison test). The median age 
adjusted T/S ratio for the biallelic group is below the 1st centile (-0.6 compared with -
0.54) and for the LoF group is below the 10th centile (-0.43 compared with -0.34). It is 
interesting to note that in the VUS group there appears to be two subgroups. The 
lower four points correspond to the variants p.G664V, p.P908R, p.R981W and 
p.T1377A. Three of these variants affect key domains within the protein and may 
impact on the function of RTEL1. These are the helicase C domain (G644V) and the 
harmonin domain (P908R and R981W). 
 
The T-circle amplification assay (Zellinger et al., 2007) was undertaken in patients 
where good quality DNA was available and revealed a significant increase in intensity 
of T-circle formation in a patient harbouring RTEL1 LoF variant p.R998* (Family 5.8, 
Figures 5.9 and 5.11) in comparison to patient with RTEL1 p.R70C, which is a variant 
of unknown significance (patient 13 in Table 5.1). These studies suggest that LoF 
status in heterozygous RTEL1 variants could be established based on the T-circle 







Figure 5.11. T-circle amplification using Phi29 polymerase detected by Southern blot analysis. 
Samples: p.R70C - patient with sporadic DC carrying this variant of unknown significance 
(patient 13 in Table 5.1); p.R998* - proband of Family 8 carrying this LoF variant (Table 5.1); 
positive control - genomic DNA extracted from WI-38 VA-13 cells (human fibroblasts), known 







In this study, we have undertaken analysis of RTEL1 in 429 patients with DC, AA, 
MDS and related phenotypes. We have identified 35 variants, where 5 are biallelic (4 
homozygous and 1 compound heterozygous) and 30 are heterozygous. Nine variants 
are novel. As a result, we have been able to probe further into the relationship 
between variants in the RTEL1 gene and this spectrum of disease. 
 
The initial disease association was made when biallelic RTEL1 variants were shown 
to cause early onset of a severe form of DC and HH (Walne et al., 2013a; Jullien et 
al., 2016; Deng et al., 2013; Ballew et al., 2013). Herein, we describe five new biallelic 
families. Interestingly, in one of these the index case presented in adulthood with 
aplastic anaemia. In another, the index case presented with HH at the age two years, 
but in this patient, we consider the homozygous RTEL1 variant to be likely benign 
because her mother who was asymptomatic was also homozygous for this variant 
(Family 5.8). 
 
In amongst the earlier papers, there was an exceptional pair of sibs, both 
heterozygous for an RTEL1 variant who presented with a severe phenotype (Ballew 
et al., 2013). Since then, several papers have clearly shown that heterozygous 
variants in RTEL1 are more often associated with pulmonary fibrosis, occurring later 
in life, often in large families, but with variable penetrance (Kannengiesser et al., 2015; 
Cogan et al., 2015; Stanley et al., 2016). The frequency of heterozygous RTEL1 
variants in idiopathic pulmonary fibrosis as a whole is yet to be firmly established. 
 
In this study, we have extended the phenotype associated with heterozygous loss of 
function RTEL1 variants to include late onset of MDS and liver disease (Families 6, 8 
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and 9, Figure 5.9). This triad of late onset pulmonary, haematological and liver 
disease is very reminiscent of that established for heterozygous variants in another 
telomere related gene, TERT, which can also present with a severe early onset 
disease when the variants are biallelic. 
 
The families we present clearly illustrate the variable penetrance of heterozygous 
RTEL1 variants. This is exemplified by Family 6 where the index case had DC 
features, which did not become apparent until age 77 years. His daughter had liver 
disease at age of 52 years, and segregation analysis identified four asymptomatic 
carriers at age below 50 years old. This family highlights not only variable penetrance 
of heterozygous LoF variants but also suggests a late onset disease predisposition. 
The same RTEL1 variant was identified in Family 7, where it was associated with 
MDS and nail dystrophy in the 45 years old index case.  Interestingly, this is the same 
variant as reported by Ballew et al. (2013) in a heterozygous state as being the cause 
of HH in two siblings (aged three and one years) with very short telomeres. In that 
family, the mother also harboured the variant and had short telomeres but was 
asymptomatic.  
 
Indeed, in most of the families where the index case has disease due to biallelic 
RTEL1 variants, both here and in previous reports, the heterozygous parents are 
generally asymptomatic. However, we must now note that these individuals may 
nevertheless be predisposed to developing disease in their later years. This is 
suggested by Family 2 (with p.G1096W) where there is a history of pulmonary disease 
in the grandmother in her 70s and for the R998* variant which has been seen in both 
severe recessive (Walne et al., 2013a; Deng et al., 2013 and Ballew et al., 2013) and 
late onset dominant settings (Family 7 and Cogan et al., 2015). Thus, it is important 
to be careful when counselling families. 
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Previously we reported the recurrent missense variant c.2941C>T; p.R981W (MAF: 6 
in 119,930 in ExAC) as a compound heterozygote in three young probands (under 12 
years old) from unrelated families causing HH (Walne et al., 2013a). Here, we 
observed the same variant in a heterozygous state in a 24-year-old patient with AA 
from a consanguineous family (patient 14 in Table 5.1). In this case, there is no strong 
evidence that this variant (c.2941C>T; p.R981W) is the cause of AA on account of the 
relatively high frequency of this variant in the ExAC population. However, we do note 
the short telomeres in this patient and the very high CADD score of this variant, 
indicating the possibility that it acts as a risk factor for disease.  
 
A key point arises, therefore, when a patient presents with an RTEL1 variant, as to 
whether or not it should be considered pathogenic, as there are a multitude of rare 
coding RTEL1 variants in the population at large. Using the ExAC database, the sum 
of number of very rare heterozygous coding alleles (at a frequency of <0.0001) is 
1,195 in an average of approximately 56,700 people. This is significantly lower than 
the number very rare coding variants that we have identified in our cohort (22 in 429 
patients, Fisher’s exact test, P = 0.003), but on a case-by-case basis this background 
poses a problem. 
 
In addition to looking at the ExAC database for population frequency there are several 
parameters that we have used to assign pathogenic status. The association of the 
rare variant with the pathology is a given, if the patient under review is presenting with 
one the RTEL1 related disease features. Telomere length measurement is now widely 
used, and our experience here is that the heterozygotes, who are often more elderly, 
may have telomere lengths that are short, but not necessarily very short. We have 
also looked at T-circles, and shown that in some cases their presence is clearly 
increased where there is a LoF variant compared to a common missense variant. 
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However, this test is not very ‘user-friendly’ and a normal range has not been 
established. The in silico prediction tools are helpful and improving, but remain a 
guide, and by no means a definitive test.  
 
Finally, the segregation of the variant with disease can be decisive. This is more often 
the case in exclusion rather than inclusion as we show in Family 5, where the index 
case presented with HH and a novel homozygous missense variant which was 
predicted to be damaging. However, this did not segregate with the disease in this 
family as the asymptomatic mother is also homozygous for this same variant. This 
suggests that this homozygous RTEL1 variant is not disease causing in this index 
case. No other candidate genes were identified in this family by whole exome 
sequencing. 
 
In summary, this study identifies several important observations. Firstly, heterozygous 
LoF RTEL1 variants are associated with myelodysplasia and liver disease in 
adulthood. Secondly, biallelic RTEL1 variants can present with just bone marrow 
failure in adulthood. Thirdly, many heterozygous variants and even some biallelic 
RTEL1 variants are likely benign. Therefore, in order to assign an accurate status to 














Variants identified in familial MDS/AML 







Whole exome sequencing (WES) entails the capture, sequencing and analysis of all 
protein coding genes in the human genome. Regardless of recent improvement in 
databases and software tools, interpretation of damaging variants and variants of 
unknown significance (VUS) is one of the major challenges presented by WES data 
analysis. This technique generates a long list of variants with a large number of them 
likely to have no known clinical significance. Nevertheless, WES can be used as a 
diagnostic approach for the identification of genetic alterations in patients with 
suspected inherited disorders. In this chapter, we present the analysis we have 
performed on our WES data to search for the gene responsible for the disease in our 
uncharacterised MDS/AML families. 
 
 
6.1.1 Genetically uncharacterised familial MDS/AML patients 
 
In our cohort (2018) there are 68 genetically uncharacterised MDS/AML families. 
Whole exome sequencing was performed on a total of 51 unrelated cases in 42 of 
these MDS/AML families (Figure 6.1).  Initially, WES was performed in 19 MDS/AML 
families and this number was expanded at different times during the course of this 
study to include the new MDS/AML families recruited into our cohort. Therefore, data 
analysis was undertaken at different times under various criteria to try to identify the 





Figure 6.1. All MDS/AML families with WES done. Affected individuals are coloured as follows: 
red: MDS, black: AML, blue: AA, grey: thrombocytopenia, green: other leukaemia/cancer. 
Note: families with MDS/AML FML047 and FML051 have no family trees due to lack of 
sufficient family information. 
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DNA or blood samples on our familial MDS/AML cohort came from all over the world 
and it constitutes patients who presented at different ages at the time of diagnosis 
ranging from newborn to adulthood. Most index cases had undergone prior genetic 
testing, which could consist of chromosomal analysis, DNA sequencing studies, 
telomere length assays, chromosomal breakage analysis or a combination of tests. 
Available samples of parents, siblings, cousins or uncles/aunties were sequenced in 
approximately 30% of the cohort, in the remaining 70% of the families principally the 







6.2.1 Data analysis   
 
Analyses of the generated WES sequence data has been undertaken assuming an 
autosomal dominant (AD) or an autosomal recessive (AR) pattern of inheritance 
depending on which group of MDS/AML families were analysed. This is because two 
families of our cohort are likely to have an AR pattern of inheritance in which there 
was history of consanguinity (Figure 6.1) and, additionally four other MDS/AML 
families could be analysed as AD or AR due a lack of family information on them 
(Figure 6.1).  Multistep filtering was used to select potentially damaging variants in 
canonical transcripts of putative candidate disease genes on the basis of allele 
frequency, functional consequence and occurrence in multiple unrelated families 
(Figure 6.2). Depending on the set of criteria selected at this point, different candidate 
genes can be proposed.  
 
In the AD analysis, WES data was firstly filtered for novel germline heterozygous 
variants when compared against the Exome Sequencing Project (ESP) and 1000 
Genomes Project (1000G) databases, which are publicly available data sets of human 
DNA sequence variation. Exome Variant Server (EVS) was created as part of the 
National Heart, Lung, And Blood Institute Exome Sequencing Project and contains 
frequency information spanning 6,503 exomes (http://evs.gs.washington.edu/EVS/), 
while 1000G includes individual-level genotype data from whole-genome and exome 
sequence data for 2,504 individuals (http://www.internationalgenome.org/). 
Subsequently, allele frequency was verified against ExAC as it is approximately 10 




Figure 6.2. Workflow of a typical autosomal dominant analysis of WES data. 
 
 
It is known that the efficacy of filtering of candidate disease variants by frequency 
depends on the size of the data and its ancestral diversity data (Lek et al., 2016). For 
this reason, we used the ExAC database to filter rare variants (novel, MAF≤0.001 or 
MAF≤0.0001) out of our WES data. As described elsewhere ExAC is an aggregation 
of high quality exome data for 60,706 individuals of diverse ancestries. This catalogue 
of human genetic diversity contains an average of one variant every eight bases of 
the exome (http://exac.broadinstitute.org/). For the AR analysis, the variants were 
filtered for rare germline biallelic variants (MAF≤0.001) when compared against the 
databases mentioned above. 
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More than 96% of the variants selected were confirmed by Sanger sequencing. The 
remaining 4% variants were found to be false positive results and these usually would 
be calls that had unequal allele fractions, poor mapping scores, or sequence data 
indicating suboptimal alignment to the reference sequence. Positive cases met each 
of the diagnostic criteria regarding variant severity, appropriate inheritance patterns 
(when other family member’s data were available), and disease-phenotype 
concordance. The candidate gene description in this chapter was carried out using 
NCBI - National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov/), 
UniProt (http://www.uniprot.org/), OMIM - Online Mendelian Inheritance in Man 
(https://www.omim.org/) and ExAC databases. 
 
 
6.2.1.1 All MDS/AML families  
 
Analysis of WES data of 30 MDS/AML families was performed assuming autosomal 
dominant as pattern of inheritance. A total of 34,888 variants somewhat rare 
(MAF≤0.05) variants were found by comparison with the current reference haploid 
human genome sequence (human genome 19). Of these, 8,100 were novel non-silent 
variants compared against ESP and 1000G project databases and further filtering 
revealed 3,857 variants segregating within families (when samples from more than 
one member were analysed, which was undertaken in 12 families). These putative 
germline variants were than filtered by rare allele frequency (MAF≤0.0001) compared 
against ExAC. Pathogenicity of the selected variants was assessed using predictable 
damaging tools such as Polyphen2 (http://genetics.bwh.harvard.edu/pph2/) and 
MutationTaster2 (http://www.mutationtaster.org/). As a result, 12 candidate genes 
with probably damaging rare heterozygous variants were identified in at least three 
MDS/AML families (Table 6.1) and 22 candidate genes with probably damaging rare 
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heterozygous variants were identified in at least two MDS/AML families (Table 6.2). 
Interestingly, 10 candidate genes harbouring rare putative germline LoF variants 
(including stopgain, frameshift indel and variants within the consensus splice site 
dinocleotides) were identified in at least two unrelated MDS/AML families (Table 6.3). 
Genes known to be associated with another AD disorder were removed. After all this 
filtering two candidate disease genes harbouring probably damaging rare 
heterozygous variants were selected (Table 6.4 and Figure 6.3). Detailed description 
of these candidate genes is shown in Table 6.5. Unfortunately, there is insufficient 
evidence to date to conclusively say whether any of these can be definitively 
considered as the disease causing gene in our families.  Hence, these probably 
damaging rare heterozygous variants identified in the selected candidate genes 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6.2. Rare possibly damaging rare heterozygous variants (MAF≤0.0001) in the same 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6.3. Rare heterozygous loss of function variants (MAF≤0.0001) in the same gene in at 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6.4. Candidate genes with possibly damaging rare heterozygous variants 




































































































































































































































































































































































































































































































































































































Table 6.5. Description of the candidate genes with possibly damaging rare heterozygous 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.2.1.2 Family FML012  
 
Thirteen MDS/AML families had WES performed in more than one family member 
(FML009, FML012, FML029, FML031, FML035/FML073, FML036, FML054, FML061, 
FML075, FML081, FML109 and, FML112 seen in Figure 6.1). Here, we describe the 
autosomal dominant analysis of WES data of family FML012, specifically from 
individuals III:7 and the index case IV:2 (Figure 6.4). This is a large family with 
MDS/AML history along with various solid cancers. The index case (IV:2, Figure 6.4) 
was a male who died of ALL at age 36 years. His grandmother (II:3, Figure 6.4) died 
of AML at the aged 46 years and his great grandfather (I:2, Figure 6.4) also died of 
AML at age 50 years. One of his grandaunts (II:5, Figure 6.4) had stomach cancer 
and another grandaunt had pancreatic cancer (II:8, Figure 6.4). His granduncle (II:7, 
Figure 6.4) had AML. Furthermore, the index case had two cousins with AML (III:4 
and III:7, Figure 6.4) and another with cervical cancer (III:5, Figure 6.4). Conveniently, 
the number of germline variants shared between these two cousins are diminished as 
they are distantly related. 
 
 
Figure 6.4. MDS/AML family tree of FML012. Affected individuals are coloured as following, 




 WES of the proband (IV:2, Figure 6.4) and his cousin (III:7, Figure 6.4) revealed an 
overall of 461 non-silent rare heterozygous variants with MAF≤0.0001, where 446 
were novel when compared to ESP and 1000G and 32 were loss of function variants 
(including stopgain, frameshift indel and variants within the consensus splice site 
dinocleotides). Strikingly, ten germline variants were found in total in family FML012 
(Table 6.6) with just two rare germline heterozygous variants in the canonical 
transcripts with MAF≤0.0001 in genes that are not associated with other autosomal 
dominant disease (CDKL1 and CEP68) (Table 6.7). Consequently, cyclin-dependent 
kinase-like 1 (CDKL1) and centrosomal protein 68kDa (CEP68) are the only 
candidate genes found in FML012 in this analysis.  
 
Additionally, dHPLC was performed on 30 constitutional MDS/AML cases as 
described in section 3.2.2.3 in chapter 3 for both genes. No further rare heterozygous 
variants in neither of the genes CDKL1 nor CEP68 were found. 
 
Unfortunately, neither CDKL1 nor CEP68 presented enough evidence to be 
considered the underlying cause of disease in this family. For instance, Sanger 
sequencing of the rare heterozygous variant (c.416C>T; p.S139F) located in CDKL1 
domain performed in two additional members (III:8 and III:9, Figure 6.5 A) of FML012 
revealed the presence of this variant in one of them (III:8) (Figure 6.5 A, B and C). 
III:8 (Figure 6.5 A) was diagnosed with arthritis and monoclonal gammopathy of 
unknown significance (MGUS). The amino acid serine in the position 139 in CDKL1 
is well conserved among mammals (Figure 6.5 D) and this amino acid substitution to 
F is considered to be probably disease causing by MutationTaster2 but not by 
Polyphen2, where this variant is predicted to be benign (Table 6.8). Furthermore, no 
additional family from our cohort was found to have a germline variant in CDKL1 to 
strengthen its case to be a disease gene. 
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Table 6.7. Rare germline heterozygous variants with MAF ≤0.0001 shared in both affected 




Figure 6.5. CDKL1 variant analysis. A. MDS/AML family tree of FML012. Affected individuals 
are coloured as following; black: AML and green: other cancer. The arrow highlights index 
case. B. Sanger sequencing trace representing the nucleotide substitution in CDKL1. C. 
Schematic CDKL1 protein showing the location of the amino acid change. D. Multiple CDKL1 
protein amino acid alignment in the position 139.   
 Gene AAChange ExAC (MAF) PolyPhen2 MutationTaster 
1 CEP68 c.A1373G:p.Q458R NR D B 
2 CDKL1 c.C416T:p.S139F 0.00001648 NA D 
3 HTT c.C55A:p.Q19K NR NA B 
 HTT c.G57T:p.Q19H NR NA B 
MAF: minor allele frequency; D: damaging; B: benign; NA: not available. 
221 
 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sanger sequencing of the novel heterozygous CEP68 variant (c.1373A≥G; p.Q458R) 
located immediately after CEP68 domain, was performed on the additional other two 
members of FML012 (III:8 and III:9, Figure 6.6 A). The CEP68  variant was identified 
in III:9 who is reported to be asymptomatic to date (Figure 6.6 A, B and C). The amino 
acid Q is conserved among mammals (Figure 6.6 D) and this variant is predicted to 
be benign by both MutationTaster2 and Polyphen 2 tools (Table 6.8). No additional 
family with similar phenotype was identified to harbor a rare heterozygous variant in 




Figure 6.6. CEP68 variant analysis. A. MDS/AML family tree of FML012. Affected individuals 
are coloured as following, black: AML and green: other cancer. The arrow highlights index 
case. B. Sanger sequencing trace representing the nucleotide substitution in CEP68. C. 
Schematic CEP68 protein showing the location of the amino acid change. D. Multiple CDKL1 





6.2.1.3 Family FML003  
 
MDS/AML families FML003 (Figure 6.7) was analysed assuming autosomal recessive 
as pattern of inheritance. Here, we describe the AR analysis of WES data of one 
member (II:6, Figure 6.7) of family FML003. It was a consanguineous marriage in 
which both parents were asymptomatic and five out of six children were affected. The 
oldest child had MDS (II:1, Figure 6.7), another three died with AA at age 10 years 
old (II:3, II:4 and II:5, Figure 6.7) and, the proband (II:6, Figure 6.7) presented with 
monosomy 7, MDS and died at age 14 years old after an autologous bone marrow 
transplant.   
 
 
Figure 6.7. MDS/AML family tree of FML003. Affected individuals are coloured as following, 
red: MDS and blue: AA. The arrow highlights index case. 
 
WES of the proband (II:6, Figure 6.7) revealed 769 non-silent variants, in which 281 
were novel when compared to ESP and 1000G databases and 33 loss of function 
variants. 23 biallelic variants were found in FML003 with MAF≤0.001, 16 were 
homozygous and 7 were compound heterozygous. From these, five genes harbouring 
rare homozygous missense variants were identified and four that carried predicted 
damaging variants were selected to be the candidate genes in this family as they were 
not associated with any autosomal recessive disease (Table 6.9 and Table 6.10). 
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Segregation analysis in these five candidate genes were carried out as DNA samples 
from both parents were available (Figure 6.8) in an attempt to exclude any of the 
identified candidate genes as disease causing. Nonetheless, the variants found in the 
selected candidate genes were also present in a heterozygous estate in both parents 
making it a challenge to identify the best disease causing gene in this family. 
 
 
Figure 6.8. Segregation analysis of candidate genes in FML003. A. MDS/AML family tree of 
FML003. Affected individuals are coloured as following, red: MDS and blue: AA. The arrow 
highlights index case. B-F. Sanger sequencing showing the amino acid changes present in 
both parents of the index case. 
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6.2.1.4 All MDS/AML families – gene-level and variant-level 
metrics combined to assess potential pathogenicity of 
a variant  
 
From WES of 51 unrelated cases in 42 uncharacterized MDS/AML families, 
approximately 70,000 somewhat rare (MAF≤0.05) variants were found by comparison 
with the current reference haploid human genome sequence (human genome 19) 
and, 26,435 of these were non-silent variants (Figure 6.9). Further filtering resulted in 
19,801 variants that segregated within the families (when samples from more than 
one member were analysed, which was undertaken in 12 families). Therefore, we 
have analysed 19,801 possibly germline somewhat rare considering autosomal 
dominant as pattern of inheritance. A further filtering using ExAC retained 4,676 




Table 6.11. Genes with variants MAF≤0.0001 identified in multiple MDS/AML families 
  Number of 
families 


















7 LRP2, MYH13 521 genes  
 












3 404 genes 
 
 










Analysing manually all 4,676 rare variants on basis of their predictability effect to the 
protein using Polyphen2 and MutationTaster2 tools would be a laborious task. 
Instead, we worked alongside with a new pipeline based on the assumption that some 
genes in the human genome are sensitive to alterations and they would be the most 
likely to contribute to disease when mutated. We used two metrics including missense 
Z and loss of function pLI (probability of LoF intolerance) scores according to 
Samocha et al., 2014 and Lek et al., 2016 to evaluate the proportion of common 
functional variation in each gene, thereby identifying genes that appeared to be 
intolerant of variants. The knowledge that damaging variants are expected to have 
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lower allele frequencies than neutral ones and the deep discovery of rare variation in 
ExAC allows inference of the degree of selection against specific functional classes 
of variation (for instance, missense or LoF) on a gene basis. It is done by examining 
the proportion of variation that is missing compared to expectations under random 
variants (Samocha et al., 2014; Lek et al., 2016).   
 
Gene-level measures of constraint such as missense Z and loss of function pLI scores 
offer additional information to variant-level metrics (such as Polyphen 2 and 
MutationTaster2) in assessing potential pathogenicity. As rare variants found in genes 
that are altered in multiple unrelated families with similar phenotypes are more likely 
to be pathogenic, we prioritised the analysis on rare variants in genes that were 
altered in 3 or more families. Hence, we further filtered 1,766 rare variants 
MAF≤0.0001 identified in 521 genes by selecting genes with missense Z score≥2.9 
or pLI≥0.9 present in 3 or more families. We have set the threshold missense Z 
score≥2.9 as Samocha et al. (2014) found that missense Z score≥3.09 corresponded 
to excessively constrained genes in their data analyses. This anlaysis resulted in 83 
genes with Z≥2.9 or pLI≥0.9 harbouring rare germline heterozygous variants 
(MAF≤0.0001). From these, 30 genes were removed as they were observed to be 
associated with other autosomal dominant diseases. This left us with 179 rare 
germline heterozygous variants in 53 candidate genes. A further filtering based on 
variants with MAF≤0.00001 and, genes with Z≥2.9 and pLI≥0.9 identified 
approximately 80 germline heterozygous rare variants in 46 genes present in 3 or 
more unrelated families. As result, eight selected candidate disease genes presented 
damaging rare variants predicted by the Polyphen 2 and MutationTaster2 tools in 3 
or 4 families (Table 6.12). The analysis workflow is described in Figure 6.10. 





Figure 6.10. Workflow of the AD analysis of WES data of 42 uncharacterised MDS/AML 
families using gene-level and variant-level metrics combined to assess potential pathogenicity 





Table 6.12. Candidate genes based on possibly damaging rare heterozygous variants with 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6.13. Description of candidate disease genes identified by using a combination of gene-













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Searching for the underlying disease gene in families with MDS/AML is a massive 
challenge due to the vast clinical and genetic heterogeneity of this rare disorder. We 
have undertaken WES in 42 uncharacterised families with MDS/AML and have not 
identified the disease causing gene in half of them. Generally in this study, the 
selection of candidate genes were performed by selecting rare predicted damaging 
variants in genes not previously associated with other disease and that occurred in 
multiple families. This generated a number of candidate genes that are listed fully in 
Tables 6.12, 6.4, 6.7, and 6.9 in chapter 6. However, with the data to hand it is not 
possible to say, which if any, will turn out to be definitive disease causing genes.  
 
One of the initial issues when analysing sequencing data is defining the threshold at 
which a variant should be considered rare or a polymorphism. Traditional methods for 
setting allele frequency thresholds for variant classification are based on the expected 
incidence of disease. However, accurate incidence and penetrance numbers of very 
rare diseases such as familial MDS/AML are not available (Shearer et al., 2014; 
Kobayashi et al., 2017). The frequency of a variant in the general population is crucial 
as the rarity of a variant is a prerequisite for pathogenicity. However, population allele 
frequency is a potential empirical data for improving variant interpretation as an allele 
frequency greater than expected for disorder is strong evidence for a benign 
classification. Without careful consideration, aggressive allele frequency thresholds 
may increase the risk of incorrectly classifying pathogenic variants with elevated allele 
frequencies as benign. If done carefully, a very low allele frequency threshold 
(including novel, MAF≤0.0001 or MAF≤0.00001) can be adopted to more accurately 




The approach of using a small cohort of presumed healthy individuals to distinguish 
benign polymorphisms from potentially pathogenic variants, as any variants observed 
in unaffected individuals are unlikely to be disease causing, is effective for early-onset 
dominant disorders with high penetrance. It is essential to consider that the likelihood 
of the presence of disease causing variants in population databases such as ExAC 
and ESP is high as they include non-healthy individuals. This likelihood increases 
even further when analysing recessive disorders or disorders with low-penetrance or 
late-onset in which unaffected carriers are expected to be present. However, the size 
of the ExAC population database is a comprehensive representation of very rare 
variants that allows for more accurate minor allele frequency calculations. 
Furthermore, scientific literature can also be used in agreement with population data 
for variant classification as rare pathogenic variants are frequently published. Overall, 
this is a scalable approach that allows for rapid adoption of new datasets and 
refinements to MAF thresholds as larger and higher-quality datasets are published 
(Walsh et al., 2016). 
 
On the other hand, variant classification is a complex process involving the evaluation 
and interpretation of multiple pieces of evidence, which in turn requires considerable 
knowledge and expertise. A variant’s absence or presence in ExAC at very low 
frequency is clearly not sufficient to indicate that the variant is pathogenic. Many 
variants are private, novel, or rare, and the vast majority of these are also not 
pathogenic (Richards et al., 2015). However, finding rare predicted damaging variant 
in the same gene in multiple families with similar phenotype and where alterations in 
the gene in question is not linked to other disease are some strong lines of evidence 




Furthermore, missense variants are a common finding in our cohort and the 
assessment of their protein functional impact is demanding without adequate 
functional studies. Therefore, the use of an intolerance ranking system can facilitate 
identification of high impact variants through the gene in which they occur. Gene-level 
score can be integrated with well-established variant-level scores to highlight 
candidate casual variants (Petrovski et al., 2013).  
 
Genes intolerant to genetic variation in the human population are more likely to cause 
some disorders. The most highly constrained missense (top 25% missense Z score) 
and LoF (pLI≥0.9) genes show higher expression levels and broader tissue 
expression than the least constrained genes and are involved in core biological 
processes (spliceosome, ribosome, and proteasome components). Genes intolerant 
of LoF variation would be expected to be dosage-sensitive, as in such genes natural 
selection does not tolerate a 50% deficit in expression due to the loss of single allele. 
Therefore, smaller changes in the expression of these genes are more likely to 
contribute to medically relevant phenotypes. Although, this extreme constraint does 
not necessarily reflect a lethal disease or status as a disease gene, but probably 
points to genes in which heterozygous LoF confers some non-trivial survival or 
reproductive disadvantage (Table 6.14). Disease genes that act after post-
reproductive age – do not necessarily have a high pLI values (e.g. BRCA1).  
 
LoF intolerant genes include virtually all known severe haploinsufficient human 
disease genes and yet there are 3,230 genes in ExAC with near complete depletion 
of predicted protein-truncating variants, with 72% of these genes having no currently 
established human disease phenotype in the OMIM (https://www.omim.org/) or 
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) databases (Lek et al., 2016). 
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Table 6.14. Z and pLI scores of genes associated with familial MDS/AML 
  Gene Z  score pLI score  
 RUNX1 2.8 0.45  
 CEBPA NA NA  
 TERC NA NA  
 TERT 6.3 0.87  
 GATA2 2.88 0.98  
 SRP72 0.45 0.01  
 ANKRD26 -2.05 0  
 ETV6 2.2 1  
 DDX41 2.97 0  
NA: not available.  
 
 
Finally, it might be necessary to use different approaches combined with WES such 
as other types of next generation sequencing methods that can identify variants in 
non-coding regions, large insertions/deletions and copy numbers variants to search 
for the underlying gene disease in the uncharacterised MDS/AML families. This 
combined use of various techniques would increase genome coverage and decrease 
the chances of missing a causal genetic alteration. Additionally, new WES data from 
further registered MDS/AML families will supplement this dataset and increase 


















7.1 Variants identified in known disease genes associated with familial 
MDS/AML and related disorders  
 
In chapter 3, seven MDS/AML families that were genetically characterised during this 
study have been discussed. Interestingly, in addition to the identification of known 
disease causing genes associated with familial MDS/AML, three MDS/AML families 
harboured variants in genes that are associated with other bone marrow failure 
syndromes including FANCA, SBDS and WAS. This highlights the marked clinical and 
genetic heterogeneity of these disorders. Bone marrow failure syndromes are a 
heterogeneous group of diseases that includes familial MDS/AML, DC, HH, FA, 
Diamond–Blackfan anaemia, Shwachman–Diamond syndrome among others. They 
present with cytopenias in at least one haematopoietic cell lineage that may develop 
into pancytopenia and with an increased risk of haematological or solid cancers (Alter, 
2017). Although the classical expression of these syndromes is very distinct, it is well 
known that they have overlapping clinical features. Furthermore, phenotypic variability 
even among patients sharing the same variant in a disease gene is recognised in 
these group of disorders (Dokal et al., 2015; Bertuch, 2016). The atypical cases of 
bone marrow failure syndromes may initially present with isolated MDS or AML and, 
the classic features may manifest over time or alternatively they may present with 
reminiscent characteristics but not entirely coherent with a known inherited disorder 
as observed in our families FML004, FML032 and FML041. Indeed, Rochowski et al. 
(2012) reported that approximately 1% of patients recovering from leukaemia after 
chemotherapy had undiagnosed FA. As also exemplified by our results, genomic 
evaluation using next generation sequencing is efficient to identify the pathogenic 
variant in genes known to cause the disease and to define a complex diagnosis 
(Zhang et al., 2015; Ghemlas et al., 2015). Use of next generation sequencing in these 
atypical patients and in healthy individuals will help further understanding the biology 
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of bone marrow failure diseases. An additional important consideration when working 
up a challenging diagnosis is to be aware of revertant somatic mosaicism. This refers 
to a rare genetic event when a pathogenic disease variant spontaneously reverts into 
a benign variant. Revertant mosaicism is likely to have taken place in cases where 
children are affected, and the asymptomatic parents do not harbour the pathogenic 
variant. This event has been observed in FA and in patients with DC harbouring TERT 
variants (Soulier et al., 2005; Jongmas et al., 2012).  
 
The specific pathway disrupted by a variant in a known disease causing gene also 
contributes to the progress and specific disease outcome. Each of these diseases 
causing genes are affected by their unique variant types (missense, LoF, indels or 
nonsense) and location (throughout the protein or in specific regions) and, by the 
mechanisms that causes the disease such as haploinsufficiency or dominant-negative 
effects, although, autosomal dominant pattern of inheritance and haploinsufficiency 
seem to be a general characteristic of familial MDS/AML. Germline heterozygous 
variants, including nonsense, missense, deletion, frameshift throughout the gene and 
gene deletion or duplication in RUNX1 cause familial platelet disorder with propensity 
to myeloid malignancies (MDS, AML and T-cell ALL). GATA2 variants are typically 
loss of function with no genotype-phenotype correlations. Impaired telomerase activity 
(due to germline variants in TERC and TERT) and extremely short telomeres induce 
chromosomal instability, causing bone marrow failure, fibrosis of the lungs and liver, 
and tumour formation. Somatic variants in the promoter region of TERT have been 
reported in melanomas, gliomas, liposarcomas, urothelial carcinomas and 
hepatocellular carcinomas. Biallelic germline variants in TERT can lead to telomere 
biology disorders including DC and HH and TERT heterozygous variants cause 
familial MDS/AML.  
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In our study, rare variants were classified as likely pathogenic, VUS and likely benign 
according to the joint consensus recommendation for the interpretation of sequence 
variants by the American College of Medical Genetics and Genomics (ACMG) and 
the association for Molecular Pathology (AMP). Likely to be pathogenic and VUS were 
further analysed in order to assign a variant as causal. This involved strict criteria for 
determining pathogenic variants: a) families that carried proven variants in known 
disease causing genes were expected to have similar disease presentation in 
accordance with the literature, b) recurrent variants were favourable to assign 
pathogenicity to a variant, c) protein impact was assessed for all proven variants using 
prediction software as a guide, d) family segregation studies were carried out when 
possible and, e) investigation of all likely pathogenic variants were performed in the 
literature and databases. 
 
The index case in FML007 who harbours a large RUNX1 deletion (described in 
section 3.2.1.1 in chapter 3) highlights that interpretation of genetic testing in blood 
can be confounding by the presence of somatic variants found in known disease 
causing genes. Despite the recommendation of use of a non-blood tissue to validate 
a germline variant, we do not have it available for all our families. However, 
segregation analysis within families can be useful in distinguishing inherited from 
somatic variants. Furthermore, it is also possible to identify if a variant is germline or 
somatic through Sanger sequencing trace analysis when the variant is a 
heterozygous indel. This is carried out by calculating an average of the ratio of the 
chromatogram peak heights of the variant and the sum of the chromatogram peak 
heights of wild type plus variant, the variant in question is likely germline when the 
results are near 50%. For obvious reasons, this method could not be performed on 




In conclusion, the observations in these known disease genes serve to highlight the 
complexity in assigning pathogenic status to a newly identified variant. They also 
show the value of next generation sequencing in picking up pathogenic variants in 





7.2 Germline heterozygous LoF DDX41 variants in a subset of familial 
myelodysplasia and acute myeloid leukaemia 
 
In chapter 4 we have described four families with MDS/AML from our cohort 
harbouring heterozygous LoF variants in DDX41, a relatively new gene associated 
with familial MDS/AML. Variants in DDX41 were reported in various families with 
MDS/AML and it is characterised by late onset, advanced state of the disease at 
diagnosis, normal karyotype and poor overall survival. This makes DDX41 different 
from the other known familial MDS/AML disease genes identified to date along with 
its unclear function in leukaemogenesis. DDX41 is shown to be involved in 
spliceosomes defects when altered in patients with familial MDS/AML, however the 
exact mechanism leading to disease is not yet established. Nonetheless, DDX41 is 
known to participate in innate immunity response by acting as an intracellular DNA 
sensor and direct interactions with bacteria pathogenic particles stimulating the 
immune response. Interestingly, Shwartz et al. (2017) reported mutations in 
SAMD9/SAMD9L to be the cause of familial MDS/AML in children. And these genes 
present some similarities with DDX41 such as a) monosomy of chromosome 7 causes 
haploinsufficiency in familial MDS/AML indicating a loss of tumor suppressor role as 
it happens with monosomy of chromosome 5, b) there are cases in paediatric familial 
MDS/AML patients with germline mutations in SAMD9/SAMD9L harbouring somatic 
mutations in the other allele, and c) SAMD9L is also involved in immune response 
(Nagamachi et al., 2013). 
 
There is data suggesting association of DDX41 variants with post-transcriptional 
regulation of protein translation in cell growth in Peters et al. (2017) studies. This 
group suggested an oncogenic role for DDX41. In addition, DDX41 deletions and 
frameshift variants as well as its reduced expression demonstrate a tumour 
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suppressor function in MDS/AML reported by Polprasert et al. (2015). Similarly, 
variants in other members of the DEAD/H-box RNA helicase family can act as tumour 
suppressors and oncogenes in cancer (Fuller-Pace, 2013). In addition, Polprasert et 
al. (2015) demonstrated the interaction of DDX41 with spliceosome proteins and that 
altered DDX41 impaired this interaction. Spliceosome defects caused by mutated 
genes can result in alterations in the balance of isoforms and in the inactivation of 
tumour suppressor genes, promoting cell proliferation. Further studies are needed in 
order to clarify the precise role of DDX41 variants in haematopoiesis and leukaemia.  
 
Patients harbouring germline variants in DDX41 are phenotypically very similar to 
sporadic AML cases. In many cases the disease develops with an acquisition of a 
second DDX41 somatic variant in the other allele, however total inactivation of DDX41 
appears to be cell-lethal. DDX41 is located on chromosome 5 and is deleted in some 
sporadic cases of MDS with del (5q) resulting in haploinsufficient expression. 
However, frameshift germline variants have not been found to be accompanied by 
deletions of the DDX41 locus on 5q (Maciejewski et al., 2017). 
 
Virtually all families with MDS/AML carrying DDX41 germline LoF variants reported in 
our study (chapter 4) had a late onset of the disease, except for family FML037 (Figure 
4.5, chapter 4) in which the index case was diagnosed aged 41 years. In addition, the 
recurrent DDX41 variant (c.3G>A, p.M1I) found in family FML037 is seen in ExAC 
with frequency of 1 in 1,189 people, raises a query about the pathogenicity of DDX41 
germline LoF variants. Deleterious variants are seen in DDX41 with a high frequency 
in the population compared to variants in other known familial MDS/AML disease 
genes. The frequency of a variant in the general population is important as rarity of a 
variant is essential for pathogenicity. According to the ACMG and AMP guidelines, an 
“allele frequency greater than expected for disorder” is strong evidence for a benign 
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classification (Richards et al., 2015). In that context, DDX41 germline variants can 
easily be mistaken and excluded as polymorphisms or interpreted falsely as 
pathogenic from some applied analysis strategies in many studies. Thus, it is 
necessary to carefully use a combination of evidence that rigorously assess the 
pathogenicity of DDX41 variants.   
 
Finally, the late onset of familial MDS/AML characteristic of DDX41 variants makes it 
harder to obtain an accurate diagnosis for this group of patients and inappropriate 
selection of asymptomatic family donors for allogenic stem cell transplantation might 
take place. Clinically, recognition of DDX41 mutated cases may have implications for 
surveillance, assessment of prognosis, and, perhaps, for design of targeted therapies. 
Further functional studies are necessary to confirm the pathogenicity of the variants 







7.3 RTEL1 LoF variants leading to myelodysplasia and liver disease 
 
RTEL1 variants in our cohort of patients with bone marrow failure disorders (DC, HH, 
AA and, familial MDS/AML) are very interesting starting with the amount of variants 
found in this gene. We have found 29 RTEL1 variants in 35 patients. The next step 
was to interpret these variants in order to identify the disease causing variant by 
filtering, annotating the variants (population variant allele frequencies in the canonical 
transcript) and using in silico variant function impact prediction. Most of these RTEL1 
variants were classified as heterozygous missense likely benign (9 variants in 14 
patients), many were heterozygous missense of unknown significance (12), few were 
biallelic likely pathogenic (4) bar one was biallelic likely benign variant and, some were 
identified as LoF variants likely pathogenic (three in four unrelated families) as 
described in chapter 5. In this section of our study, we were able to use the prediction 
tool Combined Annotation Depletion score (Kircher et al., 2014) as variant call format 
files were available on this data.  
 
CADD is a method that measures deleterious variants systematically across the 
genome. It combines many different annotations including allelic diversity, 
annotations of functionality, pathogenicity, disease severity, experimentally measured 
regulatory effects and complex trait associations into the C score, a specific measure 
for each variant. This highly ranks known pathogenic variants within individual 
genomes (Kircher et al., 2014). However, Polyphen2 and MutationTaster2 were the 
prediction tools used in all other chapters as they are also well-established 





It is largely known that biallelic variants in RTEL1 are associated with DC and HH and 
RTEL1 heterozygous variants have been associated with idiopathic and familial cases 
of interstitial pulmonary fibrosis. In this study we have identified five families carrying 
RTEL1 biallelic variants and four families carrying heterozygous RTEL1 LoF variants. 
However, the clinical phenotypes of these families vary from what is already 
established in the literature and consequently it expands the disease spectrum of 
RTEL1 (Cardoso et al., 2017). RTEL1 biallelic variants were found in two families with 
DC, however RTEL1 biallelic variants also were identified in family 5 (Figure 5.8 seen 
in chapter 5) and it is unlikely to be the disease causing in this family as the 
asymptomatic mother harbours the same biallelic variants. Furthermore, other two 
families harbouring RTEL1 biallelic variants presented with AA in adulthood again 
expanding what is reported in the literature to date. Marsh et al. (2018) have just 
reported similar data whilst this thesis was being prepared. Finally, RTEL1 
heterozygous LoF variants were identified in four families with MDS and liver disease 
in adults, expanding the spectrum of RTEL1 associated diseases. 
 
It is noteworthy that patients with complex diseases do not always present with a clear 
classical phenotype at the time of presentation. From the families described in chapter 
5 that present with MDS and liver disease with variants in RTEL1, only family 8 is 
classified as familial MDS/AML (defined by us as being when there are two or more 
members with bone marrow failure in the family, where at least one of them presents 
with MDS or AML). This family prompted us to search for further RTEL1 variants in 
independent cohorts from our lab (dyskeratosis congenita, idiopathic bone marrow 
failure). 
 
RTEL1 is part of the telomere biology- associated genes (DKC1, TERC, TERT, USB1, 
CTC1, NHP2, NOP10, WRAP53, TINF2, PARN and ACD) that cause telomeropathies 
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where germline variants result in short telomeres and bone marrow, lung, liver, and 
skin can be affected. In agreement with the literature on patients carrying biallelic or 
LoF variants presented short telomeres compared to age-matched controls. 
Furthermore, RTEL1 defect is associated with production and accumulation of T-
circles in cells and we have seen that one case carrying a LoF variant presented with 
increased T-circles when compared to a case carrying a missense variant. Further T-
circle tests should be undertaken in a larger group of samples in order to establish a 
normal range of T-circle production in RTEL1 patients. Furthermore, if enough 
samples of affected patients and resources were available, the following functional 
experiments could be performed to verify the biological impact of the germline 
heterozygous LoF RTEL1 variants identified in this study: a) demonstrate the 
expected lower expression of RTEL1 in the patients with heterozygous germline LoF 
variants compared to a control by Western blotting; b) mass spectrometry to identify 
the proteins associated with RTEL1 in the patients and in a control along with RNA 
seq and gene set enrichment analysis to recognise the possible affected biological 
pathways; c) analyse all results and verify whether there is a plausible explanation for 
the MDS and liver disease phenotypes present in these patients. 
 
In conclusion, the data from this section clearly extends the spectrum of RTEL1 
related telomeropathies. It also shows that RTEL1 can be added to the list of disease 





7.4 Variants identified in familial MDS/AML candidate genes   
 
We have been analysing WES data from MDS/AML families from the beginning of 
this project, working on different numbers of families, using adequate criteria for 
searching the genetic disease cause and generating different lists of candidate genes 
at each time. However, we have not identified the definite disease causing gene in a 
significant number of these uncharacterised MDS/AML families. Certainly, we first 
searched for predicted damaging variants in the known familial MDS/AML disease 
genes and only few of these families were characterised by predicted pathogenic 
variants in these known genes. This left us with many uncharacterised families with 
possibly variants in new disease causing genes. Finding these new disease causing 
genes is a very challenging task for many reasons including quality of the acquired 
information on the family history and the type and quality of collected sample(s). 
Consequently, new challenges arise from the chosen approaches as not only one 
technique would be enough to identifying these new causal genes. In addition, there 
are some technical problems that might occur from sample collection to preparation, 
storage and interpretation of data. Not to mention the technical challenges relating to 
genome coverage. 
 
Considering these previously mentioned challenges, the first encountered issue was 
the selection of an adequate variant allele frequency that could be considered rare 
enough to cause familial MDS/AML. We have first chosen to analyse novel variants 
as the majority of published variants in the known familial MDS/AML disease genes 
are novel. No plausible candidate gene was identified using this criteria. We have then 
analysed predicted to be damaging variants with MAF≤0.0001 as damaging variants 
in DDX41 were reported within this allele frequency. Again, no evident candidate gene 
was found. The second challenge in the analysis was the variant classification into 
251 
 
likely to be damaging and variant of unknown significance, mainly because missense 
variants are found in abundance in our WES data. Although there are many prediction 
tools to evaluate the pathogenicity of a variant, they are not enough to define its 
pathogenicity. Finally, the decision of a specific candidate gene being the possible 
underlying cause of the disease in a family is not straightforward even after the 
identification of a handful number of candidate genes that are not previously 
associated with other AD disease and that harbour predicted damaging rare germline 
variants which segregate with the disease in multiple families. This is because a) the 
results we obtained are not conclusive as about half of the families harbour variants 
in more than one identified candidate gene, b) the majority of the identified variants 
are missense making it harder to predict their pathogenicity and, c) lastly, it would 
help if any identified candidate gene was functionally linked to known familial 
MDS/AML disease genes to explain the disease development.   
 
AD analysis of WES data from 30 MDS/AML families was performed based on 
predicted damaging rare germline variants that segregate with the disease in three or 
more families generated two candidate genes seen in Table 6.4 in section 6.2.1.1 in 
chapter 6 and Figure 7.1. In addition, AD analysis of WES data from 42 MDS/AML 
families was performed based on predicted damaging rare germline variants that 
segregate with the disease in three or more families generated eight candidate genes 
that presented Z≤2.9 or pLI≥0.9 seen in Table 6.13 in section 6.2.1.4 in chapter 6 and 
Figure 7.1. These analyses identified only one candidate gene in common, which is 
trinucleotide repeat containing 6C (TNRC6C). Hence, the first interpretation would be 
that TNRC6C might be one of the genes we were searching for. However, family 
FML018 has a consanguineous marriage and AR is likely to be the inheritance mode 




Figure 7.1. Uncharacterised families with MDS/AML that harbour predicted damaging 
heterozygous rare variants in the candidate genes seen in Table 7.1. Affected individuals are 
coloured as following black: AML, red: AML, blue: AA, grey: thrombocytopenia and green: solid 
cancer. The arrow highlights the index case. *: families that harbour variants in at least two of 
the candidate genes here presented. Family FML047 presents history of leukaemia, but there 




Segregation analysis is important to clarify the inheritance pattern in family FML018, 
however there are no DNA samples available from other members of this family. 
Furthermore, it was observed that families had variants in more than one candidate 
genes, which made it harder to distinguish which variant could be pathogenic (Table 
7.1). 
Table 7.1. Candidate genes selected from AD analysis of WES data from 30 and 42 MDS/AML 
families 
1 FAT1   FML033* FAT1 is a receptor for a signalling pathway that regulates growth, gene 
expression, and cell polarity. FAT1 is up regulated in 11% of AML, 29% 
of preB acute lymphoblastic leukaemia (ALL) and 63% of T-cell acute 
lymphoblastic leukaemia (T-ALL). 4588aa 
  
FML002*   
FML042  
  FML059 




  FML109   
FML018* 
3 ARNTL FML116* Transcriptional activator which forms a core component of the circadian 
clock. Alterations in this gene have been linked to infertility, problems 




  FML018* 
4 BRD1 FML019 The encoded protein is a component of the MOZ/MORF 
acetyltransferase complex and can stimulate acetylation of histones H3 
and H4, thereby potentially playing a role in gene activation. It is related 
to the AF10 leukaemia gene (involved with translocations). 1189aa 
  
FML116*  
  FML009  
    
5 KIF13A FML045 Involved in intracellular transport and regulating various processes such 
as mannose-6-phosphate receptor (M6PR) transport to the plasma 
membrane, endosomal sorting during melanosome biogenesis and 
cytokinesis. 1805aa 
 
  FML033*  
  FML112 
6 NCOR2 FML002* Mediates transcriptional silencing of certain target genes. This protein 
acts as part of a multisubunit complex which includes histone 
deacetylases to modify chromatin structure that prevents basal 
transcriptional activity of target genes. Aberrant expression of this gene 
is associated with certain cancers. 2514aa 
  
FML018*   
FML017  
  FML089 
7 PTPN4 FML047 It is a tyrosine phosphatase (PTP) protein. PTPs are known to be 
signalling molecules that regulate a variety of cellular processes 
including cell growth, differentiation, mitotic cycle, and oncogenic 
transformation. PTPN4 prevents cell death. 926aa 
 




8 SCAF1 FML002* SCAF1, interact with the C-terminal domain (CTD) of the large subunit 
of RNA polymerase II and participate in pre-mRNA splicing. 1312aa 
  
FML056  
  FML111   
9 ZZEF1  FML075 No description of its function on NCBI nor Uniprot. No OMIM. 2961aa   
FML082 
 
    FML083   
*: families that harbour variants in at least two of the candidate genes here presented.  






Further analysis using The human protein atlas (https://www.proteinatlas.org/) 
allowed a refined selection of more suitable candidate genes from the list presented 
in Table 7.1. This showed that FAT1, BRD1, PTPN4, and ZZEF1 are unlikely to be 
good candidate genes as they are not expressed in haematopoietic cells. In addition, 
KIF13A and SCAF1 present low protein expression in haematopoietic cells. These 
results leave us with ARNTL, NCOR2, and TNRC6C as good candidate genes. 
However, one of the families that harbour germline damaging heterozygous variant in 
ARNTL and NCOR2 is FML018, the same family that was discussed previously for 
also carrying a germline damaging heterozygous variant in TNRC6C. Hence, without 
FML018, there are two other families (FML113 and FML116) harbouring variants in 
ARNTL. Finally, NCOR2 seems to be the reasonable candidate gene to have its 
pathogenicity further validated at this moment from results of this analysis as still there 
are three other families (FML002, FML017 and FML089 see Figure 7.2) that carry 
predicted damaging variants in this gene. One novel predicted to be damaging in 
frame deletion (c.1523_1525delGCT; p.508_509del) and two rare variants predicted 
to be damaging (MAF: 0.0000647, c.3179_3180insC, p.R1060fs and, MAF: 
0.00001192, c.2364G>C, p.E7888D) were identified in NCOR2 in these families. 
 
NCOR2 (2,514aa, Z:2.09 and pLI:1) is a well known transcriptional co-repressor that 
mediates transcriptional silencing of target genes and is part of NCOR complex, which 
includes histone deacetylases to modify chromatin structures that prevents basal 
transcriptional activity of target genes. NCOR2 plays key roles in the cell cycle, 
apoptosis and proliferation of many cancer cells, including head and neck squamous 
cell carcinoma and breast cancer. Furthermore, cellular differentiation of human in 
vitro generated monocytes is regulated by NCOR2 and time-dependent Interleukin-4 





Figure 7.2. Familial MDS/AML candidate gene NCOR2. A. Uncharacterised families with 
MDS/AML that harbour predicted damaging heterozygous rare variants in NCOR2. Affected 
individuals are coloured as following black: AML, red: AML, blue: AA, grey: thrombocytopenia 
and green: solid cancer. The arrow highlights the index case. *: families that harbour variants 




Although the role of NCOR2 in the FLT3/p65 signalling pathway and aberrant cell 
growth is unclear, NCOR2 nuclear protein levels are significantly increased when 
FLT3 and p65 are downregulated in vitro and in vivo (Wang et al., 2012).  FLT3 is an 
independent poor prognostic marker of sporadic AML, it has an important role in the 
survival, proliferation and differentiation of haematopoietic cells and AML blasts. 
Overexpression of FLT3 is present in 70-90% of sporadic AML. Activating mutations 
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of FLT3 may disrupt transcriptional repressor function resulting in aberrant gene 
regulation and abnormal leukaemia cell growth.  In addition, between 20% and 30% 
of AML patients have either an internal tandem duplication region or a point mutation 
in the FLT3 receptor leading to the constitutive activation of downstream signalling 
pathways and aberrant cell growth.  FLT3 internal tandem duplication induced 
translocation of NCOR2 protein from the nucleus to cytoplasm as well as it inhibited 
the function of transcriptional repressors by blocking protein interactions with NCOR2 
(Takahashi et al., 2004). A gene fusion NCO2/SCARB1 and a missense variant of 
unknown significance were identified in AML cases in the TCGA published in The 
Cancer Genome Atlas (Cancer Genome Atlas Research Network, 2013). 
 
It would be interestingly to see the differences in NCOR2 protein expression between 
the affected individuals compared to a control, considering available samples of these 
patients by Western blotting. If there were significant differences, it would be important 
to discover the pathway that might have been disrupted to give rise to MDS/AML 
phenotype by designing new experiments to be performed. Furthermore, CRISPR-
Cas9 system could be used to introduce the NCOR2 variants identified in this study 
into haematological cells and a cell culture of these modified cells and a wild type 
NCOR2 cell would be useful to verify the differences in cell growth as a result of 
specific NCOR2 variants. 
 
We have analysed MDS/AML families where we had undertaken WES in more than 
one member within the family. In chapter 6, the AD analysis of WES data from family 
FML012 (Figure 6.4, section 6.2.1.2) was described. In this family we were left with 
only two germline variants in the genes CDKL1 and CEP68 (Table 6.9, section 
6.2.1.2). As occurred previously, there is not sufficient evidence on either of these 
candidate genes to be considered disease causing in this family. Reasons for these 
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conclusion are: a) both variants are missense not predicted to be damaging by both 
prediction tools used in this study (Polyphen2 and MutationTaster2), b) both were 
found in another asymptomatic family member, c) no additional families from our 
cohort were found to harbour damaging variants in neither of these genes. Despite all 
discussed above, it is important to note CDKL1 might be the best candidate gene in 
FML012 as the individual III:8 (Figure 6.5 A) harboured a germline heterozygous 
CDKL1 variant (c.416C>T; p.S139F). She was at the time of this study asymptomatic, 
although described to have monoclonal gammopathy (MGUS). People with MGUS 
usually do not present with symptoms, but it can develop into myeloma or a related 
blood disorder (Umemura et al., 2018). To investigate the pathogenicity of this CDKL1 
missense variant, it would be reasonable to a) verify the expression of CDKL1 in the 
patient’s blood cells compared to a control by Western blotting and qPCR as CDKL1 
is known to be overexpressed in malignant tumors such as melanoma, breast cancer, 
and gastric cancer (Qin et al., 2017); b) the next decision should be made upon 
obtained results from the CDKL1 protein levels present in the affected individuals. 
Family FML003 (Figure 6.7, section 6.2.1.3 in chapter 6) is another inconclusive case 
as AR analysis generated five genes that harboured rare homozygous variants (Table 
6.10, section 6.2.1.3 in chapter 6). However all of them were found in a heterozygous 
state in both parents of the index case. This finding left us five genes as candidates. 
From these genes only epidermal growth factor receptor pathway substrate 15 
(EPS15) variant is predicted to be benign by Polyphen2 and MutationTaster2 and 
therefore this is a weak candidate gene; this still leaves four candidate genes in 
FML003 (Table 6.10, 6.2.1.3 in chapter 6). Thus, it would be necessary to have DNA 
sample from one of the affected siblings (which was not possible) in order to identify 
the likely disease causing variant in this family as well as the identification of likely 




Finally, after such an extensive search for the disease gene (s) in these 
uncharacterised families with no conclusive disease gene to date, there are some 
points that need to be considered: a) the pathogenic variant might be in a region not 





7.5 Future work 
 
Firstly, collection of ideal germline tissue (blood and another non-blood samples) and 
complete documentation of family history when possible are essential in order to 
distinguish germline from somatic variants when segregation analysis is not possible. 
Furthermore, as studies have suggested that AML occurs after a process of genetic 
and epigenetic changes that are found in preleukaemic clone before the cells are 
transformed into AML by an acquisition of additional alterations (Pandolfi et al., 2013), 
it would be interesting to perform clone evolution studies of patients with familial 
MDS/AML. Thus, collection of appropriate samples is important. The initial germline 
variant in patients with familial MDS/AML could be considered a preleukaemic event, 
required but sometimes not sufficient for cancer development as in principle, both 
germline and somatic variants of the same gene lead to AML progression. Additional 
somatic variants are reported in CEBPA, RUNX1 and DDX41 patients and clonal 
architecture of leukaemic clones revealed DDX41 variants could be a founder event 
in some patients (Polprasert et al., 2015). 
 
The whole exome sequencing technology is proven to be of great value for 
identification of pathogenic variants in inherited disorders, although many of the 
families with MDS/AML from our cohort remain uncharacterised. Performing a 
combination of techniques such as array comparative genomic hybridisation (aCGH) 
and RNA sequencing (mRNA expression analysis) when feasible, in order to cover all 
DNA regions and assemble a more complete variant information may provide 
additional help in search for the genetic cause of these families. A comprehensive 
genomic landscape of our familial MDS/AML cohort could be described using WES 
along with RNA sequencing and computational analysis. In addition, copy number 
variation could be analysed from our WES data.  
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Following up of potential disease causing variants by screening additional family 
samples and by performing segregation studies are also very good future approaches 
to strengthen the genetic evidence for the pathogenic role of identified variants (for 
instance, for the four candidate genes identified in family FML003 and for the 
candidates listed in Table 7.1). 
 
In conclusion, the recruitment of new families (to increase the allelic series of subtypes 
of patients) together with incorporation of new techniques (such as RNA sequencing) 
as well as functional analysis of specific candidate genes should enable the 





7.6 Concluding remarks 
 
Familial MDS/AML occurs in both children as well as in adults and studies of this 
disease is providing better understanding of the biology of both sporadic and familial 
forms. Furthermore, understanding when to suspect germline predisposition in a 
patient is essential as early and accurate diagnosis influence clinical care of these 
patients and their families. Hence, identification of causal genetic variants is critical 
for this diagnosis. Knowledge of which genes contribute to familial MDS/AML 
predisposition and attention to the acquired variants in genes associated with this 
inherited disease is very important. This is crucial for ensuring that appropriate donors 
are selected for allogeneic transplantation. Although complete human genomes 
alteration are not obtained from any currently single sequencing technology, exome 
sequencing is an effective disease causing variant detection method because it 
targets protein-change and amino acid substitutions which currently account for 
approximately half of the known gene alterations responsible for human inherited 
disease (Ng et al., 2010). However, WES as well as other next generation sequencing 
bring some technical, data management and interpretation issues. Many guidelines 
are being proposed in order to help overcome these challenges. 
 
Variant interpretation is one of the most encountered challenge in WES data analysis 
as it is a collaborative work of different highly trained specialists that require a long 
and complex research process. Certainly, the creation of large scale databases by 
sharing sequencing results from many different studies will help to exclude variants 
with higher minor allele frequency as causal. Computational prediction of variants on 
protein impact is a good guide on the clinical interpretation of variants of uncertain 
significance and on genome studies of diseases. However, it is important to be clear 
that these well-established in silico prediction tools are indicators and for confirming 
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a variant pathogenicity it is essential to perform a combination of approaches such as 
functional analysis, use of population database as ExAC to verify the population 
variant allele frequency and family investigation. Overall, there is a need to develop 
more efficient and standardised bioinformatics tools to filter, analyse and interpret 
WES variants.  
 
Our results also reflected the extensive genetic heterogeneity and phenotypic 
complexity of bone marrow failure diseases including familial MDS/AML. These 
disorders present significant overlapping features and variable expressivity and 
penetrance within syndromes. These along with absent, subtle, or previously 
unreported clinical findings add to the challenges of a timely and precise diagnosis.  
 
Finally, it is essential that clinicians, genetic counsellors, basic scientists and patients 


















Appendix 1 – Known familial MDS/AML causing genes – published 
mutations to date 
 
Table A1.1. Published RUNX1 mutations in familial MDS/AML cases to date 
Paper Families Variant 
Song et al. 1999 
Nature Genetics 
  
1 intragenic deletion 










3 cG286C; p.D96H 
4 c.+3G>A; p.K90fs 
5 cC877T; p.R292X 
Ripperger et al., 2009 
Leukemia 
1 c.C520T; p.R174X 
    
Jongmans et al., 2010 
Leukemia 
1 162 kb duplication in chromosome 
21 
2 105bp deletion 
Langabeer et al., 2010 
European Journal of 
Haematology 
1 c.507delA; p.W169fsX182 
    
Schmit et al., 2015 
Leukemia Research Reports 
 
about 30 affected families have 
been reported since 1999  
(Yoshimi et al., 2014 Nature 
communications) 







Table A1.1. Continued 
Antony-Debré et al., 2016 
Leukemia  
 
less than 45 affected families 

















Haslam et al., 2016 
British Journal of Haematology 
1 c.496C>T; p.Arg166X  
    
Sakurai et al., 2016 
Blood Cancer Journal 
1 285 kb heterozygous deletion 
including the promoter and the 5'-
half of RUNX1 
2 2 Mb heterozygous deletion in 
chromosome 21 encompassing the 
entire RUNX1 
gene and a large genomic region of 
5ʹ-RUNX1 
Yoshimi et al., 2016 







6 p. Gly172Glu 
7 p.Asn438Lys 
8 p.Leu445Pro 
Hamadou et al., 2016 
Annals of Hematology 
1 p.L56S 
    
Latger-Cannard et al., 2016 
Orphanet Journal of Rare 
Diseases 
  
1 c.320G > A; p.Arg107His 
2 c.467C > A; p.Ala156Glu 
3 c.602G > A; p.Arg201Gln 
4 c.611G > A; p.Arg204Gln 
5 c.587C > G; P.Thr196Arg 
6 c. 999_1003dup; 
p.Gln335Argfs261 
7 c. 1092del; p.Ile364Metfs230 
8 c. 442_449del; p.Thr148Hisfs9 




Table A1.1. Continued 
DiNardo et al., 2016 1 c.582A > C; p.K194N 
Clinical Lymphoma 
myelomaLeukemia  
2 c.610C > T; p.Arg201X 
3 c. 1098_1103dupCGGCAT; 
p.I366_G367dup 
Badin et al., 2017 1 c.583dupA; p.Ile195AsnfsX18  
Haemophilia   c. G>A; p.T246M 
Tawana et al., 2017 1 c.601C>T; p.Arg201* 
European Journal of human 
genetics 
    
Kanagal-Shamanna et al., 2017 1 c.582A>C p.K194N 
Haematologica 2 c.719delC p.Pro240Hisfs and 
c.167T>T p.Leu56Ser  
3 Partial gene deletion (at least 
exons 1-6)  
4 c.836G>A p.W279*  
5 c.496C>T p.R166*  
6 c.308dup p.T104fs 
  7 c.1098_1103dupCGGCAT 
p.I366_G367dup 
de Andrade Silva et al., 2018 1 Deletion of exon 1 and 2 of RUNX1 




Table A1.2. Published CEBPA mutations in familial MDS/AML cases to date 
Paper Families Variant 
Smith et al. 2004 
The new England 
Journal of Medicine 
1 c.212delC 
  c.1050_1085dup; 
p.302_313KAKQRNVETQQK 
Sellick et al., 2005 
Leukemia 
  
1 c.217insC;p.fsX106  
c.1071delGAGACGCinsCTGGAGGCCA; 
p.E308_Q310delinsLEAK 
  c.107ins GAC; p.E308dup 
Nanri et al., 2006 
Blood 
  
1 c.350_351insCTAC; p.I68fsX107  
c.1063ins18bp  
c.1079ins3bp 





Table A1.2. Continued 
Pabst et al., 2008 
Journal of Clinical 
Oncology 
  
1 c.744-745GC>TT;p.A199L  
c.1167G>A;p.G340S 
2 c.563-564insCG;p.Y138fsX160  
c.1094-1095insCTG;p.L315-316ins 
3 c327-328insC.;p.E59fsX107  
c.1098-1099insGTC;p.V316-317ins 
4 c.551G>A;p.A134A  
c.742-743insGCCGCCCC;p.P199fsX318 
5 c236-237insGC.;p.A29fsX160 
6 c.395del;p.F82fsX159  
c.1076-1077insAAG;p.K309-310ins 












12 c.327-328insC;p.E59fsX107  
c.1098-1099insGTC;p.V316-317ins 









16 c.216-217insCG;p.P23fsX160  
c.1165G>C;p.R339P 
17 c.286-287insTC;p.P46fsX160  
c.1076-1077insCCG;p.K309-310ins 
18 c.1094-1095insCTG;p.L315-316ins 
  c.687T>C;p.P180P 
Renneville et al., 
2009 
  
1 c.217–218insC  
c.1083–1085delAAG 




Table A1.2. Continued 




1 c.350_351insCTAC; p.I68fsX107  
c.1063–1064ins18-bp  
c.1079–1080insCAG 
  c.1085–1086insAAG 
Stelljes et al., 2011 
Leukemia  
  
1 c. 338delC; p.  
c.1085insGAA; p. 
  c. 1072_1083dup; p. 
Green et al., 2013 
British Journal of 
Haematology 
1 c.68delC, p.P23fs 
  c.K302_K313dup 
Tawana et al., 2015 
Blood 
  
1 c.218delC; p.P23RfsX137   
c.1054_1089dup; p.K302_K313dup  
c.1087_1089dup; p.K313dup 
2 c.218_219insC; p.H24AfsX84  
c.991_992insGA; p.N281RfsX38  
c.1067_1068insGCG; p.R306dup 
3 c.218_219insC; p.H24AfsX84  
c.1047_1088dup; p. R300_K313dup 
4 c.297_315del; p.E50AfsX104  
c.1087_1089dup, c.1061_1210del; p.K313dup, 
p.K304_A353del  
c.1087_1089dup; p.K313dup 




6 c.218_219insC; p.H24AfsX84  
c.1075_1081delinsCTGGAGGCCA; 
p.E309_Q311 delins LEAK  
c.1075_1077dup; p.E309dup 
7 c.339delC; p.D63EfsX97  
c.1087_1089dup; p.K313dup  
c.1076_1087dup; p.E309-Q312dup 
8 c.308delG; p.G53AfsX107  
c.1126_1127ins1079_1227; p.K326 
insT310_X359 
9 c.291delC; p.A48PfsX112  
c.1085_1087dup; p.Q312dup 
10 c.464_465insT; p.F106LfsX2  
c.G1207C; c.A1210C; p.A353P; p.M354L 
  c.1087_1089dup; p.K313dup 
Pathak et al., 2016 
Haematologica 
1 c.932A>C; p.Q311P 
    
Ram et al., 2017 
Blood Advances 
1 c.68dupC; p.H24fs*84 




Table A1.3. Published TERC mutations in familial MDS/AML cases to date 
Paper Families Variant 
Kirwan et al. 2009 
Human mutation 
and in 
Holme et al., 2012 




Table A1.4. Published TERT mutations in familial MDS/AML cases to date 
Paper Families Variant 
Kirwan et al. 2009 
Human mutation 
and in  
Holme et al., 2012 
British Journal of Haematology 
1 c.1892G>A; p.Arg631Gln 
2 c.2354C>T; p.Pro785Leu   
1 c.248G>C; p.Arg83Pro 
 
Table A1.5. Published GATA2 mutations in familial MDS/AML cases to date 
Paper Families Variant 





3 cG286C; p.D96H 
4 c.+3G>A; p.K90fs 
Hsu et al., 2011 
Blood 
  
1 c.1192C>T; p. R398W 
2 c.1192C>T; p. R398W 
3 c.1192C>T; p. R398W 
4 c.1061>T; p.T354M 
5 c.243_244delAinsGC; p.G81fs 
6 c.1192C>T; p. R398W 
7 c.1113 C>G; p.N371K 
8 c.1083_1094del 12 bp; p.R361delRNAN 
9 c.1–200_871; 527del 2033 bp M1del290 
10 c.1186 C>T; p.R396W 
11 c.1061 C>T; p.T354M 
12 c.1187 G>A; p.R396Q 
13 c.1061 C>T; p.T354M 
14 c.778_779ins 10 bp D259fs 
15 c.1192C>T; p. R398W 
16 c. 951_952ins 11 bp N317fs 
17 c. 751 C>T; p. P254L 





Table A1.5. Continued 
Ostergaard et al., 2011 
Nature Genetics 
1 c.310_311insCC; p.Leu105ProfsX15 
2 c.230-1_230insC; p.Arg78ProfsX107 
Dickinson et al., 2011 
Blood 
1 c.1192C>T; p. R398W 
2 c.1018-1 G>T; del 340-381 
Kazenwadel et al., 2012 
Blood 
1 c.; p.Thr354Me 
2 c.;p.Met1del290 
Holme et al., 2012 
British Journal of 
Haematology 
  
1 c.310_311insCC; p.Leu105ProfsX15 
2 c.121C>G; p.Pro41Ala 
3 c.1187G>A, p.Arg396Glu 
4 c.1061C>T, p.Thr354Met 
Bodor et al., 2012 
Haematologica 
Secondary mutations in 
ASXL1 
1 c.; p.Thr354Met   
    
Pasquet et al., 2013 
Blood 
  
1 c.1187G>A; p.R396Q 
2 c.1114G>A,; p.A372T 
3 c.1162A>G; p.M388V 
4 c.c.988C>T; p.R330X 
5 c.610C>T,; p.R204X 
6 c.670G>T; p.E224X 
7 deletion of 61 kb 
Green et al., 2013 
British Journal of 
Haematology 
1 c.310_311insCC; p.L321F 
  c.310_311insCC; p.R330Q 
Gao et al., 2014 
Journal of Haematology 
and Oncology 
1 c.; p.p.Thr358Asn 
2 c.; p.Leu359Val 
Churpek et al., 2015 
Blood 
  
1 c.10171+572 C>T 
2 c.1192C>T; p.R398W 
3 c.1061C>T; p.T354M 
Malhi et al., 2016 
Pediatric Transplantation 
1 c.917G>A; p.Trp306* 
2 c.1009 C>T; p.Arg337X 






4 c.599delG, p.G200VfsX18 
5 3.1-3.3 Mb het del encompassing GATA2 
 
Table A1.6. Published SRP72 mutations in familial MDS/AML cases to date 
Paper Families Variant 
Kirwan et al. 2009 
The American Journal of 
Human Genetics 
1 c.1064_1065del; p.Thr355Lysfs*19 
2 c.620G>A; p.Arg207His 
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Table A1.7. Published ANKRD26 5’UTR mutations in familial MDS/AML cases to date 
Paper Families Variant 
Pippucci et al. 2011 























11 c.-128G> A 
12 c.-134G>A 





























Table A1.7. Continued 
Perez Botero et al., 2015 
Blood Cancer 
1 c.-116 C4T 
  ASXL1 c.2290delC 
Ouchi-Uchiyama et al., 2016 
Pediatric Blood Cancer 
  
1 c.-118C >T 
2 c.-118C >T 
3 c.-134G>A 
4 c.-134G>A 
Yoshimi et al., 2016 
Annals of Oncology 
1 c.-134G > A 
    
Vincenot et al., 2016 
Annales de Biologie Clinique 
1 c.-127A>T 
    
Tsang et al., 2017 
Modern pathology 
1 c.-134G > A 
2   
Marconi et al., 2017 
Journal of Haematology and Oncology 
1 c.-125T>G 
    
Averina et al., 2017 
Thrombosis Research 
1 c.-128G>T 
    




2 c.-134G > A 
3 c.-140C > G 
Guison et al., 2017 
Mediterranean Journal of Hematology 
and Infectious Diseases 
1 c.-127C>A 
    
Zaninetti et al., 2017 




Table A1.8. Published ETV6 mutations in familial MDS/AML cases to date 
Paper Families Variant 
Zhang et al. 2015 
Nature Genetics 
  
1 c.1106G>A ; p.Arg369Gln 
2 c.1195C>T; p.Arg399Cys 
3 c.641C>T; p.Pro214Leu 
Noetzli et al., 2015 
Nature Genetics 
  
1 c.641C>T; p.Pro214Leu 
2 c.641C>T; p.Pro214Leu 
3 c.1252A>G; p.Arg418Gly 
Topka et al., 201 
Plos Genetics 
1 c.T1046C; p. L349P 
2 c.1153-5_1153_1delAACAG; p. N385fs 












Table A1.8. Continued 
Melazzini et al., 2016 
Haematologica 
  
1 c.641C>T; p.P214L  
2 c.1252A>G; p.R418G  
c.1153-1_1165del; p.N385Vfs*7 
3 c.1138T>A; p.W380R 
4 c.1105C>T; p.R369W 
5 c.641C>T; p.P214L  
6 c.1153-1_1165del; p.N385Vfs*7 
Duployez et al., 2017 




Table A1.9. Published DDX41 mutations in familial MDS/AML cases to date 
See Table 4.1 in chapter 4, section 4.14, page 144. 
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Appendix 2 – Primer sequences 
 
Table A2.1. Primers used for rolling circle amplification 
 Primer sequence 
Arqbidopsis Thio-(C3TA3)3 5'-CCCTAAACCCTAAACCCTaaa-3' 
Homo sapiens hC21Thio 5'-CCCTAACCCTAACCCTAAccc-3' 
 
Table A2.2. Primers used for monochrome multiplex qPCR 






Table A2.3. Primers used for dHPLC – TERT promoter 
 Forward primer Reverse primer Oligo 
length 
(bp) 
TERT promoter GGCCGATTCGACCTCTCT AGCACCTCGCGGTAGTGG 453 
 
Table A2.4. Primers used for dHPLC – ANKRD26 5’UTR 
 Forward primer Reverse primer Oligo 
length 
(bp) 




Table A2.5. Primers used for dHPLC - CDKL1 
CDKL1 
exons 
Forward primer Reverse primer Oligo 
length 
(bp) 
1 TCTCCTGAGTTGCTGGGAC GAGGCAGAAGCATGGCTT G 362 
2 GGACAAACAACTTACTTTTTATTGG GCCTTACCTAGTCTTAAAAAGAG 315 
3 CTAAGATTTTTCACTACTAAAGCC GTGTGACATAAACTTTGTACAAG 402 
4 TAGTCATGTGTTTCATTTATCCC TAGAGCATTTAGATCCTTTGTTG 358 
5 CCACAAAATTGGGCACAGG TGAGACTGAGAACTTGGCTC 391 
6 CAGCATTGATGGAAGAAAACC GGCTCAGGAGGTGAATAAC 432 
7 GGACGTGAGGAAGGTGC TTTCATTGCATGGATTGACATAAG 321 
8 GACTGGTGTGTTTTCCTGC CTCAAGTCTAGATTCCAACTC 384 
9 CTCTTTTGTGATATATTCTAAATAATG GGCCTCCCAGTTTCTTGC 359 
 
Table A2.6. Primers used for dHPLC – CEP68 
CEP68 
exons 
Forward primer Reverse primer Oligo 
length (bp) 
2A GCAAGACTTCCTGAACACAG GGTCAGTCCCAATCCAGC 324 
2B TCCTATGGGAGAGGGAGC GAAAGGATGCAAGATGGTGAG 386 
3A CCACAAGGAAACTCCTGGG CCTGTGGAGGAAGCAGAG 341 
3B TGAGCCTTCCCAGAACAAC TGCCTAGCCCAGAAGCATC 387 
3C GCATCTCTGCTTCCTCCAC ACGGCTATCAAGGTGCTTTG 377 
3D CTCTCCTTCCAGGCTGAG CCATGCCACCCTGTTTCTG 370 
3E TGATAGCCGTGTGCCAGC GGGAGAGCCCATATCAAGG 352 
3F TAAGCAGTGGCCCTCCAG GAAACCTGTGTCAGCCGAG 354 
3G GCAAGCACCTTGATATGGG AGCTGGCTTTGGCTGGAG 334 
3H GGA AGTGGAAAGTGATGACG CAGCAGTCCAGAGGAGAC 340 
3I CAGACAGTGATGGGCCAG GGGGGAAGAGACAAGACAC 375 
4 AGTCTGTCT CCAAGTCCTC GCGTTCCGCTTTAAGAATGTG 382 
5 ACACATTAGAGGGGA ATAAGG TACCAGGGATAGTGCGGT C 285 




Table A2.7. Primers used for Sanger sequencing validation 
 Forward primer Reverse primer Oligo 
length 
(bp) 
RUNX1 exon 3 CTACACAAATGCCCTAAAAGTG ACCGAGTTTCTAGGGATTCC 330 
GATA2 exon 4 CCACCCAAAGAAGTGTCTCCTGA GCCGGCACATAGGAGGGGTAG 392 
GATA2 exon 6 GTCAGGGAGGGGGGTC GCCCTTCTGGCGCTCAC 345 
TERT exon 2 GTTTCTGGAGCTGCTTGGGA AGCCCCTACTGCATTCAGCT 455 
SBDS exon 2 GGCTGAGGTTACAGTGACC TGCTTGGTTAGTCTTTCCTCC 478 
FANCAexon 27 TGCTCAGGCCATCCAGTTC CCTGAGATGGGCACAAAGC 322 
FANCAexon 36 GTA GTG GCC TGT AGG AGC CCACCACCACGAGAACTC 368 
WAS exon 10 ACTGGACGTTCTGGACCAC CCAACCTTTCAACCCTATCAC 353 
DDX41 exon 1 CTCCGAGGTCGTTCCTAC GTCCTCGTCGTCCTCATC 200 
DDX41 exon 3 GACCGACGGCTTGATCTG GACTCTTTGCGCGCTGAG 402 
DDX41 exon 8A CAACACCCATTCAGATCCAG GTCTCCATCTGCTCTTTCAC 510 
DDX41 exon 15 AGAACTATGGTAAGAGCCTGG GGTCCATCAGCACTGACTC 319 
RTEL1 exon 20 AGCACTGAGGCCTGAGGTC AAGCTGTGAGAGGCAGGGG 423 
RTEL1 exon 25 GCAGCAGATGAGGGTCTTC CAAAGCCAGGTGAGTCGC 362 
RTEL1 exon 29 TTTCTCAGGCAGCAGCCC AGAGAACAGAGACCACCTTG 351 
RTEL1 exon 30A CCAAGGTGGTCTCTGTTCTC CCACGCAGGAGTCTGAGG 326 
RTEL1 exon 30B ACTACAAGGGTTCCGATGAC GGTCGTCGTCTTGCTTATAG 513 
RTEL1 exon 32 GCAGTTGTCCTGAGCAGC TCAATCAGACCCGGCACAG 415 
DUT Exon 3 GGTAATTCATCATAGCAAGGTTG GGTGCTTCTTTTAGGACACAG 365 
EPS15 Exon 23 TGAGCTGTTTTTGGTTTGATCT AGAATGAATGACAGCAGCAGG 549 
PDIA3 Exon 9 TCTGCATATTGAGAGATGAGAG AACGAAGTCTTCATTTAGACCC 339 
UNC13C Exon 3 GGAGCTGACCCTGCTTAG CAGCATCTTGCACTCAAAGC 294 
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Appendix 4 – Deletion of RUNX1 in family FML053 
 
 
Figure A4.1. Deletion of RUNX1 in family FML053. An UCSC Genome Browser 
(https://genome.ucsc.edu/) window showing the position of the 162kb RUNX1 deletion in the 
chromosome 21. The horizontal red bar indicates the deletion. B.BAM file showing the RUNX1 
position in the chromosome 21. The horizontal red bar indicates the region that is included in 
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